[["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP gene encodes TAR DNA-binding protein 43 (TDP-43), which is involved in RNA processing and DNA repair. In the context of the described mitochondrial respiratory chain complex I (CxI) pathway, TARDBP may influence the stability or function of complex I subunits such as ND1, ND2, ND3, ND4, ND5, and ND6. Mutations in TARDBP are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the loss of motor neurons. Additionally, TARDBP mutations have been implicated in frontotemporal dementia (FTD), suggesting a role in both ALS and FTD. The biological effect of TARDBP alleles, particularly those that disrupt its function, can lead to the mislocalization and aggregation of TDP-43, contributing to neuronal dysfunction and death.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP gene encodes the TDP-43 protein, which is involved in RNA processing and DNA repair. Mutations in TARDBP have been strongly associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations can lead to the mislocalization and aggregation of TDP-43, which disrupts normal cellular functions and contributes to neurodegeneration. The pathway described includes genes related to complex I of the mitochondrial electron transport chain, which is essential for ATP production. Dysfunction in this pathway can lead to energy deficits in neurons, exacerbating the neurodegenerative process. TARDBP's role in this pathway suggests its involvement in maintaining mitochondrial integrity and function, and its dysregulation may contribute to the progression of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP gene encodes TAR DNA-binding protein 43 (TDP-43), which plays a critical role in RNA processing and regulation. Mutations in TARDBP are strongly associated with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease characterized by the loss of motor neurons. These mutations can lead to TDP-43 mislocalization and proteolytic cleavage, resulting in the accumulation of pathological TDP-43 inclusions in neuronal cells. This disruption in TDP-43 function impairs RNA metabolism and contributes to neuronal dysfunction and degeneration. TARDBP mutations have also been linked to frontotemporal lobar degeneration (FTLD), indicating a broader role in neurodegenerative disorders. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor involved in the formation of a ubiquitin ligase complex that targets HIF1A for degradation under normoxic conditions. When VHL is mutated or inactivated, HIF1A is stabilized, leading to the activation of downstream targets such as VEGFA, PDGFB, TGFA, and TGFB isoforms. This results in increased angiogenesis, cell proliferation, and survival, contributing to the development of tumors. This pathway is central in the pathogenesis of von Hippel-Lindau disease, a hereditary cancer syndrome characterized by the formation of benign and malignant tumors in multiple organ systems, including the kidneys, retina, and central nervous system.\n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor that regulates the degradation of HIF1A under normoxic conditions. Loss of VHL function leads to stabilization of HIF1A, which then dimerizes with ARNT to activate transcription of downstream genes like VEGFA, PDGFB, and TGFA. This results in increased angiogenesis and cell proliferation. The pathway described is central to the pathogenesis of Von Hippel-Lindau disease, a hereditary condition characterized by the development of benign and malignant tumors in various organs. \n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene encodes a tumor suppressor protein that is central to the ubiquitin-proteasome system, specifically targeting the HIF (hypoxia-inducible factor) proteins for degradation under normoxic conditions. In the provided pathway, VHL, along with RBX1, ELOC, ELOB, and CUL2, forms an E3 ubiquitin ligase complex that targets HIF1A for degradation. When VHL is dysfunctional, HIF1A accumulates and forms a complex with ARNT, leading to the activation of downstream genes such as VEGFA, TGFB, PDGFB, and TGFA. These genes are involved in angiogenesis, cell proliferation, and survival. The dysregulation of this pathway contributes to the development of clear cell renal cell carcinoma (ccRCC). \n\n\\boxed{Clear Cell Renal Cell Carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a cyclin-dependent kinase inhibitor that plays a crucial role in regulating the cell cycle and acting as a tumor suppressor. Mutations in CDKN2A are associated with the inactivation of p16 protein, which leads to uncontrolled cell proliferation. This loss of tumor suppression contributes to the development of various cancers, notably melanoma and certain types of neurofibromatosis. The pathway described illustrates how CDKN2A interacts with the p53 and RB1 pathways, which are central to cell cycle control and DNA repair. Disruption of CDKN2A function can lead to unchecked cell division and genomic instability, increasing the risk of cancer. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a cyclin-dependent kinase inhibitor that plays a critical role in the G1 to S phase transition of the cell cycle by inhibiting CDK4/6. In the provided pathway, CDKN2A negatively regulates MDM2, which in turn regulates TP53. TP53 activates CDKN1A, which inhibits CDK4/6, and ultimately leads to the inactivation of RB1, thereby suppressing E2F activity. Mutations or loss of CDKN2A function can disrupt this regulatory network, leading to uncontrolled cell proliferation. This disruption is commonly observed in several cancers, most notably melanoma. Therefore, the biological effect of a defective CDKN2A allele is the promotion of tumor development, particularly in melanoma.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a cyclin-dependent kinase inhibitor that regulates the cell cycle by inhibiting CDK4/6, preventing the phosphorylation of RB1, and thus suppressing the activation of E2F. Mutation or deletion of CDKN2A leads to loss of this regulatory function, allowing uncontrolled cell proliferation. This contributes to the development of melanoma, a type of skin cancer. The pathway described highlights how CDKN2A normally suppresses the MDM2-TP53-CDKN1A-RB1-E2F axis, and its dysfunction disrupts the tumor suppressive mechanism. This disruption is a well-documented contributor to melanoma.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) allele is central to a pathway involving the production of Abeta, which leads to downstream signaling through mAChR, GNAQ, PLCB, IP3, ITPR, and Ca\u00b2\u207a release, contributing to mitochondrial Ca\u00b2\u207a influx via MCU and potentially triggering MPTP opening and cytochrome c release. This sequence of events is implicated in neurodegenerative processes. The accumulation of Abeta and subsequent Ca\u00b2\u207a dysregulation are key features in Alzheimer's disease, a neurodegenerative disorder characterized by amyloid plaques and neuronal dysfunction. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway outlines a sequence initiated by the amyloid precursor protein (APP), which leads to the production of amyloid beta (Abeta). This Abeta then activates muscarinic acetylcholine receptors (mAChR), triggering a cascade that increases intracellular calcium levels via IP3 and ITPR, and ultimately results in mitochondrial calcium uptake through MCU. This cascade can lead to mitochondrial dysfunction and the release of cytochrome c (CYCS), which is a key event in apoptosis. This pathway is strongly implicated in Alzheimer's disease, characterized by the accumulation of Abeta plaques and neurodegeneration. Thus, the APP allele contributes to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP gene encodes the amyloid beta precursor protein, which is central to the pathogenesis of Alzheimer's disease. The provided pathway outlines a sequence starting with APP, leading to the production of Abeta, which can accumulate and form plaques in the brain, a hallmark of Alzheimer's. The downstream effectors, such as mAChR, GNAQ, PLCB, IP3, ITPR, and Ca2+, are involved in calcium signaling and mitochondrial dysfunction, which are known to contribute to neuronal damage and death. The involvement of MCU and MPTP points to mitochondrial calcium overload and release of cytochrome c, triggering apoptosis. These events are strongly associated with the progression of Alzheimer\u2019s disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel crucial for regulating neuronal excitability. Mutations in KCNC3 are associated with spinocerebellar ataxia type 13 (SCA13), an autosomal dominant neurodegenerative disorder characterized by progressive ataxia, dysarthria, and other cerebellar signs. These mutations disrupt normal channel function, leading to impaired neuronal signaling and degeneration in the cerebellum and other affected brain regions. \n\n\\boxed{Spinocerebellar Ataxia Type 13}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel, specifically a subunit of the neuronal potassium channel. Mutations in KCNC3 have been implicated in spinocerebellar ataxia type 13 (SCA13), a rare neurodegenerative disorder characterized by progressive ataxia, seizures, and cognitive decline. The biological effect of the KCNC3 allele with pathogenic variants is dysfunction of the potassium channels, leading to altered neuronal excitability and impaired cerebellar function. These alterations contribute to the clinical features of SCA13. \n\n\\boxed{Spinocerebellar Ataxia Type 13}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit that plays a critical role in regulating neuronal excitability. Mutations in KCNC3 have been associated with spinocerebellar ataxia type 13 (SCA13), a neurodegenerative disorder characterized by progressive ataxia, dysarthria, and ophthalmoplegia. These mutations are typically missense, leading to dysfunctional KCNC3 channels and impaired neuronal function. The biological effect of these alleles is the disruption of normal potassium channel function, resulting in altered neuronal firing patterns and degeneration of cerebellar and brainstem neurons. This contributes to the clinical manifestation of SCA13. \n\n\\boxed{Spinocerebellar Ataxia Type 13}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe described pathway involves the amyloid precursor protein (APP) and its downstream effects, including the production of amyloid beta (Abeta), which activates muscarinic acetylcholine receptors (mAChR), leading to a cascade involving GNAQ, PLCB, IP3, ITPR, and increased intracellular calcium. This calcium signaling can influence mitochondrial calcium uptake via MCU and may lead to mitochondrial permeability transition pore (MPTP) opening, releasing cytochrome c (CYCS) and inducing apoptosis. This pathway is implicated in Alzheimer's disease, where Abeta accumulation and mitochondrial dysfunction contribute to neuronal death and cognitive decline.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the amyloid precursor protein (APP), which is cleaved to produce amyloid-beta (A\u03b2), a key player in Alzheimer's disease pathology. A\u03b2 accumulation leads to activation of muscarinic acetylcholine receptors (mAChR), triggering a cascade involving GNAQ, PLCB, and IP3, which increases intracellular calcium levels via ITPR. Elevated calcium activates mitochondrial calcium uptake through MCU, leading to mitochondrial dysfunction and the opening of the mitochondrial permeability transition pore (MPTP). This results in the release of cytochrome c (CYCS), initiating apoptosis. This sequence of events is strongly associated with the pathogenesis of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) allele is central to a pathway that leads to the production of Abeta, a peptide implicated in Alzheimer's disease. The pathway involves activation of muscarinic acetylcholine receptors (mAChR), leading to intracellular signaling through GNAQ, PLCB, IP3, ITPR, and ultimately increased intracellular calcium levels. Elevated calcium can lead to mitochondrial calcium uptake via MCU, potentially triggering the mitochondrial permeability transition pore (MPTP), which can result in cytochrome c release and apoptosis. This cascade is highly relevant to the pathogenesis of Alzheimer's disease, where amyloid accumulation and calcium dysregulation are key contributors to neuronal damage and cognitive decline.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3 is a gene that encodes the ataxin-3 protein, which is primarily involved in ubiquitin-proteasome system functioning. Mutations in the ATXN3 gene lead to an expansion of a CAG trinucleotide repeat, resulting in a toxic gain-of-function of the mutant ataxin-3 protein. This is the underlying cause of spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of motor coordination, often accompanied by ophthalmoplegia, dysarthria, and other neurological symptoms. The mutant ATXN3 contributes to the disease by inducing protein misfolding, aggregation, and impaired cellular function, particularly in neurons of the cerebellum and brainstem. \n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 allele, specifically the pathogenic variant, is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder results from the expansion of a CAG trinucleotide repeat in the ATXN3 gene, leading to the production of an abnormally long ataxin-3 protein. This expanded protein is toxic and leads to the degeneration of neurons in the cerebellum and brainstem, resulting in progressive ataxia, ophthalmoplegia, dystonia, and other neurological symptoms. ATXN3 is part of a pathway involving glutamate signaling and calcium dysregulation, contributing to neuronal dysfunction and cell death. \n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe presence of the ATXN3 allele in this genomic pathway suggests a role in neurodegenerative processes. This pathway involves glutamate signaling through GRM1, which activates PLCB and leads to Ca\u00b2\u207a release via ITPR1, enhanced by ATXN2 and ATXN3. This Ca\u00b2\u207a overload is transported into mitochondria via MCU, possibly leading to MPTP activation and release of CYCS, a key step in apoptosis. ATXN3 is implicated in spinocerebellar ataxia type 3 (SCA3), a neurodegenerative disease characterized by progressive loss of motor control and cognitive function. The involvement of ATXN3 in Ca\u00b2\u207a dysregulation and mitochondrial dysfunction aligns with its role in SCA3 pathogenesis.\n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that detoxifies reactive oxygen species. Mutations in SOD1 are a common cause of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The pathway described involves the unfolded protein response (UPR), with SOD1 potentially impacting this response through its interaction with the ER stress pathway. This may lead to neuronal dysfunction and death, contributing to the progression of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway involves the gene *SOD1*, which encodes superoxide dismutase 1, an enzyme that neutralizes superoxide radicals. The network shows that SOD1 influences BIP (a chaperone protein), which in turn affects EIF2AK3, leading to the phosphorylation of EIF2S1 and subsequent activation of ATF4, which upregulates DDIT3. This signaling cascade is associated with the unfolded protein response (UPR) and cellular stress. Mutations in *SOD1* are primarily linked to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. These mutations can lead to toxic protein aggregation, mitochondrial dysfunction, and neuronal death. The pathway suggests that dysregulation of SOD1 may disrupt cellular homeostasis, contributing to neurodegeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves SOD1, which is a key component of the unfolded protein response (UPR) in the endoplasmic reticulum (ER). SOD1, when mutated, leads to the misfolding of proteins and accumulation in the ER, triggering the UPR through the PERK pathway, involving BIP, EIF2AK3, EIF2S1, ATF4, and DDIT3. This pathway is a protective response to ER stress but can become chronically activated, leading to cell death. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the loss of motor neurons. The SOD1 allele contributes to this disease by causing toxic protein aggregation and mitochondrial dysfunction. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene is central to the amyloidogenic pathway, where it is cleaved to produce Abeta peptides. Accumulation of Abeta, particularly in the form of plaques, is a hallmark of Alzheimer's disease. The network provided includes multiple proteasome subunits, which are involved in the degradation of Abeta. Dysfunction in this pathway can lead to impaired clearance of Abeta, contributing to its accumulation. This contributes to the pathogenesis of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene is central to the production of amyloid-beta peptides, which are key components of the pathological amyloid plaques found in Alzheimer's disease. The given pathway highlights the proteasome system's role in degrading Abeta, and dysfunction in this system may impair Abeta clearance. Several proteasome subunits are listed, indicating the importance of proteasome function in this context. Mutations in the APP gene or defects in proteasome function can lead to accumulation of Abeta, contributing to neurotoxicity and the progression of Alzheimer's disease. Therefore, the biological effect of this APP allele, in the context of the provided pathway, is its contribution to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene is central to the amyloidogenic pathway, which involves the production of amyloid-beta (A\u03b2) peptides. These peptides are implicated in the formation of amyloid plaques, a hallmark of Alzheimer's disease. The pathway includes components of the 26S proteasome, which is involved in protein degradation. Dysregulation in this pathway, particularly in the processing and clearance of A\u03b2, contributes to the accumulation of toxic A\u03b2 species. This accumulation leads to neurodegeneration and the characteristic cognitive decline in Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway involves a series of molecular interactions starting with FGFR3, which activates GRB2, leading to SOS, RAS, RAF, MEK, ERK, MSK1, and ultimately MYC. This signaling cascade is part of the MAPK/ERK pathway, crucial for cell proliferation, differentiation, and survival. Aberrant activation of FGFR3, such as through mutations or overexpression, can lead to uncontrolled cell growth. This pathway is known to be involved in various cancers, particularly those in the bone, skin, and bladder. FGFR3 mutations are commonly found in bladder cancer and are also associated with hereditary conditions like achondroplasia, a form of dwarfism. In the context of cancer, FGFR3 signaling can promote tumor growth and progression. Therefore, this FGFR3 allele contributes to \\boxed{Bladder Cancer}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway, as defined, is a signaling cascade that starts with FGFR3 activation, leading through GRB2, SOS, RAS, RAF, MEK, ERK, MSK1, and finally to MYC. This pathway is part of the RAS-RAF-MAPK signaling pathway, which is central to cell proliferation and survival. Mutations in FGFR3 are well-documented in various cancers, particularly in conditions like multiple myeloma and certain leukemias. In these diseases, FGFR3 mutations can lead to constitutive activation of the pathway, promoting uncontrolled cell growth. Specifically, activating FGFR3 mutations are associated with the development of multiple myeloma, a cancer of plasma cells. These mutations often result in enhanced signaling through the RAS-MAPK axis, contributing to tumor progression and resistance to therapy.\n\n\\boxed{Multiple Myeloma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway described involves activation of RAS and subsequent MAPK signaling, leading to increased MYC expression, a transcription factor involved in cell proliferation and survival. Mutations in FGFR3 are associated with constitutive activation of this pathway, leading to uncontrolled cell growth. This is a known mechanism in certain cancers, particularly those involving the RAS-MAPK pathway. Given the context of the genes involved and the known oncogenic role of FGFR3 activation, the biological effect of this FGFR3 allele likely contributes to tumorigenesis, specifically in bladder cancer and achondroplasia, though the latter is a developmental disorder, whereas the former is a cancer. The most specific cancer association with FGFR3 mutations is bladder cancer.\n\n\\boxed{Bladder cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the pathway involving STX1A and CACNA1B, influencing calcium influx through VGCC(N-type) channels. Mutations in HTT, particularly CAG trinucleotide repeat expansions, lead to the production of a dysfunctional huntingtin protein. This disrupts normal protein function and leads to progressive neurodegeneration, primarily affecting the basal ganglia and cerebral cortex. The disease characterized by these genetic and molecular changes is Huntington's disease.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is associated with Huntington's disease when mutated. In the given pathway, HTT interacts with STX1A, which in turn modulates the VGCC(N-type) channel, influencing calcium influx. Mutations in HTT can disrupt this interaction, leading to dysregulation of calcium signaling, which is implicated in neuronal dysfunction and degeneration. This disruption is a key contributor to the pathogenesis of Huntington's disease, a neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the pathway involving STX1A and CACNA1B, contributing to calcium signaling through VGCC(N-type). Mutations in the HTT gene, particularly CAG trinucleotide repeat expansions, lead to the production of a mutant huntingtin protein. This mutant protein causes toxic gain-of-function effects, disrupting normal cellular processes, including calcium homeostasis. These disruptions are implicated in the progressive degeneration of neurons, particularly in the striatum and cortex. The disease associated with HTT mutations is Huntington's disease.\n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with early-onset, autosomal recessive Parkinson's disease. This pathway, involving PRKN, UBCH7/8, CDCREL1, and others, is critical for protein degradation and cellular quality control. Dysfunctional parkin can lead to accumulation of misfolded proteins and mitochondrial dysfunction, contributing to neurodegeneration. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system, which is crucial for protein degradation. Mutations in PRKN are associated with early-onset autosomal recessive Parkinson's disease. The provided pathway includes PRKN, along with ubiquitin conjugating enzymes (UBE2L3, UBE2L6) and CDCREL1, suggesting a role in protein degradation and cellular quality control. Since PRKN is a known causative gene for Parkinson's disease, this allele likely contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin-protein ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive juvenile-onset Parkinson's disease (AR-JPDB), also known as early-onset parkinsonism. This pathway involves ubiquitination processes, with PRKN playing a critical role in the degradation of misfolded or damaged proteins. The presence of PRKN in this network, along with other ubiquitin-related genes, underscores its importance in maintaining protein homeostasis. Dysfunctional PRKN can lead to the accumulation of toxic proteins, contributing to neurodegeneration. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described is part of the Wnt/\u03b2-catenin signaling cascade. AXIN1, a component of the destruction complex that regulates \u03b2-catenin (CTNNB1), is involved in the negative regulation of this pathway. A mutation or malfunction in AXIN1 could lead to the stabilization of \u03b2-catenin, promoting its nuclear translocation and subsequent activation of TCF/LEF transcription factors. This results in the upregulation of downstream target genes such as MYC and CCND1, which are associated with cell proliferation and survival. Dysregulation of the Wnt pathway is a hallmark of several cancers, particularly colorectal cancer, where APC and AXIN1 mutations are frequently observed. Thus, an aberrant AXIN1 allele contributes to the development of \\boxed{Colorectal Cancer}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway describes a Wnt/\u03b2-catenin signaling cascade. AXIN1 is a critical negative regulator of this pathway, acting to stabilize GSK3B and APC, which target \u03b2-catenin (CTNNB1) for degradation. A mutation or loss of function in AXIN1 would disrupt this degradation process, leading to the accumulation of \u03b2-catenin. This results in its translocation to the nucleus, where it binds to TCF/LEF transcription factors and activates the transcription of downstream targets such as MYC and CCND1, which are involved in cell proliferation and survival. Dysregulation of Wnt/\u03b2-catenin signaling is a hallmark of colorectal cancer. Thus, an AXIN1 allele that impairs its function could contribute to the development of colorectal cancer.\n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway outlines the Wnt signaling cascade, with AXIN1 playing a key role in the degradation of CTNNB1 (\u03b2-catenin). A mutation in AXIN1 that disrupts this degradation could lead to stabilization and accumulation of \u03b2-catenin, resulting in the activation of TCF/LEF transcription factors and subsequent upregulation of downstream targets such as MYC and CCND1. This pathway over-activation is commonly observed in colorectal cancer. Therefore, mutations in AXIN1 are associated with an increased risk of colorectal cancer.\n\n\\boxed{Colorectal cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR allele, or androgen receptor, is a key player in the genomic pathway described, which involves several hormones and regulatory molecules influencing the expression of KLK3, a gene associated with prostate-specific antigen (PSA). This pathway is central to androgen signaling, which is critical in the development and progression of prostate cancer. Dysregulation or mutations in the AR gene can lead to increased sensitivity or resistance to androgens, promoting tumor growth. Therefore, the biological effect of this AR allele contributes to the development and progression of prostate cancer.\n\n\\boxed{Prostate Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR (androgen receptor) gene is central to the pathway involving androgenic and estrogenic signaling, including testosterone (T), dihydrotestosterone (DHT), estradiol (E2), progesterone (P4), and other ligands. The pathway is directed toward the activation of the AR, leading to the expression of KLK3 (prostate-specific antigen, PSA). Dysregulation of AR function can lead to aberrant signaling in prostate tissues, increasing the risk of prostate cancer. Specifically, genetic variations in the AR gene, such as certain alleles, may alter receptor sensitivity or function, contributing to prostate cancer development. Thus, this AR allele contributes to **prostate cancer**.\n\n\\boxed{Prostate cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR (androgen receptor) gene is central to the genomic pathway involving androgens like testosterone (T), dihydrotestosterone (DHT), and its interaction with the androgen receptor (AR) leads to the activation of KLK3, which encodes prostate-specific antigen (PSA). This pathway is crucial in prostate development and function. Dysregulation or mutations in the AR gene can lead to hyperactivation of the androgenic pathway, which is implicated in prostate cancer. The AR allele in question likely enhances or sustains androgen signaling, thereby promoting prostate cell proliferation and contributing to the progression of prostate cancer.\n\n\\boxed{Prostate Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the processing of amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). These mutations lead to altered cleavage of APP, resulting in increased production of amyloid-beta (A\u03b2) peptides, particularly A\u03b242, which is more prone to aggregation. The accumulation of A\u03b2 contributes to the formation of amyloid plaques, a hallmark of AD, and disrupts calcium homeostasis, as indicated by the pathway involving ITPR, MCU, and MPTP. This disruption can trigger mitochondrial dysfunction and apoptosis, further contributing to neuronal loss and cognitive decline. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of gamma-secretase, which is involved in the cleavage of amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). These mutations disrupt normal proteolytic processing of APP, leading to increased production of beta-amyloid peptides, particularly A\u03b242, which aggregates to form amyloid plaques \u2014 a hallmark of AD. This pathway involves calcium signaling, with PSEN1 influencing intracellular calcium release and mitochondrial calcium uptake, contributing to neuronal dysfunction and apoptosis. These dysfunctions are linked to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex involved in the cleavage of amyloid precursor protein (APP). This pathway involves calcium signaling, with PSEN1 influencing intracellular calcium dynamics through interactions with ITPR and MCU, leading to mitochondrial calcium uptake and subsequent activation of the MPTP, resulting in the release of CYCS and initiation of apoptosis. Dysregulation of this pathway is implicated in neurodegenerative diseases, specifically Alzheimer's disease. Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease, highlighting its critical role in disease pathogenesis.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway suggests a signaling cascade initiated by the SPTBN2 gene, which may influence the GRM1 receptor, leading to GNAQ activation and subsequent PLCB activity, resulting in IP3 production and Ca\u00b2\u207a release via ITPR. This pathway is involved in intracellular calcium signaling, crucial for processes like neuronal function and cell communication. Mutations or dysregulation in this pathway could potentially lead to neurological disorders or conditions where calcium signaling is impaired. The involvement of GRM1, a glutamate receptor, indicates a possible role in neurodegenerative or psychiatric diseases. Based on the genes involved and their known roles in calcium signaling and neuronal function, the SPTBN2 allele may contribute to \\boxed{Alzheimer's Disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SPTBN2 gene encodes a non-erythrocytic spectrin beta chain, involved in maintaining the structural integrity of the cell membrane and in signal transduction pathways. The given pathway implicates SPTBN2 in a network that includes GRM1, which is a glutamate receptor, and leads to intracellular calcium signaling through IP3 and ITPR. Dysregulation of calcium signaling is implicated in various neurological and psychiatric disorders. Specifically, mutations in SPTBN2 have been associated with spinocerebellar ataxia type 11, an autosomal recessive neurodegenerative disorder characterized by progressive dysfunction of the cerebellum and other brain regions. This disease results in impaired motor coordination and is linked to the structural and functional roles of SPTBN2 in neuronal cells.\n\n\\boxed{Spinocerebellar Ataxia Type 11}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe described pathway involves SPTBN2, a spectrin protein, interacting with GRM1, leading to a cascade involving GNAQ, PLCB isoforms, IP3, and ITPR, which ultimately results in Ca\u00b2\u207a release. This pathway is implicated in calcium signaling and intracellular communication. Mutations in SPTBN2 have been associated with autosomal recessive cerebellar ataxia. This disease is characterized by progressive loss of coordination and balance due to degeneration of the cerebellum. The SPTBN2 allele likely contributes to this condition by disrupting normal neuronal function through impaired calcium signaling in cerebellar neurons.\n\n\\boxed{Autosomal Recessive Cerebellar Ataxia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes a subunit of the P/Q-type voltage-gated calcium channel, which plays a crucial role in neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with familial hemiplegic migraine, a rare form of migraine that can cause temporary paralysis on one side of the body. This condition is often linked to defects in calcium channel function, leading to abnormal neuronal activity and migraine episodes. The gene is also implicated in other neurological disorders, including ataxia and episodic ataxia. The specific allele in question influences the function of these calcium channels, thereby contributing to the pathogenesis of familial hemiplegic migraine.\n\n\\boxed{familial hemiplegic migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha-1A subunit of the P/Q-type voltage-gated calcium channel, which is crucial for neurotransmitter release at synaptic terminals. Mutations in CACNA1A are associated with a range of neurological disorders, including spinocerebellar ataxia type 1 (SCA1), episodic ataxia type 2, and hemiplegic migraine. These conditions are characterized by impaired motor coordination, seizures, and migraine headaches, respectively. The dysfunction of the calcium channel disrupts normal neuronal signaling, leading to the observed clinical manifestations. \n\n\\boxed{Spinocerebellar ataxia type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha-1A subunit of the P/Q-type voltage-gated calcium channel, which plays a critical role in neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with several neurological disorders, including episodic ataxia type 2, spinocerebellar ataxia type 6, and familial hemiplegic migraine. These conditions are characterized by impaired motor coordination, seizures, and migraine headaches, respectively. The dysfunction of calcium channels due to CACNA1A mutations disrupts normal neuronal signaling and calcium homeostasis, leading to the observed clinical manifestations.\n\n\\boxed{Familial Hemiplegic Migraine}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the activity of lysosomal enzymes like GBA and GALC. Mutations in PSAP can lead to a deficiency in these saposins, impairing lysosomal enzyme function. This deficiency contributes to the development of lysosomal storage diseases. Specifically, PSAP mutations are associated with a condition known as saposin-deficient lysosomal storage disease, which may manifest as a form of Sandhoff disease or a similar neurodegenerative disorder. The pathway defined as PSAP* // (GBA, GALC) indicates that the PSAP allele interacts with GBA and GALC, which are involved in the metabolism of glycosphingolipids. Disruption of this pathway leads to the accumulation of these lipids, causing cellular and systemic damage, particularly in the nervous system.\n\n\\boxed{Sandhoff disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the activity of several lysosomal enzymes, including GBA and GALC. Mutations in PSAP can lead to a deficiency in these saposins, impairing the function of GBA and GALC. This results in the accumulation of their respective substrates\u2014glucosylceramide and galactosylceramide\u2014in lysosomes, leading to cellular damage. This pathway is implicated in a lysosomal storage disorder known as Krabbe disease, although PSAP mutations are more commonly associated with a related condition called saposin deficiency or variant late-infantile neuronalceroid lipofuscinosis. However, the specific disease context involving PSAP in relation to GBA and GALC is most directly linked to a condition known as **Krabbe disease**.\n\n\\boxed{Krabbe disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor protein that is cleaved into saposins, which are essential for the activity of lysosomal enzymes such as GBA and GALC. Mutations in PSAP can lead to a deficiency in these saposins, impairing the function of GBA and GALC. This pathway is involved in the breakdown of complex lipids. Deficiency in GBA is associated with Gaucher disease, while deficiency in GALC is linked to Krabbe disease. However, the specific disease associated with PSAP mutations is neuronal ceroid lipofuscinosis (NCL), also known as saposin deficiency. This condition is characterized by progressive neurological deterioration and is inherited in an autosomal recessive manner.\n\n\\boxed{Neuronal ceroid lipofuscinosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of motor control, leading to ataxia, dystonia, and other neurological symptoms. ATXN3 encodes a protein that functions in autophagy and is implicated in the ubiquitin-proteasome system. Mutations in ATXN3 lead to the expansion of a CAG trinucleotide repeat, resulting in a toxic gain of function of the mutant protein. This leads to the accumulation of misfolded proteins and cellular dysfunction in the brain. The provided pathway involves autophagy-related genes, which may be impacted by the ATXN3 allele. Therefore, the biological effect of this ATXN3 allele contributes to the progression of $\\boxed{\\text{Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease)}}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3 is a gene involved in the ubiquitin-proteasome system and autophagy, as indicated by its interaction with components of the autophagy pathway such as BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1. Mutations in ATXN3 are primarily associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive impairment of motor coordination, ophthalmoplegia, and other neurological symptoms. The pathogenic mechanism involves the expansion of a CAG trinucleotide repeat in the ATXN3 gene, leading to the production of a toxic, aggregation-prone protein that disrupts neuronal function. The interaction of ATXN3 with autophagy-related genes suggests a possible link between impaired autophagy and the degenerative processes observed in SCA3.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This is a neurodegenerative disorder characterized by progressive loss of motor control, often accompanied by other symptoms such as ophthalmoplegia, dystonia, and peripheral neuropathy. The pathway provided includes genes involved in autophagy, such as BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1, which are critical for the formation of autophagosomes. ATXN3 is implicated in the ubiquitin-proteasome system and autophagy, suggesting its role in protein degradation. Mutations in ATXN3 lead to the accumulation of toxic proteins, contributing to neuronal dysfunction and degeneration. Thus, the ATXN3 allele contributes to \\boxed{Spinocerebellar Ataxia Type 3}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, specifically the mutated forms of the PRNP gene, is primarily associated with prion diseases. These are a group of rare, fatal neurodegenerative disorders characterized by the misfolding of the prion protein (PrP), leading to accumulation of pathological prion protein (PrPSc) and subsequent neuronal damage. The pathway described involves PRNP interacting with CAV (caveolin) proteins, which may influence membrane organization and signaling, and ultimately leads to activation of FYN, PI3K, PRKCD, NOX2, and ROS (reactive oxygen species) production. This oxidative stress and signaling cascade can contribute to neuronal dysfunction and death, which are hallmarks of prion-related diseases.\n\n\\boxed{Prion Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, particularly the pathogenic variants like PRNP 129Q217K, contributes to the development of prion diseases, specifically variant Creutzfeldt-Jakob Disease (vCJD). Prion proteins (PRNP) are central to the pathway, initiating a cascade that involves CAV, FYN, PI3K, PRKCD, NOX2, and ROS. This pathway appears to modulate oxidative stress and potentially neurodegenerative processes. The disease is a rare, rapidly progressive, and fatal neurodegenerative disorder caused by misfolded prion proteins. These misfolded proteins lead to neuronal dysfunction and death, resulting in progressive dementia and neurological symptoms.\n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the prion protein (PRNP), which is central to prion diseases. These are a group of rare, neurodegenerative disorders caused by the misfolding of the prion protein into a pathological form. This misfolding leads to the accumulation of abnormal prion protein (PrPSc), which can convert normal prion protein (PrPC) into more PrPSc, propagating the disease. The pathway includes proteins involved in membrane organization (CAV1-3), signal transduction (FYN, PI3K, PRKCD), and ROS production (NOX2, ROS), which may contribute to oxidative stress and cell damage in the brain. These processes are implicated in the pathogenesis of prion diseases. \n\n\\boxed{Prion disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS gene is part of a signaling pathway that includes KRAS, PI3K, PIP3, AKT, and BAD. Mutations in NRAS, particularly activating ones, lead to constitutive activation of the PI3K/AKT pathway, promoting cell survival and proliferation. This dysregulation contributes to uncontrolled cell growth and is commonly observed in various cancers. Specifically, NRAS mutations are frequently associated with melanoma, a type of skin cancer. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS family proteins (KRAS and NRAS) activating PI3K, leading to the production of PIP3, which in turn activates AKT. AKT phosphorylates and inactivates BAD, a pro-apoptotic protein, thereby promoting cell survival. Mutations in NRAS that constitutively activate the RAS protein can lead to continuous signaling through the PI3K/AKT pathway, which promotes cell proliferation and survival. This dysregulation is a hallmark of various cancers. Specifically, NRAS mutations are commonly associated with melanoma, a type of skin cancer. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway describes a signaling cascade initiated by NRAS and KRAS, which activate PI3K, leading to PIP3 production and subsequent AKT activation. AKT phosphorylates BAD, preventing apoptosis. Mutations in NRAS, particularly in genes like NRAS, can cause constitutive activation of this pathway, leading to uncontrolled cell proliferation and survival. This dysregulation is implicated in various cancers. Specifically, NRAS mutations are frequently observed in melanoma, leading to resistance to therapy and poor prognosis. \n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein that functions in ubiquitin-mediated proteolysis. Mutations in ATXN3, especially those leading to polyglutamine expansion, are associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of coordination, muscle stiffness, and other neurological symptoms. The pathway described involves calcium signaling and mitochondrial dysfunction, which are implicated in neurodegeneration. ATXN3 may contribute to these processes through its role in protein quality control and its potential interaction with calcium-regulated pathways. \n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in the ubiquitin-proteasome system. The pathway described involves calcium signaling through the glutamate receptor GRM1, leading to IP3 and subsequent calcium release via ITPR1, with ATXN3 playing a regulatory role. Mutations in ATXN3, particularly the expansion of a CAG trinucleotide repeat, lead to toxic protein accumulation and are associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive degeneration of the cerebellum and other brain regions, resulting in ataxia, dystonia, and other motor and non-motor symptoms.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive ataxia, dysarthria, and other neurological symptoms. The mutant ATXN3 allele contains an expanded CAG trinucleotide repeat, leading to the production of an aberrant ataxin-3 protein that causes toxic gain-of-function effects, resulting in selective degeneration of neurons in the central nervous system. This expansion disrupts normal cellular functions, contributes to protein misfolding and aggregation, and impairs mitochondrial function and calcium homeostasis, which are consistent with the described pathway involving Ca2+ signaling and mitochondrial dysfunction. \n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene is a tumor suppressor that negatively regulates the PI3K/AKT signaling pathway by dephosphorylating PIP3. In the given pathway, PTEN* (a mutated or inactivated form of PTEN) leads to increased PIP3 levels, which in turn activates AKT1, AKT2, and AKT3. This results in enhanced cell survival, proliferation, and resistance to apoptosis, promoting tumorigenesis. Loss of PTEN function is a well-established driver in multiple cancers, particularly in conditions like Cowden syndrome and various solid tumors, including endometrial, breast, and glioblastoma cancers. The constitutive activation of the AKT pathway due to PTEN inactivation is a major contributor to uncontrolled cell growth and cancer development.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene is a tumor suppressor that negatively regulates the PI3K/AKT signaling pathway by dephosphorylating PIP3. In the given pathway, PTEN* (a mutant or loss-of-function allele) would fail to dephosphorylate PIP3, leading to its accumulation. This results in increased AKT activation, which promotes cell survival, growth, and proliferation. Dysregulation of this pathway is strongly associated with various cancers, particularly those involving the phosphoinositide 3-kinase (PI3K) pathway. The most well-documented disease linked to PTEN mutation is **Cowden syndrome**, a hereditary condition that predisposes individuals to benign and malignant tumors, including breast, thyroid, and uterine cancers. \n\n\\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPTEN is a tumor suppressor gene that negatively regulates the PI3K/AKT signaling pathway by dephosphorylating PIP3. In the provided pathway, PTEN* (likely a mutant or loss-of-function allele) would fail to dephosphorylate PIP3, leading to its accumulation. This results in increased AKT activation, which promotes cell survival, proliferation, and growth. Dysregulation of this pathway is strongly associated with the development of various cancers. The loss of PTEN function is a well-documented contributor to the development of **Phosphatase and Tensin Homolog (PTEN)-deficient cancers**, most notably **endometrial cancer**, **breast cancer**, and **melanoma**. These tumors often exhibit genomic instability and increased AKT signaling due to PTEN dysfunction.\n\n\\boxed{Endometrial cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This autosomal dominant neurodegenerative disorder is characterized by progressive movement disorders, including ataxia, dystonia, and ophthalmoplegia. The pathway defined includes genes involved in autophagy, such as BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1, which are essential for maintaining cellular homeostasis. Mutations in ATXN3, particularly CAG trinucleotide repeat expansions, lead to the production of a toxic protein that disrupts normal autophagy and contributes to neuronal degeneration. This disruption in the autophagic pathway likely exacerbates the pathogenesis of SCA3.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in the ubiquitin-proteasome system and autophagy. The provided network includes components of the autophagy pathway, such as BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1, which are all involved in autophagosome formation and regulation. Mutations in ATXN3, particularly the expansion of a CAG trinucleotide repeat, lead to the production of a toxic, aggregation-prone form of ataxin-3. This results in the degeneration of cerebellar and brainstem neurons, characteristic of spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder contributes to motor dysfunction, speech difficulties, and other neurological symptoms.\n\n\\boxed{Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with Machado-Joseph disease (also known as spinocerebellar ataxia type 3), a neurodegenerative disorder characterized by progressive loss of motor control, muscle stiffness, and other neurological symptoms. ATXN3 is a key component of the autophagy pathway, and its dysfunction may impair cellular clearance mechanisms, contributing to the accumulation of toxic proteins and neuronal degeneration. The ATXN3 allele in the given pathway is likely involved in autophagy regulation through its interaction with BECN1 and other autophagy-related genes, suggesting that its malfunction could disrupt autophagy and promote disease. \n\n\\boxed{Machado-Joseph disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key component of the gamma-secretase complex, which is involved in the proteolytic processing of the amyloid precursor protein (APP). This processing produces amyloid-beta peptides, whose accumulation is a hallmark of Alzheimer's disease. The pathway described involves the unfolded protein response (UPR), with PSEN1 playing a role in initiating the signaling cascade through EIF2AK3, leading to the activation of ATF4 and DDIT3. Dysregulation of this pathway may contribute to endoplasmic reticulum stress, which is implicated in neurodegeneration. PSEN1 mutations are strongly associated with early-onset familial Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key component of the gamma-secretase complex and is involved in the proteolytic processing of amyloid precursor protein (APP), leading to the production of amyloid-beta peptides. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease. The provided pathway illustrates a stress response mechanism initiated by PSEN1, which activates EIF2AK3, leading to the phosphorylation of EIF2S1, and ultimately to the activation of ATF4 and DDIT3, which are involved in the unfolded protein response and stress-induced transcription. This pathway suggests that PSEN1 influences cellular stress responses, which may contribute to the pathogenesis of Alzheimer's disease through mechanisms involving endoplasmic reticulum stress and amyloidosis.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key component of the gamma-secretase complex and plays a critical role in the processing of amyloid precursor protein (APP), leading to the production of beta-amyloid peptides. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). The provided pathway outlines a stress response mechanism initiated by PSEN1, which influences the unfolded protein response (UPR) through the PERK pathway, ultimately leading to DDIT3 expression. This suggests that PSEN1 contributes to neurodegeneration by disrupting protein homeostasis, a hallmark of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the processing of amyloid precursor protein (APP). Aberrant processing of APP by this complex leads to the accumulation of amyloid-beta peptides, which form plaques in the brain\u2014hallmarks of Alzheimer's disease. The pathway PSEN1* -| ERN1 -> XBP1 suggests that PSEN1 dysfunction can trigger the unfolded protein response (UPR) via ERN1 (also known as IRE1), leading to activation of XBP1, a transcription factor involved in ER stress response. Chronic ER stress and UPR activation are implicated in neurodegeneration. Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex involved in the processing of amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). In the provided pathway, PSEN1 activates ERN1, which in turn activates XBP1, a transcription factor involved in the unfolded protein response (UPR). This pathway is critical for maintaining endoplasmic reticulum (ER) homeostasis. Aberrant PSEN1 function can lead to dysregulated ER stress signaling, contributing to neurodegeneration. The biological effect of a pathogenic PSEN1 allele is thus primarily linked to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the cleavage of amyloid precursor protein (APP). The pathway PSEN1 -| ERN1 -> XBP1 suggests a role in the unfolded protein response (UPR) mediated by the IRE1 pathway. Mutations in PSEN1 are tightly linked to early-onset Alzheimer's disease (AD). These mutations lead to abnormal processing of APP, resulting in increased production of beta-amyloid peptides, which accumulate as plaques in the brain. This accumulation is a hallmark of AD and contributes to neuronal dysfunction and death. Thus, the PSEN1 allele contributes to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 gene encodes sequestosome 1, a protein that plays a crucial role in the ubiquitin-proteasome system and autophagy. In the given pathway, SQSTM1 is involved in the PINK1-PRKN-mediated mitochondrial quality control pathway, which is essential for mitochondrial function and cellular health. Mutations in SQSTM1 have been implicated in neurodegenerative disorders, particularly amyotrophic lateral sclerosis (ALS). These mutations can disrupt the autophagic clearance of damaged mitochondria, leading to the accumulation of toxic proteins and mitochondrial dysfunction, which are hallmarks of ALS. Therefore, the SQSTM1 allele contributes to the development of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 gene encodes sequestosome 1, a key protein in the autophagy pathway. In the context of the provided genomic pathway involving PINK1 and PRKN, SQSTM1 interacts with LC3 proteins (MAP1LC3A, B, B2, C), which are central to autophagosome formation. Mutations in SQSTM1 can disrupt this pathway, leading to impaired mitochondrial quality control and increased accumulation of damaged organelles. This dysfunction is implicated in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Therefore, the SQSTM1 allele in this context is most likely associated with amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic lateral sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 gene encodes sequestosome 1, a protein involved in autophagy and the ubiquitin-proteasome system. In the provided pathway on chromosome 5, SQSTM1 interacts with PINK1 and PRKN, which are key components of the mitophagy pathway. Mutations in SQSTM1 have been associated with neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). These mutations can disrupt the normal function of SQSTM1, impairing its ability to participate in the degradation of damaged mitochondria, leading to the accumulation of toxic proteins and mitochondrial dysfunction, which are hallmarks of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS family of genes (KRAS and NRAS) activating PI3K through phosphorylation, leading to the production of PIP3, which in turn activates AKT. AKT then phosphorylates and inactivates BAD, a pro-apoptotic protein, thereby promoting cell survival. Mutations in NRAS, especially in the context of this pathway, can lead to constitutive activation of the PI3K/AKT axis, resulting in uncontrolled cell proliferation and resistance to apoptosis. This type of dysregulation is commonly observed in various cancers, particularly in melanoma, where NRAS mutations are frequently found and contribute to tumor development and progression.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves activation of NRAS and KRAS, which phosphorylate and activate PI3K. PI3K generates PIP3, which in turn activates AKT. AKT then phosphorylates and inactivates BAD, a pro-apoptotic protein, thereby promoting cell survival and proliferation. Mutations in NRAS, particularly in this pathway, are commonly implicated in various cancers. These mutations lead to constitutive activation of the pathway, contributing to uncontrolled cell growth. NRAS mutations are frequently observed in melanoma, and to a lesser extent in other cancers like bladder cancer and some leukemias. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS-MAPK and PI3K-AKT signaling cascades, which are critical for cell growth, survival, and proliferation. Activating mutations in NRAS, such as those in the KRAS and NRAS genes, lead to constitutive activation of these pathways. This uncontrolled signaling promotes unregulated cell growth and can contribute to tumorigenesis. Given the genes involved, including PIK3CA, AKT1-3, and BAD, the pathway is commonly dysregulated in various cancers. Specifically, NRAS mutations are well-documented in melanoma, but also occur in other cancers such as thyroid, bladder, and certain leukemias. The biological effect of an NRAS allele with such mutations is the promotion of malignant transformation and tumor development.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor gene involved in the ubiquitination pathway, which regulates the stability of hypoxia-inducible factors (HIFs) such as EPAS1. In the absence of functional VHL, EPAS1 accumulates and dimerizes with ARNT to activate transcription of genes like VEGFA, CXCL8, SLC2A1 (GLUT1), and EPO, which promote angiogenesis, cell proliferation, and survival. This aberrant signaling contributes to the development of clear cell renal cell carcinoma (ccRCC). The pathway described reflects the loss of VHL function, leading to constitutive activation of HIF-target genes. This dysregulated pathway is a hallmark of VHL syndrome and is a major driver of renal cancer.\n\n\\boxed{Clear cell renal cell carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor gene that, when mutated, leads to the loss of function of the VHL protein. This protein is a critical component of a ubiquitin ligase complex that targets the HIF (hypoxia-inducible factor) proteins for degradation. Without functional VHL, HIF accumulates, leading to the upregulation of genes involved in angiogenesis, cell survival, and glucose metabolism, such as VEGFA, CXCL8, SLC2A1 (GLUT1), and EPO. These effects are central to the development of clear cell renal cell carcinoma (ccRCC). The provided pathway illustrates the mechanism by which the VHL allele contributes to disease through the HIF-1\u03b1 pathway.\n\n\\boxed{Clear Cell Renal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor involved in a pathway that regulates hypoxia-inducible factor (HIF) through the ubiquitination and degradation of HIF-\u03b1 subunits. In the given pathway, VHL, along with RBX1, ELOC, ELOB, and CUL2, forms a ubiquitin ligase complex that targets EPAS1 (a HIF-\u03b1 subunit) for degradation when oxygen levels are normal. When VHL is dysfunctional, EPAS1 accumulates, dimerizes with ARNT, and activates transcription of downstream genes such as VEGFA, CXCL8, SLC2A1 (GLUT1), and EPO. This promotes angiogenesis, glycolysis, and erythropoiesis, which are hallmarks of hypoxia. Mutation or loss of VHL function leads to constitutive activation of HIF signaling, contributing to tumor development, particularly in clear cell renal cell carcinoma (ccRCC). \n\n\\boxed{Clear cell renal cell carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system and mitochondrial quality control. Mutations in PRKN are a common cause of early-onset autosomal recessive Parkinson's disease. Parkin plays a key role in mitophagy, the selective autophagy of damaged mitochondria. The pathway defined by PRKN and MFN1/2, which are involved in mitochondrial fusion, highlights the importance of mitochondrial dynamics and function. Disruption of this pathway through PRKN mutations can lead to impaired mitochondrial function and neuronal degeneration, contributing to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination of proteins, particularly in mitochondrial quality control. Mutations in PRKN are associated with autosomal recessive juvenile parkinsonism, also known as PARK2. This neurodegenerative disorder is characterized by early-onset Parkinson's disease symptoms, including bradykinesia, rigidity, and resting tremor. The PRKN pathway, along with MFN1 and MFN2\u2014genes involved in mitochondrial fusion\u2014plays a critical role in maintaining mitochondrial integrity. Dysfunction in this pathway can lead to mitochondrial impairment, neuronal stress, and ultimately, neurodegeneration. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin-protein ligase involved in mitochondrial quality control through autophagy. Mutations in PRKN are a major cause of early-onset, autosomal recessive Parkinson's disease. The pathway involving PRKN and the mitofusins (MFN1/2) is crucial for mitochondrial dynamics, fusion, and function. Disruption of this network impairs mitochondrial integrity and function, leading to neurodegeneration. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway describes a regulatory network where cyclin D (CCND) and CDK4 activity phosphorylates RB1, leading to the release of E2F transcription factors. This process is central to cell cycle progression, particularly the G1 to S phase transition. Mutations or overexpression of CDK4 can result in constitutive activation of this pathway, bypassing normal cell cycle checkpoints. This uncontrolled cell proliferation is a hallmark of cancer. Specifically, mutations in CDK4 are implicated in melanoma and other cancers. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 gene is part of a critical pathway involved in cell cycle regulation, specifically in the G1 to S phase transition. When CDK4 interacts with cyclin D (CCND) proteins, it phosphorylates RB1, leading to the release of E2F transcription factors, which activate genes necessary for DNA synthesis and cell division. Mutations or overexpression of CDK4 can disrupt this regulation, leading to uncontrolled cell proliferation. Such dysregulation is commonly observed in various cancers, where the cell cycle checkpoints are compromised. The most significant contribution of CDK4 dysregulation is in the development of melanoma and certain types of breast cancer. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway involves the interaction between cyclin D (CCND) and CDK4, which together form a complex that phosphorylates RB1. This phosphorylation inactivates RB1, leading to the activation of E2F transcription factors, which drive the cell cycle from G1 to S phase. Mutations or overexpression of CDK4 can lead to uncontrolled cell proliferation by disrupting the normal regulation of the cell cycle. This dysregulation is a hallmark of many cancers, particularly those involving the retinoblastoma pathway. The CDK4 allele is implicated in the development of various cancers, most notably melanoma and some types of breast and ovarian cancers.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway illustrates a key signaling cascade involved in cell proliferation and survival. NRAS, along with KRAS, activates PI3K, leading to PIP3 production, which in turn activates AKT. AKT phosphorylates and inactivates BAD, a pro-apoptotic protein, thereby promoting cell survival. Mutations in NRAS can lead to constitutive activation of this pathway, driving uncontrolled cell growth. Such mutations are commonly found in various cancers, including melanoma, leukemia, and solid tumors. The persistent activation of this pathway contributes to tumorigenesis. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS-PI3K-AKT signaling cascade, a critical pathway in cell growth, survival, and proliferation. NRAS is a key upstream activator of this pathway. Activating mutations in NRAS, such as those leading to constitutive activation, result in continuous signaling through PI3K, PIP3, and AKT, promoting cell survival and proliferation, and inhibiting apoptosis (as indicated by the BAD phosphorylation and inactivation). This aberrant signaling is a well-documented driver of various cancers, including melanoma, acute myeloid leukemia, and other solid tumors. In particular, NRAS mutations are frequently observed in melanoma and have been linked to its pathogenesis.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, when mutated, can lead to constitutive activation of the RAS signaling pathway. This activation results in continuous stimulation of downstream effectors such as PI3K, leading to increased PIP3 production and subsequent activation of AKT. The AKT pathway is crucial for cell survival and proliferation, and its persistent activation can contribute to uncontrolled cell growth. In this context, mutations in NRAS are commonly associated with certain cancers, particularly those involving the RAS-PI3K-AKT signaling cascade. These mutations are frequently observed in melanoma, as well as in some hematologic malignancies and solid tumors.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the activity of several lysosomal enzymes, including GBA and GALC. Mutations in PSAP can lead to a deficiency in these saposins, impairing the function of the associated enzymes. This results in the accumulation of glycosphingolipids in lysosomes, causing cellular dysfunction. The condition associated with PSAP mutations is Krabbe disease, a rare, severe, inherited metabolic disorder that primarily affects the central nervous system. \n\n\\boxed{Krabbe disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins that are essential for the activity of lysosomal enzymes, including GBA and GALC. Mutations in PSAP can lead to a deficiency in these enzymes, contributing to the development of lysosomal storage disorders. Specifically, mutations in PSAP are associated with Krabbe disease, a rare inherited disorder characterized by progressive neurological degeneration due to the accumulation of galactocerebroside. \n\n\\boxed{Krabbe disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the activity of several lysosomal enzymes, including GBA and GALC. Mutations in PSAP lead to the deficiency of saposins, affecting the function of these enzymes. This results in the accumulation of sphingolipids, which causes progressive neurodegeneration. The condition associated with PSAP mutations is called **Johanson-Blizzard syndrome**, a rare autosomal recessive disorder characterized by exocrine pancreatic insufficiency, facial dysmorphism, and sensorineural hearing loss. It also contributes to a broader spectrum of sphingolipid storage diseases. \n\n\\boxed{Johanson-Blizzard syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, as part of this genomic pathway, plays a key role in the activation of downstream signaling through GAB1, PI3K, PIP3, and AKT, which modulates BAD activity. This pathway is crucial for cell survival, growth, and proliferation. Mutations or overactivation of MET can lead to uncontrolled cell growth and contribute to the development of cancer. Specifically, MET alterations are frequently observed in various malignancies, including lung, gastric, and thyroid cancers, and are associated with tumor progression and resistance to therapy. \n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway described involves the activation of MET, leading to downstream signaling through GAB1, PI3K, PIP3, and AKT, which modulates BAD activity. This signaling cascade is critical for cell survival, proliferation, and migration. Deregulation of MET, particularly through activating mutations or amplifications, can lead to uncontrolled cell growth and is implicated in various cancers. MET overactivation is known to contribute to oncogenesis, especially in diseases such as non-small cell lung cancer, gastric cancer, and some types of glioblastoma. The MET allele in question, by activating this pathway, likely promotes tumor growth and progression.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele is associated with the MET proto-oncogene, a receptor tyrosine kinase that activates downstream signaling pathways, including the PI3K/AKT pathway, which is crucial for cell survival, proliferation, and migration. Mutations or overactivation of MET can lead to uncontrolled cell growth and are implicated in several cancers. Specifically, MET alterations contribute to the development of various malignancies, such as non-small cell lung cancer (NSCLC), gastric cancer, and some pediatric cancers. \n\n\\boxed{Non-Small Cell Lung Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a tyrosine kinase that, when fused with BCR (as in the BCR-ABL fusion protein), leads to constitutive activation of the PI3K/AKT signaling pathway. This uncontrolled activation promotes cell proliferation and survival, contributing to the development of chronic myeloid leukemia (CML). The pathway involves CRKL, CBL, and CRK as adaptor proteins that relay signals from BCR-ABL to PI3K, leading to production of PIP3, which activates AKT. AKT then phosphorylates and inactivates BAD, a pro-apoptotic protein, further preventing cell death. This aberrant signaling is a hallmark of CML and is a target for tyrosine kinase inhibitors.\n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that, when aberrantly activated through chromosomal translocations such as in the BCR-ABL fusion protein, leads to constitutive signaling in the PI3K/AKT pathway. This uncontrolled activation promotes cell proliferation, survival, and resistance to apoptosis. The pathway involves CRKL, CBL, and CRK as adaptor proteins, which mediate signal transduction to PI3K, leading to PIP3 production and subsequent AKT activation. AKT phosphorylates and inactivates BAD, a pro-apoptotic protein, preventing cell death. This dysregulated pathway is characteristic of chronic myeloid leukemia (CML). \n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that, when mutated or dysregulated, can lead to uncontrolled cell growth. In the context of the BCR-ABL fusion protein, which is a hallmark of chronic myeloid leukemia (CML), ABL1 contributes to constitutive activation of downstream signaling pathways including PI3K-AKT, promoting cell proliferation and survival. This aberrant signaling is central to the pathogenesis of CML. \n\n\\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination of proteins, particularly in the process of mitophagy. Mutations in PRKN are primarily associated with early-onset autosomal recessive Parkinson's disease. The pathway described involves PRKN acting upstream to PLCG1, leading to the release of intracellular calcium through IP3 and ITPR receptors. This pathway may be involved in cellular signaling and calcium homeostasis, which are crucial for neuronal function. Disruption in this pathway might contribute to neurodegeneration observed in Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination and degradation of proteins. In the given pathway, PRKN appears to initiate a signaling cascade leading to PLCG1 activation, which generates IP3, triggering Ca\u00b2\u207a release through ITPR receptors. Mutations in PRKN are strongly associated with autosomal recessive juvenile parkinsonism, also known as Parkinson disease 7 (PARK7). This condition manifests with early-onset Parkinson\u2019s disease symptoms such as tremor, rigidity, and bradykinesia. The dysfunction of parkin likely disrupts the normal cellular processes involving Ca\u00b2\u207a homeostasis and protein quality control, leading to neuronal degeneration in dopaminergic neurons, the hallmark of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination and degradation of damaged proteins.Mutations in PRKN are associated with autosomal recessive juvenile Parkinson's disease, also known as Parkinson disease 3 (PARK3). This pathway involves PRKN activating PLCG1, leading to IP3 production, which then binds to ITPR receptors to release intracellular Ca\u00b2\u207a. Dysregulation of calcium signaling due to PRKN mutations may contribute to neuronal dysfunction and degeneration observed in Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is central to the pathogenesis of prion diseases. A specific allele of PRNP, particularly the codon 129 methionine/valine polymorphism, contributes to susceptibility to Creutzfeldt-Jakob disease (CJD), including the sporadic, familial, and variant forms. When this allele is present in a homozygous state, it significantly increases the risk of developing CJD upon exposure to prion agents. These neurodegenerative diseases are characterized by the conversion of the normal prion protein into a pathological form, leading to neuronal dysfunction and death.\n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, and specific alleles of this gene can contribute to prion diseases. These are neurodegenerative disorders characterized by the misfolding of the prion protein into a pathogenic form, leading to the accumulation of abnormal prion protein (PrPSc) in the brain. This accumulation causes neuronal damage and ultimately results in cognitive decline and death. The pathway PRNP* -> NOTCH1 suggests a potential interaction between the prion protein and the NOTCH1 receptor, which is involved in cell fate determination and signaling. While the exact role of this interaction in disease is not fully understood, the PRNP allele is most directly associated with prion diseases such as Creutzfeldt-Jakob disease.\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is central to the pathogenesis of prion diseases. These are a group of rare, transmissible, and often fatal neurodegenerative disorders. Mutations in the PRNP gene can lead to the misfolding of the prion protein, triggering a cascade of events that result in neuronal damage and death. The specific interaction mentioned, PRNP* -> NOTCH1, suggests a potential signaling pathway involving the prion protein and the Notch receptor, which plays roles in cell-cell communication and development. While the exact biological effect of this particular PRNP allele is not fully elucidated, it is likely related to the dysregulation of normal prion protein function, contributing to the progression of prion-related diseases.\n\n\\boxed{Creutzfeldt-Jakob Disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor that is part of a ubiquitin ligase complex involved in targeting hypoxia-inducible factors (HIFs) for degradation. In the provided pathway, VHL is part of a complex that regulates EPAS1 (also known as HIF-2\u03b1), which, when stabilized, interacts with ARNT to activate the transcription of genes such as VEGFA, CXCL8, SLC2A1 (GLUT1), and EPO. These genes are involved in angiogenesis, inflammation, glucose transport, and erythropoiesis. Mutations in VHL lead to the stabilization of HIFs, resulting in constitutive activation of these downstream genes. This contributes to the development of clear cell renal cell carcinoma (ccRCC), a common type of kidney cancer. \n\n\\boxed{Clear Cell Renal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele is involved in a genomic pathway that regulates hypoxia-inducible gene expression. The VHL protein is a component of an E3 ubiquitin ligase complex that targets the HIF (hypoxia-inducible factor) \u03b1 subunits for degradation under normoxic conditions. In the absence of functional VHL, HIF \u03b1 subunits accumulate, leading to the activation of genes such as VEGFA, CXCL8, SLC2A1 (GLUT1), and EPO, which are involved in angiogenesis, inflammation, and erythropoiesis. This pathway is dysregulated in von Hippel-Lindau disease, a hereditary cancer syndrome associated with the development of benign and malignant tumors, including hemangioblastomas, pheochromocytomas, and clear cell renal cell carcinomas.\n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor that plays a central role in the ubiquitin-proteasome system, specifically in the degradation of the HIF (hypoxia-inducible factor) transcription factors. When functional, the VHL protein targets HIF-1\u03b1 for degradation. In the absence of functional VHL, HIF-1\u03b1 accumulates, leading to the activation of genes involved in angiogenesis, glucose metabolism, and cell survival, such as VEGFA, CXCL8, SLC2A1, and EPO. This pathway is activated under hypoxic conditions but is dysregulated in VHL-deficient cells, leading to uncontrolled tumor growth. This genetic defect is associated with von Hippel-Lindau disease, a hereditary condition characterized by the development of benign and malignant tumors in various organs. \n\n\\boxed{von Hippel-Lindau disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the HTT (huntingtin) gene, which is central to the pathogenesis of Huntington's disease. The network begins with HTT, which likely affects the scaffolding and function of the NMDA receptor (NMDAR) complex via DLG4, leading to increased calcium influx. This elevated calcium enters the mitochondria through MCU, leading to mitochondrial calcium overload. Excessive calcium can trigger the mitochondrial permeability transition pore (MPTP), causing the release of cytochrome c (CYCS) and subsequent activation of the intrinsic apoptotic pathway through APAF1, CASP9, and CASP3. This cascade leads to neuronal death, a hallmark of Huntington's disease. Thus, the HTT allele in this context is implicated in Huntington's disease.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, associated with the gene *HTT* (huntingtin), is involved in a pathway leading to neurodegeneration. This allele encodes a mutant form of the huntingtin protein, which causes disruptions in the NMDA receptor (NMDAR) signaling cascade, mitochondrial calcium uptake via MCU, and the permeability transition pore (MPTP). These dysfunctions ultimately trigger the release of cytochrome c (CYCS), activating the apoptotic cascade through APAF1, CASP9, and CASP3. This pathway is specifically implicated in Huntington's disease, a genetic disorder characterized by progressive neurodegeneration, motor dysfunction, cognitive decline, and psychiatric symptoms. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, associated with the gene *HTT* (huntingtin), is implicated in Huntington's disease. This neurodegenerative disorder arises from a CAG trinucleotide repeat expansion within the *HTT* gene, leading to the production of a mutant huntingtin protein. This mutant protein disrupts multiple cellular processes, including mitochondrial function, calcium homeostasis, and the apoptotic pathway. The pathway described involves HTT interacting with DLG4 and NMDAR, leading to calcium influx, mitochondrial calcium overload, and ultimately apoptosis through the CASP9 and CASP3 cascade. This cascade contributes to neuronal death, a hallmark of Huntington's disease. \n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nKCNC3 encodes a voltage-gated potassium channel subunit that plays a crucial role in neuronal excitability. Mutations in KCNC3 have been associated with spinocerebellar ataxia type 13 (SCA13), a neurodegenerative disorder characterized by progressive ataxia, ophthalmoplegia, and other neurological symptoms. The malfunction of KCNC3 due to allelic variation disrupts normal potassium channel function, leading to impaired neuronal firing and subsequent degeneration in the cerebellum and other brain regions. This genetic alteration contributes to the clinical manifestations of SCA13. \n\n\\boxed{Spinocerebellar Ataxia Type 13}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit that plays a crucial role in neuronal excitability. Mutations in KCNC3 are known to cause an autosomal dominant form of epilepsy, specifically *Epilepsy, familial, with migraines and paroxysmal dyskinesia* (also known as *Epilepsy 29* or *EPM29*). This condition is characterized by seizures, migraines, and episodic involuntary movements. The allele contributes to the disease by disrupting the normal function of potassium channels, thereby altering the electrical activity in neurons and leading to hyperexcitability. This disruption in ion homeostasis is central to the manifestation of the pathological symptoms associated with the disorder.\n\n\\boxed{Epilepsy, familial, with migraines and paroxysmal dyskinesia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel, specifically the Kv3.3 subunit, which is critical for the repolarization phase of action potentials in neurons. Mutations in KCNC3 have been associated with spinocerebellar ataxia type 13 (SCA13), a neurodegenerative disorder characterized by progressive ataxia, oculomotor apraxia, and cognitive impairment. These mutations typically lead to dysfunctional potassium channels, disrupting neuronal excitability and contributing to the degeneration of cerebellar and brainstem structures. The pathway involving K+ ions and KCNC3 is essential for maintaining proper neuronal function, and its disruption is directly linked to the pathophysiology of SCA13.\n\n\\boxed{Spinocerebellar Ataxia Type 13}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a common cause of early-onset autosomal recessive Parkinson\u2019s disease (PD). The pathway described involves PRKN initiating a cascade leading to PLCG1 activation, subsequent IP3 production, and Ca\u00b2\u207a release through ITPR receptors. This pathway is implicated in cellular calcium signaling and stress responses. Dysfunctional parkin may impair this pathway, contributing to neuronal dysfunction and degeneration. Therefore, mutations in PRKN are strongly associated with Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a common cause of early-onset autosomal recessive parkinsonism, specifically Parkinson's disease. Parkin plays a role in mitochondrial quality control and neuronal survival. Disruption of its function leads to accumulation of damaged mitochondria and increased oxidative stress, contributing to dopaminergic neuron degeneration in the substantia nigra. This pathway, involving PLCG1, IP3, ITRP, and Ca\u00b2\u207a, suggests a role for calcium signaling in the neurodegenerative process. PRKN mutations impair this signaling, exacerbating neuronal dysfunction and death. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive juvenile Parkinson's disease (ARJP), a form of early-onset Parkinson's disease. The pathway described involves PRKN influencing PLCG1, leading to IP3 production, which in turn activates ITPR channels to release Ca\u00b2\u207a. Dysregulation of calcium homeostasis has been implicated in neurodegenerative processes. Therefore, the PRKN allele, when mutated, contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele is associated with prion diseases, a group of rare, fatal neurodegenerative disorders. These diseases are caused by the misfolding of the prion protein (PrP), leading to progressive damage in the brain. The provided pathway suggests a stress response mechanism involving the unfolded protein response (UPR), with PRNP interacting with HSPA5 (BIP), a chaperone involved in protein folding. This pathway is activated under conditions of endoplasmic reticulum (ER) stress, indicating that PRNP may play a role in cellular stress responses. However, in the context of prion disease, the misfolded PRNP protein can trigger a pathological cascade, contributing to conditions such as Creutzfeldt-Jakob disease (CJD).\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele is associated with prion diseases, a group of neurodegenerative disorders. In this pathway, PRNP interacts with BIP, which is part of the unfolded protein response (UPR) in the endoplasmic reticulum. This interaction triggers a cascade involving EIF2AK3, leading to the activation of ATF4 and ultimately DDIT3. These processes are involved in stress responses and can lead to neuronal dysfunction and death. The pathway indicates that the PRNP allele contributes to the pathogenesis of prion-related diseases, particularly those involving the accumulation of misfolded prion proteins and subsequent neurotoxicity. \n\n\\boxed{Prion Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, specifically the mutant form, is associated with prion diseases such as Creutzfeldt-Jakob disease (CJD). In the provided pathway, PRNP interacts with BIP, a chaperone protein involved in the unfolded protein response (UPR), which is activated under endoplasmic reticulum (ER) stress. This network includes key UPR components like EIF2AK3 (PERK), which phosphorylates EIF2S1, leading to activation of ATF4 and ultimately DDIT3 (CHOP), a pro-apoptotic gene. The PRNP allele may contribute to the misfolding and accumulation of the prion protein, inducing ER stress and activating this pathway, resulting in neuronal apoptosis and neurodegeneration. This process is central to the pathogenesis of prion-related diseases.  \n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes a voltage-gated calcium channel subunit, crucial for neuronal and muscular function. Mutations in CACNA1A are associated with a range of neurological disorders, including episodic ataxia, hemiplegic migraine, and spinocerebellar ataxia type 6. These conditions are characterized by impaired calcium influx, leading to altered neuronal excitability and function. Specifically, the CACNA1A allele contributes to the pathogenesis of spinocerebellar ataxia type 6, a progressive neurodegenerative disorder affecting coordination and balance. \n\n\\boxed{Spinocerebellar Ataxia Type 6}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes a subunit of the voltage-gated calcium channel involved in calcium influx into cells. Mutations in CACNA1A are associated with various neurological disorders, including episodic ataxia, spinocerebellar ataxia type 6 (SCA6), and familial hemiplegic migraine type 1. These conditions are characterized by impaired motor coordination, seizures, and migraine headaches. The biological effect of the CACNA1A allele is the dysregulation of calcium signaling in neurons, which disrupts normal neuronal function. This leads to the clinical manifestations seen in the aforementioned diseases.\n\n\\boxed{Spinocerebellar Ataxia Type 6}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes a subunit of a voltage-gated calcium channel, which plays a crucial role in regulating calcium influx into cells. Mutations in this gene can disrupt normal calcium signaling, leading to a variety of neurological and muscular disorders. Specifically, certain alleles of CACNA1A have been implicated in spinocerebellar ataxia type 1 (SCA1), a progressive neurodegenerative disease characterized by loss of coordination and balance. The biological effect of the CACNA1A allele is thus primarily associated with this condition.\n\n\\boxed{Spinocerebellar Ataxia Type 1}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TBK1 gene plays a critical role in the autophagy pathway, particularly in the selective degradation of damaged organelles and proteins through autophagy. The given pathway indicates that TBK1 is involved in the conversion of LC3-I to LC3-II, a key step in autophagosome formation, through its interaction with adaptor proteins such as SQSTM1, OPTN, NDP52, TAX1BP1, and NBR1. Mutations in TBK1 that impair this function can lead to defective autophagy, which may result in the accumulation of damaged cellular components. This dysfunction has been linked to neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TBK1 gene encodes TANK-binding kinase 1, a key regulator in the autophagy and innate immune signaling pathways. It phosphorylates SQSTM1, OPTN, NDP52, TAX1BP1, and NBR1, promoting their binding to LC3-II, which is essential for selective autophagy. Mutations in TBK1 that impair this function can disrupt autophagy and lead to the accumulation of damaged proteins and organelles. This dysfunction is implicated in neurodegenerative and inflammatory diseases, notably amyotrophic lateral sclerosis (ALS). TBK1 mutations are also associated with a rare neurodegenerative disorder known as Charcot-Marie-Tooth disease type 2J and a form of hereditary spastic paraplegia. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TBK1 allele described is involved in the autophagy pathway, specifically in the interaction with receptors like SQSTM1, OPTN, NDP52, TAX1BP1, and NBR1 leading to LC3-II formation. TBK1 is a key kinase in the autophagy process, helping in the tagging of damaged organelles and proteins for degradation. Mutations in TBK1 have been linked to the neurodegenerative disorder amyotrophic lateral sclerosis (ALS). These mutations can impede autophagy, leading to the accumulation of toxic proteins and dysfunction in motor neurons.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is a key component in the pathogenesis of Parkinson's disease. Mutations or overexpression of SNCA can lead to the formation of Lewy bodies, which are abnormal protein aggregates found in the brain of individuals with Parkinson's disease. These aggregates are associated with neuronal dysfunction and death, leading to the characteristic motor and non-motor symptoms of the disease. The pathway described involves mitochondrial complex I (CxI), which is critical for ATP production. Impairment of this complex may exacerbate mitochondrial dysfunction, further contributing to the progression of the disease. Therefore, the SNCA allele contributes to the development of \\boxed{Parkinson's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is a key component in the formation of Lewy bodies, pathological inclusions found in neurons. Mutations or overexpression of SNCA have been strongly associated with Parkinson's disease (PD), a neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the substantia nigra. The SNCA allele in the provided pathway may contribute to PD through its involvement in protein misfolding, aggregation, and subsequent neuronal dysfunction. The inclusion of complex I (CxI) subunits in the network suggests a potential link between mitochondrial dysfunction and SNCA-related pathogenesis. This interplay between SNCA and mitochondrial integrity may underlie the progression of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein involved in synaptic function and regulation of neurotransmitter release. Mutations in SNCA, or increased expression due to genetic factors, are strongly associated with Parkinson's disease. The pathway described includes complex I components of the mitochondrial electron transport chain, which is crucial for ATP production. Dysfunction in this pathway can lead to mitochondrial impairment, oxidative stress, and neuronal damage. SNCA's interaction with complex I may contribute to the mitochondrial abnormalities seen in Parkinson's disease. Thus, the SNCA allele contributes to the pathogenesis of \\boxed{Parkinson's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPARK7 encodes DJ1, a protein involved in various cellular processes including antioxidant defense, protein folding, and regulation of apoptosis. The given pathway suggests that DJ1 interacts with DAXX and ASK1, which are upstream regulators of JNK, a key component of the stress-activated protein kinase pathway. JNK activation is linked to neurodegenerative processes. Mutations in PARK7 can disrupt these interactions, leading to mitochondrial dysfunction and oxidative stress, which are implicated in neurodegenerative diseases. Specifically, mutations in PARK7 are associated with Parkinson's disease, as DJ1 plays a role in maintaining neuronal health and protecting against oxidative damage. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPARK7, also known as DJ1, is a gene associated with early-onset Parkinson's disease. The pathway described involves DJ1 interacting with the DAXX and ASK1 proteins, which then activate JNK (c-Jun N-terminal kinase), a key player in stress response and apoptosis. Mutations in PARK7 can disrupt this pathway, leading to increased oxidative stress and mitochondrial dysfunction, which are implicated in neurodegenerative processes. These disruptions contribute to the degeneration of dopaminergic neurons, a hallmark of Parkinson's disease. Therefore, the biological effect of a PARK7 allele with disease-associated mutations is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPARK7 (also known as DJ1) encodes the DJ1 protein, which is involved in protecting cells from oxidative stress and maintaining mitochondrial function. The pathway described suggests a connection between DJ1 and the JNK (c-Jun N-terminal kinase) signaling cascade, which is involved in stress responses and apoptosis. Mutations in PARK7 have been linked to early-onset Parkinson's disease. This allele likely contributes to the pathogenesis of Parkinson's disease by impairing the protective functions of DJ1, leading to neuronal degeneration. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene encodes a serine/threonine kinase that is a key component of the MAPK signaling pathway, which is crucial for cell growth and survival. Mutations in BRAF, particularly the V600E mutation, lead to constitutive activation of the BRAF kinase, which in turn continuously activates the downstream MEK and ERK proteins, promoting uncontrolled cell proliferation. This aberrant signaling is frequently observed in several cancers, including melanoma, thyroid cancer, and colorectal cancer. The persistent activation of the MAPK pathway due to BRAF mutations contributes to tumor development and progression.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene is a key component of the MAPK/ERK signaling pathway, which regulates cell growth and division. Mutations in BRAF, particularly the V600E mutation, result in constitutive activation of the BRAF kinase, leading to continuous signaling through MEK and ERK. This uncontrolled activation promotes unregulated cell proliferation and can lead to the development of various cancers. Notably, BRAF mutations are commonly found in melanoma, thyroid cancer, and certain types of colorectal cancer. The persistent activation of this pathway contributes to tumor growth and progression.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene encodes a serine/threonine kinase that is a key component of the RAS/RAF/MEK/ERK signaling pathway, which is crucial for cell growth and proliferation. The specified pathway, BRAF \u2192 MEK \u2192 ERK, is a well-known mitogen-activated protein kinase (MAPK) cascade. Mutations in BRAF, particularly the V600E mutation, lead to constitutive activation of this pathway, promoting uncontrolled cell division. This aberrant signaling is commonly found in several cancers, most notably melanoma. The presence of the BRAF V600E allele is strongly associated with melanoma and other malignancies, including thyroid cancer, colorectal cancer, and some leukemias. It is a biomarker for targeted therapy with BRAF inhibitors.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT gene encodes adenine phosphoribosyltransferase, an enzyme involved in the purine salvage pathway. Mutations in the APRT gene can lead to a deficiency in this enzyme, impairing the body's ability to recycle adenine into adenosine monophosphate (AMP). This results in the accumulation of 2,8-dihydroxyadenine, which can form crystals and deposits in the urinary tract, leading to kidney stones and, in severe cases, kidney failure. This condition is known as 2,8-dihydroxyadenine urolithiasis or adenine phosphoribosyltransferase deficiency. \n\n\\boxed{Adenine phosphoribosyltransferase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT gene encodes adenine phosphoribosyltransferase, an enzyme involved in the salvage pathway of purine synthesis. Mutations in the APRT gene can lead to a deficiency in this enzyme, impairing the body's ability to recycle adenine. This deficiency results in the accumulation of 2,8-dihydroxyadenine, which can form crystals and cause damage to the urinary tract. The condition is known as 2,8-dihydroxyadenine urolithiasis or adenine phosphoribosyltransferase deficiency. This disease is characterized by recurrent kidney stones and urinary tract obstruction. \n\n\\boxed{Adenine phosphoribosyltransferase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT gene encodes adenine phosphoribosyltransferase, an enzyme involved in the salvage pathway of purine nucleotide synthesis. A mutation in the APRT gene can lead to a deficiency in this enzyme, resulting in the accumulation of adenine and its metabolites, which can form uric acid crystals. This condition is associated with a rare autosomal recessive disorder known as adenine phosphoribosyltransferase deficiency, also called Purinosis. This disease can lead to the formation of kidney stones and, in severe cases, renal failure. \n\n\\boxed{Purinosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes the retinoblastoma protein, a key tumor suppressor involved in regulating the cell cycle. The pathway defined by RB1 and E2F proteins is central to control of the G1/S transition. Mutations in RB1 can lead to uncontrolled cell proliferation, as the E2F transcription factors, which are normally repressed by RB1, become active and promote DNA synthesis. This loss of control contributes to the development of retinoblastoma, a rare eye cancer that typically affects children. Inheriting one mutant copy of RB1 increases the risk of developing this disease, and a second hit in the other allele is often required for tumor formation. \n\n\\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes the retinoblastoma protein, a tumor suppressor that plays a critical role in regulating the cell cycle by controlling the activity of E2F transcription factors. Mutations in RB1 can lead to uncontrolled cell proliferation and are associated with retinoblastoma, a rare but aggressive tumor of the retina, typically occurring in children. In addition, RB1 mutations have been implicated in other cancers, such as osteosarcoma and small cell lung cancer. The interaction between RB1 and E2F proteins is fundamental in maintaining genomic stability and preventing neoplastic transformation.\n\n\\boxed{(Retinoblastoma)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes a tumor suppressor protein that regulates the cell cycle by inhibiting E2F transcription factors. Mutations in RB1 lead to uncontrolled cell proliferation, as E2F factors are no longer repressed. This loss of tumor suppression is a key event in the development of retinoblastoma, a rare childhood eye cancer. The RB1-E2F pathway is critical in controlling cell cycle progression, and disruption of this pathway contributes to the onset of retinoblastoma.\n\n\\boxed{Retinoblastoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the ATXN3 allele in this genomic pathway involves its role in the regulation of intracellular calcium signaling. ATXN3 is part of a complex that modulates the activity of the inositol 1,4,5-trisphosphate receptor (ITPR1), which is crucial for the release of calcium from the endoplasmic reticulum. Dysregulation of calcium homeostasis can lead to mitochondrial dysfunction, oxidative stress, and apoptosis. This pathway is implicated in neurodegenerative diseases, particularly those involving protein aggregation and mitochondrial dysfunction. ATXN3 is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, a progressive neurological disorder characterized by ataxia, dystonia, and other motor impairments.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes a protein involved in ubiquitin-mediated proteolysis and is associated with the polyglutamine (CAG repeat) expansion disease, spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This pathway highlights the role of ATXN3 in calcium signaling through its interaction with ITPR1, which is involved in the release of intracellular calcium. Mutations or expansions in ATXN3 disrupt this pathway, contributing to neurodegenerative processes, particularly in the cerebellum and brainstem. \n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 allele is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is caused by the expansion of a CAG trinucleotide repeat in the ATXN3 gene, leading to the production of an abnormal ataxin-3 protein. This protein accumulates in neurons, causing progressive degeneration of the cerebellum and other brain regions, resulting in loss of coordination, muscle spasms, and other neurological symptoms.\n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the dismutation of superoxide radicals into oxygen and hydrogen peroxide. The given pathway outlines a network involving SOD1, which is connected to HSPA5 (BIP), ATF6, and DDIT3. This pathway is part of the unfolded protein response (UPR) in the endoplasmic reticulum (ER). Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations lead to the production of misfolded SOD1 proteins, triggering ER stress and UPR activation, which may contribute to neuronal degeneration. \n\n\\boxed{Amyotrophic lateral sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves SOD1, which is associated with the unfolded protein response in the endoplasmic reticulum, as it interacts with BIP (HSPA5), ATF6, and DDIT3. Mutations in SOD1 are primarily linked to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. This allele likely contributes to the misfolding or dysfunction of SOD1, leading to toxic accumulation and neuronal death. \n\n\\boxed{Amyotrophic lateral sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves SOD1, HSPA5 (BIP), ATF6, and DDIT3, which are associated with the unfolded protein response (UPR) in the endoplasmic reticulum. SOD1, a copper-zinc superoxide dismutase, is primarily involved in scavenging superoxide radicals. Mutations in SOD1 are strongly linked to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. These mutations lead to misfolding and accumulation of SOD1, triggering ER stress and UPR pathways, as seen in the described network. The involvement of ATF6 and DDIT3 suggests that the pathway is activated in response to SOD1-related ER stress, contributing to neuronal toxicity and disease progression. \n\n\\boxed{Amyotrophic lateral sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPTEN is a tumor suppressor gene that negatively regulates the PI3K/AKT signaling pathway by dephosphorylating PIP3. In the given pathway, PTEN* (likely a mutant or loss-of-function allele) would fail to dephosphorylate PIP3, leading to its accumulation. This results in increased AKT activation, which promotes cell survival, proliferation, and inhibition of apoptosis. Such dysregulation is implicated in various cancers, particularly those involving the PI3K/AKT/mTOR pathway. PTEN mutations are frequently observed in conditions like glioblastoma, breast cancer, endometrial cancer, and Cowden syndrome. These mutations disrupt normal cellular control mechanisms, contributing to uncontrolled cell growth and tumor development.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPTEN is a tumor suppressor gene that negatively regulates the PI3K/AKT/mTOR signaling pathway by dephosphorylating PIP3. A loss-of-function mutation in PTEN leads to constitutive activation of AKT, promoting cell proliferation, survival, and migration. This genetic alteration contributes to the development of various cancers, most notably Cowden syndrome, a hereditary condition associated with an increased risk of benign and malignant tumors. It is also implicated in other malignancies such as breast, endometrial, and thyroid cancers. \n\n\\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPTEN is a tumor suppressor gene that negatively regulates the PI3K/AKT signaling pathway by dephosphorylating PIP3. Loss of PTEN function leads to increased PIP3 levels, which in turn activates AKT kinases (AKT1, AKT2, AKT3). This results in enhanced cell survival, proliferation, and resistance to apoptosis, all of which contribute to cancer development. Mutations or deletions in PTEN are associated with several cancers, including glioblastoma, breast cancer, and endometrial cancer. PTEN deficiency is also linked to the inherited disorder Cowden syndrome, which predisposes individuals to multiple types of malignancies.\n\n\\boxed{Cowden syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, particularly the mutant forms, contributes to prion diseases, a group of fatal, neurodegenerative disorders. The pathway described shows that activation of PRNP leads to NMDAR, which increases intracellular calcium, and through the mitochondrial calcium uniporter (MCU), calcium is imported into mitochondria. This can lead to mitochondrial dysfunction, opening of the mitochondrial permeability transition pore (MPTP), and release of cytochrome c (CYCS), initiating apoptosis via APAF1, CASP9, and CASP3. This sequence is associated with neuronal damage and death. The disease most directly linked to PRNP mutations is Creutzfeldt-Jakob disease (CJD). \n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, specifically the variant associated with the prion protein (PRNP), contributes to prion disease, a group of neurodegenerative disorders. In this pathway, PRNP initiates a cascade involving NMDAR and Ca\u00b2\u207a influx, leading to mitochondrial calcium overload through MCU, potentially triggering the mitochondrial permeability transition pore (MPTP). This leads to the release of cytochrome c (CYCS), which activates APAF1 and downstream caspases (CASP9 and CASP3), promoting apoptosis. This mechanism is implicated in neurodegenerative conditions like Creutzfeldt-Jakob disease (CJD). \n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele encodes the prion protein, which is central to the prion disease pathway. Upon misfolding, it triggers a cascade leading to neurodegeneration. The pathway involves NMDA receptors, calcium influx, mitochondrial dysfunction through MCU and MPTP, and subsequent apoptosis via CYCS, APAF1, CASP9, and CASP3. This sequence is implicated in neurotoxicity and cell death.  \n\\boxed{Creutzfeldt-Jakob Disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the SOD1 gene, which encodes superoxide dismutase 1, an enzyme that normally detoxifies superoxide radicals. In this network, SOD1 is upstream of BCL2, a key regulator of apoptosis. If the SOD1 allele is dysfunctional, it may lead to accumulation of oxidative damage, which could reduce BCL2 activity, allowing BAX and BAK1 to activate, leading to mitochondrial outer membrane permeabilization, release of CYCS, and activation of the intrinsic apoptotic pathway via APAF1, CASP9, and CASP3. This excessive apoptosis is characteristic of neurodegenerative diseases. Mutations in SOD1 are strongly linked to amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disorder that leads to muscle atrophy and paralysis.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway describes a sequence of molecular events leading to apoptosis. SOD1, a critical antioxidant enzyme, is upstream and influences BCL2, which regulates apoptosis. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. These mutations can lead to the misfolding and aggregation of SOD1, resulting in motor neuron degeneration. The downstream elements of the pathway, including BAX, BAK1, CYCS, APAF1, CASP9, and CASP3, are key players in the intrinsic apoptotic pathway, suggesting that SOD1's dysfunction can disrupt normal apoptosis regulation, contributing to the disease pathogenesis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway outlines a molecular mechanism involving SOD1, a gene encoding superoxide dismutase 1, which is crucial for neutralizing superoxide radicals. The pathway suggests that a defect or mutation in SOD1 could lead to the activation of the intrinsic apoptotic pathway, as seen through the subsequent activation of BCL2, BAX, BAK1, CYCS, APAF1, CASP9, and CASP3. This sequence is central to programmed cell death. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. Accumulation of misfolded SOD1 protein can lead to oxidative stress and apoptosis, contributing to neuronal death in ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele contributes to the activation of a signaling pathway that promotes cell proliferation and survival. Starting with MET, the pathway activates GRB2, which recruits SOS, leading to RAS activation. Activated RAS phosphorylates RAF, which in turn activates MEK, resulting in the activation of ERK. ERK then phosphorylates and upregulates CCND1, promoting the G1/S transition of the cell cycle. This pathway is frequently dysregulated in various cancers due to mutations or amplifications in the MET gene or downstream components. Such activation can lead to uncontrolled cell growth and tumor development. This pathway is commonly implicated in cancers like gastric cancer, papillary thyroid cancer, and some types of lung cancer.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, starting with the MET proto-oncogene, is involved in cellular processes such as survival, proliferation, and migration. Mutations in MET can lead to constitutive activation of this pathway, promoting uncontrolled cell growth. This pathway activates downstream effectors like GRB2, SOS, RAS, RAF, MEK, ERK, and ultimately CCND1, which is a key regulator of the cell cycle. Dysregulation of this pathway is implicated in various cancers, particularly those involving the RAS-RAF-MEK-ERK signaling cascade. The MET allele, when mutated or overexpressed, contributes to tumor development and progression. This pathway is frequently dysregulated in cancers such as non-small cell lung cancer, gastric cancer, and some types of melanoma. \n\n\\boxed{Lung Adenocarcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, as part of the defined pathway, is involved in a signaling cascade that leads to cell proliferation and survival through the activation of ERK and subsequent upregulation of CCND1. This pathway is frequently dysregulated in cancer, particularly when MET is overactive due to mutations or amplifications. Such dysregulation can lead to uncontrolled cell growth and tumor development. The MET pathway is notably implicated in several cancers, with a strong association to a specific type of lung cancer.\n\n\\boxed{Non-small cell lung cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination and degradation of proteins, particularly in the context of mitochondrial quality control. Mutations in PRKN are associated with early-onset parkinsonism. This gene is part of a pathway that includes MAO (monoamine oxidase) enzymes, which metabolize monoamines such as dopamine, leading to the formation of DOPAL, a neurotoxic compound. Impairment in this pathway can lead to the accumulation of DOPAL and subsequent neuronal damage, particularly in dopaminergic neurons. This contributes to the pathogenesis of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination and degradation of proteins. Mutations in PRKN are associated with Parkinson's disease (PD), particularly the autosomal recessive form. The pathway described includes PRKN and MAO (MAOA and MAOB), which are involved in dopamine metabolism. PRKN mutations lead to impaired mitochondrial function and increased oxidative stress, contributing to the degeneration of dopaminergic neurons in the substantia nigra, a hallmark of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination and degradation of proteins. Mutations in PRKN are a major cause of early-onset Parkinson\u2019s disease (PD), an inherited neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. The pathway described includes PRKN, which may be involved in mitochondrial quality control and autophagy. The network also involves MAO, which metabolizes dopamine to DOPAL, a neurotoxic compound. Dysfunctional parkin may impair mitochondrial function, increase oxidative stress, and contribute to dopaminergic neuron death, thus playing a crucial role in the pathogenesis of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene, located on chromosome 17, encodes the tumor suppressor protein p53, which is central to the DNA damage response and apoptosis. The described pathway involves TP53 regulating genes such as CDKN1A, GADD45A/B/G, BAX, BAK1, DDB2, and POLK, all of which are involved in cell cycle arrest, DNA repair, and programmed cell death. Mutations in TP53 can disrupt this pathway, leading to genomic instability and uncontrolled cell proliferation. Loss of TP53 function is a hallmark of many cancers, as it eliminates a key barrier to malignant transformation. This gene is frequently mutated in a variety of human cancers, particularly in Li-Fraumeni syndrome, a hereditary condition that predisposes individuals to multiple types of cancer.\n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene encodes the p53 protein, a critical tumor suppressor involved in regulating the cell cycle, DNA repair, and apoptosis. The given pathway highlights TP53's role in activating downstream genes such as CDKN1A, GADD45A/B/G, BAX, BAK1, DDB2, and POLK, which are involved in DNA repair, cell cycle arrest, and apoptosis. Mutations in TP53 can lead to loss of its tumor suppressive function, resulting in uncontrolled cell proliferation and genomic instability. Such mutations are commonly found in a variety of cancers, including Li-Fraumeni syndrome, a hereditary cancer predisposition syndrome. The TP53 allele with these network interactions is strongly associated with increased cancer risk.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene, located on chromosome 17, encodes the tumor protein p53, a key regulator of apoptosis, cell cycle arrest, and DNA repair. The pathway defined by TP53 interacting with CDKN1A, GADD45 (A, B, G), BAX, BAK1, DDB2, and POLK indicates its central role in DNA damage response and apoptosis. Mutations in TP53 can lead to loss of function, disrupting these critical processes and allowing damaged cells to survive, leading to uncontrolled cell proliferation and tumorigenesis. This is a well-known cause of various cancers, particularly Li-Fraumeni syndrome, a hereditary condition characterized by a high risk of developing multiple types of cancer at an early age. \n\n\\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe described pathway begins with the amyloid beta precursor protein (APP), which is cleaved to produce A\u03b2 peptides. These peptides trigger a cascade involving the GRM5 receptor and downstream signaling through GNAQ, PLCB, IP3, and ITPR, leading to an increase in intracellular Ca\u00b2\u207a levels. Elevated Ca\u00b2\u207a promotes mitochondrial Ca\u00b2\u207a uptake via MCU, potentially leading to mitochondrial permeability transition pore (MPTP) opening. This results in the release of cytochrome c (CYCS), which activates APAF1 and subsequent caspases (CASP9, CASP3), promoting apoptosis. This pathway is closely related to Alzheimer's disease, where abnormal APP processing and A\u03b2 accumulation are key features. The pathway reflects the neurodegenerative processes involving amyloid pathology and apoptosis. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway outlines a sequence beginning with the Amyloid Beta Precursor Protein (APP) which is central to the production of amyloid-beta (Abeta). Abeta accumulation is a hallmark of Alzheimer's disease. This pathway continues through a series of molecular interactions involving calcium signaling and mitochondrial permeability transition, ultimately leading to apoptosis. Key players include GRM5, GNAQ, PLCB, ITPR, MCU, and others involved in calcium regulation and mitochondrial function. The activation of CASP3, a key executor of apoptosis, suggests that this pathway is involved in neuronal cell death. The involvement of APP and its downstream effects aligns with the pathophysiology of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe described pathway outlines a sequence from the amyloid precursor protein (APP) to the activation of caspase 3, which is a key executor of apoptosis. This cascade is primarily associated with Alzheimer's disease (AD), where the accumulation of \u03b2-amyloid (Abeta) fragments leads to mitochondrial dysfunction, calcium dysregulation, and apoptosis. The involvement of GRM5, PLCB, IP3, and ITPR indicates activation of the inositol trisphosphate (IP3) pathway, which increases intracellular calcium levels. Elevated calcium activates the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS) and initiating the intrinsic apoptotic pathway via APAF1 and caspase 9, ultimately leading to caspase 3 activation. This pathway is implicated in neuronal death seen in AD.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele is associated with prion diseases, a group of rare, transmissible neurodegenerative disorders. These diseases, including Creutzfeldt-Jakob disease (CJD), are caused by the misfolding of the prion protein (PrP). The pathway begins with PRNP, which interacts with RYR and ITPR, leading to calcium release and mitochondrial calcium uptake via MCU. This calcium dysregulation can trigger the mitochondrial permeability transition pore (MPTP), resulting in cytochrome c release and activation of the apoptotic cascade via APAF1, CASP9, and CASP3. This sequence contributes to neuronal death and disease progression. \n\n\\boxed{Prion disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele is associated with prion diseases, a group of fatal neurodegenerative disorders. The pathway outlined demonstrates how PRNP interacts with calcium release and mitochondrial permeability transition pore (MPTP) activation, leading to cytochrome c (CYCS) release and subsequent apoptotic cascades involving APAF1, CASP9, and CASP3. This process links PRNP dysfunction to neurodegeneration through calcium deregulation and apoptosis. The biological effect of specific PRNP alleles, such as those encoding disease-associated prion proteins, is the induction of these pathologic processes, resulting in conditions like Creutzfeldt-Jakob disease (CJD).\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, specifically the prion protein, is central to a pathway involving calcium dysregulation and apoptosis. PRNP activates RYR and ITPR, leading to increased cytoplasmic Ca\u00b2\u207a, which enters mitochondria via MCU. This triggers the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS) and initiating the intrinsic apoptotic pathway through APAF1, CASP9, and CASP3. This sequence suggests a role in neurodegenerative processes involving excessive apoptosis. The PRNP gene is most notably associated with prion diseases, such as Creutzfeldt-Jakob disease. These diseases involve misfolded prion proteins that lead to neuronal damage and death. Thus, this PRNP allele contributes to \\boxed{Creutzfeldt-Jakob disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the dismutation of superoxide radicals into oxygen and hydrogen peroxide, playing a critical role in protecting cells from oxidative damage. Mutations in the SOD1 gene are strongly associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations lead to the production of a toxic, misfolded SOD1 protein that accumulates in motor neurons, triggering their degeneration. This pathway involves the proteasome system, which is responsible for degrading misfolded proteins. However, the DERL1 gene, which is part of this pathway, may be involved in the recognition and targeting of proteins for proteasomal degradation. Dysfunction in this pathway can result in the accumulation of toxic SOD1, contributing to the progression of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an antioxidant enzyme that plays a critical role in protecting cells from oxidative damage by catalyzing the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in the SOD1 gene are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by progressive weakness and death of motor neurons. These mutations often lead to misfolding and aggregation of the SOD1 protein, which may result in toxicity to motor neurons. The provided pathway appears to involve proteasome-mediated degradation of misfolded or ubiquitinated proteins, suggesting that SOD1's function or dysfunction may be linked to the proteasome system, contributing to the disease pathology of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that detoxifies superoxide radicals. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The pathway described involves SOD1 interacting with DERL1, leading to the ubiquitination and proteasomal degradation of proteins. This suggests that SOD1 may be involved in protein quality control and degradation processes. Dysfunctional SOD1 can lead to the accumulation of toxic protein aggregates, contributing to neuronal degeneration. Therefore, the biological effect of this SOD1 allele is the contribution to the development of amyotrophic lateral sclerosis (ALS).\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase involved in signaling pathways regulating cell growth, differentiation, and survival. Mutations or dysregulation of ERBB4 have been implicated in several diseases. In the context of the NRG // ERBB4* pathway, ERBB4 is a key player in interactions with neuregulins (NRG1-NRG4), which are involved in developmental processes and synaptic plasticity. Dysfunctional ERBB4 signaling is associated with neurodevelopmental and neurodegenerative disorders. Specifically, it has been linked to schizophrenia, as genetic variations in ERBB4 have been identified in genome-wide association studies (GWAS) related to this condition. ERBB4 also plays a role in breast cancer, where it can act as a tumor suppressor or contribute to cancer progression depending on the context.\n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a key role in neuronal development and function. It is involved in signal transduction pathways, often in conjunction with ligands such as neuregulins (NRG1-4). Mutations or alterations in ERBB4 can disrupt these signaling processes, leading to neurodevelopmental disorders. Specifically, ERBB4 has been implicated in autism spectrum disorder (ASD), as it is associated with synaptic plasticity and brain connectivity. Variants in ERBB4 may contribute to the etiology of ASD by affecting neural circuit formation and function. \n\n\\boxed{Autism Spectrum Disorder}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele is involved in the NRG-ERBB4 signaling pathway, which plays a critical role in neuronal development, synaptic function, and myelination. Disruption or mutations in ERBB4 can lead to impaired signaling, affecting neurodevelopment and function. This pathway's dysregulation has been linked to psychiatric and neurodevelopmental disorders, particularly schizophrenia. Studies have shown that genetic variations in ERBB4 may contribute to the risk of developing schizophrenia by altering the structure or function of the ErbB4 receptor, which is essential in the central nervous system. Thus, the biological effect of this ERBB4 allele is its contribution to the etiology of schizophrenia.\n\n\\boxed{Schizophrenia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the molecular pathway HTT* -> MLK2 -> MKK7 -> JNK. This pathway is involved in stress response and apoptosis. Mutations in the HTT gene, specifically CAG trinucleotide repeat expansions, lead to the production of a mutant huntingtin protein. This mutant protein causes conformational changes and aggregation, leading to neuronal dysfunction and death. These pathological processes are characteristic of Huntington's disease, an inherited neurodegenerative disorder. The altered HTT allele disrupts normal cellular signaling, contributing to the progressive loss of motor control, cognitive decline, and psychiatric symptoms associated with Huntington's disease.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is associated with the pathogenesis of Huntington's disease. This neurodegenerative disorder is caused by a CAG trinucleotide repeat expansion in the HTT gene, leading to the production of a mutant huntingtin protein. This mutant protein causes progressive degeneration of neurons in the brain, particularly in the basal ganglia and cerebral cortex. The pathway described\u2014HTT* -> MLK2 -> MKK7 -> JNK\u2014suggests that the mutant HTT protein may activate a stress-activated protein kinase (JNK) signaling cascade, which has been implicated in neuronal apoptosis and dysfunction. This pathway could contribute to the neurodegeneration observed in Huntington's disease.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the molecular pathway HTT* -> MLK2 -> MKK7 -> JNK. Mutations in the HTT gene, specifically expansions of CAG trinucleotide repeats, lead to the production of a mutant huntingtin protein that disrupts normal cellular functions, particularly in neurons. This disruption is implicated in the progressive degeneration of nerve cells in specific regions of the brain, leading to the neurodegenerative disorder Huntington's disease. Huntington's disease is characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. The pathway involving MLK2, MKK7, and JNK is linked to stress response and apoptosis, further explaining the neuronal loss observed in the disease. \n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in developmental processes and neural function. When activated by ligands such as NRG1, it influences cell signaling pathways important in brain development and function. Mutations or dysregulation in ERBB4 have been implicated in autism spectrum disorders (ASD). This pathway, involving NRG and ERBB4, is crucial for proper neuronal connectivity and synaptic function. Disruption of this pathway can lead to impaired neural circuitry, contributing to the neurodevelopmental features of ASD. \n\n\\boxed{Autism Spectrum Disorder}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele, when interacting with NRG ligands, plays a crucial role in neurodevelopment, myelination, and neural circuit formation. Mutations or dysregulation of ERBB4 can disrupt these processes. This pathway is particularly implicated in developmental and psychiatric disorders. Specifically, ERBB4 has been associated with schizophrenia, where it contributes to altered synaptic plasticity and connectivity in the brain. \n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele is part of the NRG // ERBB4 pathway, which involves neuregulins (NRG1-4) and the ERBB4 receptor. ERBB4 is a tyrosine kinase receptor that, when activated by neuregulins, plays a role in various cellular processes such as growth, differentiation, and survival. Mutations or dysregulation in ERBB4 can lead to impaired signaling, potentially contributing to developmental and neurologic disorders. ERBB4 has been implicated in schizophrenia, where it may affect brain development and synaptic function. Additionally, ERBB4 alterations have been associated with breast cancer and other cancers due to its involvement in cell proliferation and survival pathways. The biological effect of this ERBB4 allele is therefore most directly linked to schizophrenia.\n\n\\boxed{Schizophrenia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive juvenile Parkinson\u2019s disease (PJD). The pathway described shows PRKN interacting with MAO (monoamine oxidase) and leading to DOPAL (dopamine aldehyde), indicating a role in dopamine metabolism. Dysfunction of parkin may impair the degradation of damaged proteins, leading to accumulation and subsequent neuronal degeneration, particularly in dopaminergic neurons in the substantia nigra, a hallmark of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination and subsequent degradation of proteins. Mutations in PRKN are associated with autosomal recessive early-onset Parkinson's disease (PD). The pathway described includes PRKN and MAO enzymes, which are involved in the metabolism of dopamine. The PRKN allele contributes to the pathogenesis of Parkinson's disease by impairing the degradation of damaged proteins, leading to the accumulation of toxic proteins and the degeneration of dopaminergic neurons in the substantia nigra. This results in the characteristic motor symptoms of PD, such as tremors, rigidity, and bradykinesia.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination and degradation of proteins. Mutations in PRKN are associated with early-onset autosomal recessive Parkinson's disease. The pathway involves PRKN interacting with MAO (MAOA/MAOB), which catalyze the oxidation of dopamine to DOPAL, a neurotoxin. This interaction may influence dopaminergic neuron survival. PRKN's role in mitochondrial quality control and dopamine metabolism suggests its involvement in neuronal health. Genetic defects in PRKN can impair these functions, leading to neurodegeneration. Therefore, the biological effect of a PRKN allele with pathogenic variants is contributing to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen, playing a critical role in antioxidant defense. The pathway described involves the endoplasmic reticulum (ER) stress response, beginning with SOD1, which may be influenced by oxidative stress. This leads to activation of the unfolded protein response (UPR) through the PERK pathway, involving EIF2AK3 (PERK), EIF2S1 (eIF2\u03b1), and ATF4, ultimately leading to the induction of DDIT3 (CHOP), a key mediator of ER stress-induced apoptosis. Dysregulation of this pathway is implicated in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS), where SOD1 mutations are a known cause. These mutations can lead to protein misfolding, ER stress, and neuronal death.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described shows a molecular cascade initiated by SOD1, which is linked to BIP (also known as HSPA5), a chaperone protein involved in the unfolded protein response (UPR). This pathway leads to the activation of EIF2AK3 (PERK), which phosphorylates EIF2S1, ultimately leading to the activation of ATF4 and the expression of DDIT3 (CHOP), a key mediator of endoplasmic reticulum (ER) stress-induced apoptosis. SOD1 mutations are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. These mutations can lead to the misfolding and aggregation of SOD1, causing ER stress and subsequent activation of this pathway, culminating in neuronal death. \n\n\\boxed{Amyotrophic lateral sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves SOD1, which is linked to BIP, EIF2AK3, EIF2S1, ATF4, and DDIT3. This network is associated with the unfolded protein response (UPR) and oxidative stress pathways. SOD1 is an enzyme that catalyzes the dismutation of superoxide radicals into oxygen and hydrogen peroxide. Mutations in the SOD1 gene are primarily linked to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. These mutations lead to the production of misfolded SOD1 protein, which can accumulate and cause cellular toxicity, particularly in motor neurons, leading to the clinical symptoms of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in mitochondrial quality control via the ubiquitin-proteasome system. Mutations in PRKN are a major cause of autosomal recessive early-onset Parkinson's disease (EOPD). These mutations often result in loss of parkin function, leading to impaired mitochondrial function, increased oxidative stress, and neuronal degeneration, particularly in dopaminergic neurons of the substantia nigra. This contributes to the classic motor symptoms of Parkinson's disease, such as bradykinesia, rigidity, and resting tremor. The pathway elements mentioned, including ubiquitin-conjugating enzymes and ubiquitin ligases, are all involved in the ubiquitination process, which is critical for the proper degradation of misfolded or damaged proteins. Dysfunction in this pathway exacerbates neurodegenerative processes. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination and degradation of misfolded or damaged proteins. Mutations in PRKN are a major cause of early-onset autosomal recessive Parkinson's disease (PD). The pathway described involves components of the ubiquitin-proteasome system, including ubiquitin conjugating enzymes (UBCH7/8 and UBE2L3/UBE2L6), and SNCAIP, which interacts with alpha-synuclein. Dysfunctional parkin may lead to the accumulation of toxic proteins, particularly alpha-synuclein, contributing to neuronal degeneration in the substantia nigra. This pathway disruption is implicated in the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a common cause of early-onset autosomal recessive Parkinson's disease. This pathway, involving PRKN, UBCH7/8, and UBE2L3/UBE2L6, is crucial for the ubiquitination and degradation of misfolded or damaged proteins. Disruption in this process can lead to the accumulation of toxic proteins, contributing to neuronal degeneration. Specifically, PRKN mutations impair mitochondrial function and lead to the loss of dopaminergic neurons, hallmark features of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive juvenile Parkinson's disease (AR-JP). The pathway includes ubiquitin conjugating enzymes (UBCH7/8 and UBE2L3/UBE2L6) and the ubiquitin receptor PAELR, suggesting a role in protein degradation and quality control. PRKN mutations lead to impaired mitochondrial function and increased neuronal vulnerability, contributing to neurodegeneration. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin-protein ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a common cause of early-onset autosomal recessive Parkinson's disease (PD). Parkin plays a critical role in mitochondrial quality control by targeting damaged mitochondria for degradation via mitophagy. Loss-of-function mutations in PRKN impair this process, leading to the accumulation of defective mitochondria and subsequent neuronal degeneration, particularly in dopaminergic neurons of the substantia nigra. This contributes to the progressive loss of motor function characteristic of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive juvenile parkinsonism, also known as Parkinson disease 6 (PD6). This pathway, involving ubiquitin conjugating enzymes (UBCH7/8) and other components like PAELR and GPR37, plays a role in mitochondrial quality control and protein degradation. Dysfunction in this pathway due to PRKN mutations can lead to impaired mitochondrial function and accumulation of damaged proteins, contributing to neurodegeneration. \n\n\\boxed{Parkinson disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene is a key component of the MAPK/ERK signaling pathway, and mutations in BRAF can lead to constitutive activation of this pathway, promoting uncontrolled cell proliferation. The given pathway (BRAF* -> MEK -> ERK) indicates that a mutated BRAF allele (BRAF*) is activating the downstream components MEK and ERK. This aberrant activation is commonly observed in several cancers, particularly melanoma, where the V600E mutation in BRAF is frequently found. This mutation leads to continuous signaling through the MEK-ERK cascade, contributing to tumor growth and progression.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene encodes a serine/threonine kinase that plays a key role in the MAPK/ERK signaling pathway, which is essential for cell growth, differentiation, and survival. Mutations in BRAF, particularly the V600E mutation, lead to constitutive activation of the BRAF kinase, resulting in continuous activation of the MEK-ERK cascade. This uncontrolled signaling promotes unregulated cell proliferation and can lead to the development of various cancers. Specifically, BRAF V600E mutations are commonly found in melanoma, a type of skin cancer, and are also associated with certain thyroid cancers, colorectal cancers, and others. These mutations are a major driver in tumorigenesis and are often targeted in cancer therapy.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene is part of the MAP kinase signaling pathway, which is crucial for cell growth and proliferation. Mutations in BRAF, particularly the V600E mutation, lead to constitutive activation of the BRAF kinase, which continuously activates MEK and ERK downstream. This uncontrolled activation promotes cell proliferation and survival, contributing to the development of cancer. The BRAF V600E mutation is commonly found in melanoma, a type of skin cancer, and also in other malignancies such as thyroid cancer, colorectal cancer, and hairy cell leukemia. This mutation is a key driver in these cancers and is a target for therapeutic intervention with BRAF inhibitors.  \n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor protein that is cleaved into saposins, which are essential for the activity of several lysosomal enzymes, including GBA (glucosylceramidase beta) and GALC (galactosylceramidase). Mutations in PSAP can lead to a deficiency in saposins, impairing the function of these enzymes. This results in the accumulation of their substrates, such as glucosylceramide and galactosylceramide, in lysosomes. This condition is associated with a group of lysosomal storage diseases known as saposin-related disorders. Specifically, mutations in PSAP are linked to a neurodegenerative disorder called **Saposin B deficiency**, which is also known as **Krabbe disease** when caused by GALC deficiency. However, PSAP mutations more specifically contribute to **Saposin B deficiency**, a rare autosomal recessive disorder. \n\n\\boxed{Saposin B deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the activity of several lysosomal enzymes, including glucosylceramidase beta (GBA) and galactosylceramidase (GALC). Mutations in PSAP can lead to reduced saposin function, impairing the activity of these enzymes. This results in the accumulation of lipids within lysosomes, leading to the development of a rare, inherited metabolic disorder known as saposin deficiency, which is a form of lysosomal storage disease. Specifically, mutations in PSAP are associated with Krabbe disease, a severe neurodegenerative disorder caused by a deficiency in GALC, which is dependent on saposin for its function. Thus, the PSAP allele contributes to Krabbe disease.\n\n\\boxed{Krabbe disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the activity of lysosomal enzymes such as GBA (glucosylceramidase beta) and GALC (galactosylceramidase). Mutations in PSAP can lead to a deficiency in saposins, impairing the function of these enzymes. This defect results in the accumulation of substrates like glucosylceramide and galactosylceramide, which are normally metabolized by GBA and GALC, respectively. This pathway is central to the lysosomal storage disorder known as Krabbe disease, but more commonly, deficiencies in GBA are associated with Gaucher disease. However, PSAP mutations are directly linked to a rare disorder called Saposin deficiency, which can present with neurological symptoms and is sometimes classified under a group of diseases known as metachronologic leukodystrophies. \n\n\\boxed{Krabbe disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes for ataxin-3, a protein involved in the ubiquitin-proteasome system. A missense mutation in ATXN3 leads to the expansion of a CAG trinucleotide repeat, which causes the production of a toxic, unstable protein. This mutation is responsible for spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. SCA3 is a neurodegenerative disorder characterized by progressive loss of motor control, ataxia, and other neurological symptoms. The presence of ATXN3* in the pathway suggests its involvement in calcium signaling, which may contribute to neuronal dysfunction and cell death in SCA3.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in the ubiquitin-proteasome system. A pathogenic allele of ATXN3, specifically with expansions of CAG trinucleotide repeats, leads to the development of spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive ataxia, dystonia, and other neurological symptoms due to the toxic accumulation of misfolded ataxin-3 in neurons. The expanded ATXN3 allele contributes to the dysfunction of the glutamate signaling pathway, affecting calcium homeostasis and mitochondrial function, which are integral to the disease's pathogenesis.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is involved in a signaling pathway that begins with glutamate acting on the GRM1 receptor, leading to the production of IP3, which triggers calcium release through ITPR1. ATXN3, along with ATXN2, modulates this process. Mutations in ATXN3 are associated with a neurodegenerative disorder known as spinocerebellar ataxia type 3 (SCA3), also called Machado-Joseph disease. This condition is characterized by progressive degeneration of the cerebellum and other brain regions, resulting in loss of coordination, muscle stiffness, and other neurological symptoms. The involvement of ATXN3 in calcium signaling pathways suggests that dysregulation of these pathways may contribute to neuronal dysfunction and cell death in SCA3.\n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene encodes the tumor suppressor protein p53, which is crucial in regulating the cell cycle and initiating apoptosis in response to DNA damage. The provided pathway includes genes like CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, all involved in DNA repair, apoptosis, and cell cycle arrest. Mutations in TP53 can disrupt these processes, leading to uncontrolled cell growth and tumorigenesis. Loss of p53 function is commonly observed in various cancers, especially in Li-Fraumeni syndrome, a hereditary disorder with a high predisposition to multiple types of cancer.\n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene, located on chromosome 17, is a tumor suppressor gene that plays a central role in regulating the cell cycle, DNA repair, and apoptosis. When functioning properly, TP53 helps prevent the formation of tumors by stopping the growth of damaged cells or inducing their death. However, mutations in TP53 can lead to its dysfunction, allowing damaged cells to continue dividing and potentially forming tumors. This gene is frequently mutated in a wide range of cancers, including breast, ovarian, lung, and colorectal cancers. The pathway defined includes genes involved in DNA repair (DDB2, POLK), cell cycle arrest (CDKN1A, GADD45A/B/G), and apoptosis (BAX, BAK1), which are all regulated by TP53. Dysfunctional TP53 disrupts these critical processes, contributing to uncontrolled cell growth and tumorigenesis. \n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene, located on chromosome 17, encodes the p53 protein, a critical tumor suppressor involved in regulating the cell cycle and initiating apoptosis in response to DNA damage. The defined pathway includes genes like CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, all of which are downstream effectors of p53 in responses to stress, DNA repair, and apoptosis. Mutations in TP53 can disrupt these pathways, leading to uncontrolled cell proliferation and tumor formation. Germline mutations in TP53 are strongly associated with Li-Fraumeni syndrome, a hereditary disorder that predisposes individuals to a wide range of cancers, including sarcomas, breast cancer, and brain tumors. Therefore, the biological effect of a dysfunctional TP53 allele is the development of multiple cancers.\n\n\\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a component of the gamma-secretase complex involved in the proteolytic processing of amyloid precursor protein (APP). This pathway, as defined, involves PSEN1 activating GSK3B, which in turn modulates the kinesin motor complex (KIF5+KLC). Dysregulation in this pathway can lead to abnormal tau phosphorylation and amyloid-beta production, both of which are hallmarks of Alzheimer's disease. Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease. These mutations disrupt normal gamma-secretase function, leading to increased production of amyloid-beta peptides, which aggregate and form plaques in the brain, contributing to neurodegeneration and cognitive decline. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key component of the gamma-secretase complex, which is involved in the cleavage of amyloid precursor protein (APP) to produce amyloid-beta peptides. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease. In the provided pathway, PSEN1 activates GSK3B, which phosphorylates tau protein, a hallmark of Alzheimer's pathology. GSK3B also interacts with kinesin motor complexes (KIF5 and KLC), which are involved in intracellular transport. Dysregulation of this pathway due to PSEN1 mutations may impair normal tau phosphorylation and axonal transport, leading to neurodegeneration. Therefore, the biological effect of PSEN1 alleles contributing to this pathway is primarily linked to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex involved in the proteolytic processing of amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). These mutations can lead to altered cleavage of APP, resulting in increased production of amyloid-beta 42, a toxic peptide that accumulates in the brain and is a hallmark of AD pathology. The pathway involves PSEN1 regulating GSK3B, which in turn influences the activity of kinesin motors (KIF5) and light chains (KLC), potentially impacting intracellular transport and neuronal function. Dysregulation in this pathway contributes to neurodegeneration and the clinical symptoms of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS gene encodes the Gs alpha subunit, a key component of the G protein-coupled receptor signaling pathway. In the given pathway, GNAS activates ADCY, leading to cAMP production, which in turn activates PKA and CREB, ultimately influencing ACTH. Mutations in GNAS can disrupt this signaling cascade, affecting hormone regulation. A notable disease associated with GNAS mutations is pseudohypoparathyroidism, which results from resistance to parathyroid hormone due to impaired Gs alpha function. This leads to hypocalcemia and hyperphosphatemia. Another associated condition is Albright hereditary osteodystrophy, characterized by skeletal abnormalities and end-organ resistance toPTH. The GNAS allele therefore contributes to endocrine disorders involving hormone signaling defects. $\\boxed{\\text{Pseudohypoparathyroidism}}$", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS gene encodes the \u03b1-subunit of the stimulatory G protein (Gs\u03b1), which is a critical component of the cAMP signaling pathway. Mutations in GNAS can lead to dysregulation of this pathway, affecting multiple downstream\u6548\u5e94 such as cAMP production, PKA activation, and CREB-mediated transcription. This pathway is involved in various cellular processes, including proliferation, differentiation, and hormone secretion. Gain-of-function mutations in GNAS are associated with conditions like McCune-Albright syndrome, characterized by fibrous dysplasia of bone, precocious puberty, and skin abnormalities. Loss-of-function mutations in GNAS can cause pseudohypoparathyroidism, a disorder marked by resistance to parathyroid hormone. The specific biological effect of GNAS alleles depends on the mutation type and the tissue context, but they are often implicated in endocrine and skeletal disorders.\n\n\\boxed{McCune-Albright syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS gene encodes the Gs alpha subunit, which is crucial in the cAMP signaling pathway. Mutations in GNAS can lead to dysfunctional Gs proteins, impairing the activation of ADCY and downstream effectors like PKA, CREB, and ultimately ACTH. This can disrupt critical cellular functions, particularly in tissues dependent on cAMP signaling. In the context of POMC, which is involved in ACTH production, such disruptions can impair hormone regulation. This pathway's dysfunction is strongly associated with **Albright hereditary osteodystrophy (AHO)**, which includes features like pseudohypoparathyroidism and fibrous dysplasia. These conditions arise due to resistance to parathyroid hormone and other Gs-coupled hormone receptors, leading to end-organ resistance and abnormal skeletal development.\n\n\\boxed{Albright hereditary osteodystrophy}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key component of the gamma-secretase complex, which is involved in the cleavage of amyloid precursor protein (APP) to produce amyloid-beta peptides. These peptides accumulate in the brain and are a hallmark of Alzheimer's disease. The pathway described includes PSEN1, which activates GSK3B, a kinase known to phosphorylate tau protein. This leads to the formation of neurofibrillary tangles, another hallmark of Alzheimer's disease. The KIF5 and KLC proteins are involved in intracellular transport, and their interaction with GSK3B may modulate the pathology. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease. Therefore, the biological effect of this PSEN1 allele is the contribution to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, which is a critical component of the gamma-secretase complex involved in the proteolytic cleavage of amyloid precursor protein (APP). This pathway, defined by PSEN1 \u2192 GSK3B -| (KIF5+KLC), suggests a regulatory interaction involving GSK3B and the kinesin motor complex. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). These mutations impair the function of gamma-secretase, leading to increased production of amyloid-beta peptides, which accumulate as plaques in the brain\u2014hallmark features of AD. The effect of the PSEN1 allele, therefore, is the promotion of amyloid-beta pathogenesis, contributing to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a critical component of the gamma-secretase complex, which is involved in the proteolytic processing of amyloid precursor protein (APP). This processing generates amyloid-beta (A\u03b2) peptides, which are central to the pathology of Alzheimer's disease. The pathway defined includes PSEN1 activating GSK3B, which in turn phosphorylates tau protein. Phosphorylated tau aggregates into neurofibrillary tangles, a hallmark of Alzheimer's disease. Additionally, GSK3B modulates the function of KIF5 and KLC proteins, which are involved in intracellular transport. Dysregulation in this pathway is implicated in the accumulation of A\u03b2 and tau, leading to neuronal dysfunction and degeneration. This genetic pathway is intimately involved in the development of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a cyclin-dependent kinase inhibitor that plays a critical role in regulating the cell cycle and acting as a tumor suppressor. Mutations or loss of function in CDKN2A can lead to uncontrolled cell proliferation, a hallmark of cancer. In the provided pathway, CDKN2A negatively regulates MDM2, which in turn regulates TP53, a key tumor suppressor protein. When CDKN2A is dysfunctional, MDM2 can inappropriately inhibit TP53, preventing its activation of CDKN1A and subsequent inhibition of the G1/S transition through RB1 and E2F pathways. This dysregulation contributes to the development of melanoma and other cancers. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a cyclin-dependent kinase inhibitor that plays a critical role in cell cycle regulation and acts as a tumor suppressor. Mutations or loss of function in CDKN2A can lead to uncontrolled cell proliferation, contributing to the development of cancer. Specifically, germline mutations in CDKN2A are associated with familial melanoma and other cancers, including neurofibromatosis type 1 and certain types of lung cancer. The CDKN2A pathway, as defined, links to TP53 and RB1, key players in the p53 and Rb tumor suppressor pathways, which are frequently disrupted in various malignancies. The disruption of this network can impair the ability of cells to undergo apoptosis or halt the cell cycle in response to DNA damage, promoting tumorigenesis. Therefore, the biological effect of a defective CDKN2A allele contributes to the development of cancer.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a tumor suppressor protein that regulates the cell cycle by inhibiting cyclin-dependent kinases. In the provided pathway, CDKN2A is upstream of MDM2, which negatively regulates TP53. TP53 activates CDKN1A, which in turn inhibits cyclin D and CDK4/6, preventing the inactivation of RB1. RB1, when active, suppresses E2F, a transcription factor involved in cell cycle progression. Mutations in CDKN2A can disrupt this pathway, leading to uncontrolled cell proliferation. This disruption is commonly associated with melanoma and some forms of neuroendocrine tumors. Thus, the CDKN2A allele contributes to the development of melanoma.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described reflects the Wnt/\u03b2-catenin signaling cascade, where CTNNB1 (\u03b2-catenin) is a key mediator. When the negative regulators (GSK3B, AXIN, APC) are inactivated or mutated, CTNNB1 becomes stabilized and translocates to the nucleus, activating TCF/LEF transcription factors. This leads to the upregulation of target genes such as BIRC5, MYC, and CCND1, which are involved in cell proliferation and survival. Dysregulation of this pathway is commonly observed in colorectal cancer and other cancers. The CTNNB1 allele described contributes to uncontrolled cell growth, a hallmark of malignant transformation. \n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CTNNB1 allele is a central component of the Wnt/\u03b2-catenin signaling pathway. When CTNNB1 is stabilized and accumulates in the nucleus, it binds to TCF/LEF transcription factors to activate downstream target genes, such as BIRC5, MYC, and CCND1, which promote cell proliferation and survival. Mutations or dysregulation of CTNNB1 can lead to constitutive activation of this pathway, contributing to uncontrolled cell growth. This pathway is frequently dysregulated in colorectal cancer (CRC). The activation of genes like MYC and CCND1, which drive cell cycle progression, is a hallmark of CRC. Therefore, the CTNNB1 allele contributes to the development of $\\boxed{\\text{Colorectal Cancer}}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described is a canonical Wnt signaling pathway. CTNNB1 (\u03b2-catenin) is central to this pathway; its stabilization leads to the activation of TCF/LEF transcription factors, which in turn upregulate the expression of target genes such as BIRC5, MYC, and CCND1. These genes are involved in cell proliferation and survival. When CTNNB1 is dysregulated \u2014 for instance, due to mutations that prevent its degradation \u2014 it can lead to uncontrolled activation of this pathway. This dysregulation is commonly observed in colorectal cancer, where inactivating mutations in APC, or activating mutations in CTNNB1 itself, result in constitutive Wnt signaling. This persistent signaling promotes tumor growth and is a hallmark of the disease.\n\n\\boxed{Colorectal Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 gene encodes sigma non-opioid intracellular receptor 1, which is implicated in calcium signaling and mitochondrial function. Its involvement in the pathway suggests a role in calcium homeostasis and mitochondrial permeability transition. Disruption of this pathway may lead to mitochondrial dysfunction and cytochrome c release, contributing to apoptosis. Given its connection to calcium signaling and mitochondrial integrity, SIGMAR1 may be associated with neurodegenerative diseases, specifically Parkinson's disease, where mitochondrial dysfunction and altered calcium dynamics are key pathogenic features.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 gene encodes a protein involved in intracellular signaling and calcium regulation. Within the provided pathway, SIGMAR1 activates ITPR, which triggers the release of Ca\u00b2\u207a. This calcium then enters the mitochondria via MCU, possibly leading to the opening of MPTP and the release of CYCS, a key step in apoptosis. Dysregulation of this pathway can contribute to excessive mitochondrial calcium uptake and apoptosis, which may be implicated in neurodegenerative diseases. Specifically, mutations in SIGMAR1 have been associated with Alzheimer's disease, where impaired calcium homeostasis and mitochondrial dysfunction play significant roles in neuronal loss. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 gene encodes a protein involved in intracellular calcium signaling, functioning as a non-opioid receptor. It is part of a pathway that includes ITPR (inositol 1,4,5-trisphosphate receptors), which regulate calcium release into the cytoplasm, and MCU (mitochondrial calcium uniporter), which transports calcium into mitochondria. Dysregulation of this pathway may lead to mitochondrial dysfunction, increased permeability of the mitochondrial membrane via MPTP, and cytochrome c release, all of which are linked to apoptosis and neurodegeneration. Mutations or dysregulation of SIGMAR1 could impair calcium homeostasis, contributing to neurodegenerative conditions. Evidence suggests that SIGMAR1 is associated with Alzheimer\u2019s disease, possibly through its role in amyloid-\u03b2 pathology and mitochondrial dysfunction.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves PINK1, a kinase involved in mitophagy, and its interaction with the HTRA2/TRAP1 complex, which regulates cytochrome c release and subsequent apoptosis via APAF1, CASP9, and CASP3. Mutations in PINK1 are known to cause autosomal recessive early-onset Parkinson's disease. This allele likely contributes to impaired mitochondrial quality control and apoptotic regulation, leading to neurodegeneration. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves PINK1, which is critical for mitochondrial quality control through the PINK1-Parkin pathway. When PINK1 is functional, it promotes the degradation of damaged mitochondria via mitophagy. In the provided pathway, PINK1 is linked to the activation of apoptotic signaling through a series of events leading to cytochrome c release and caspase activation. A loss-of-function mutation in PINK1 is associated with autosomal recessive Parkinson\u2019s disease. This is because PINK1 plays a protective role in neuronal cells, and its dysfunction leads to mitochondrial dysfunction, oxidative stress, and ultimately, neurodegeneration. This pathway is an example of how PINK1 participates in both mitochondrial health and apoptosis regulation, which are key in the pathogenesis of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele is involved in a genomic pathway that includes mitochondrial dysfunction and apoptosis. PINK1 is a serine/threonine kinase that plays a critical role in protecting mitochondria from stress and damage. The pathway outlined suggests a connection between PINK1 and the intrinsic apoptotic cascade, which is triggered by the release of cytochrome c (CYCS) and activation of APAF1, leading to caspase activation. Mutations in PINK1 are associated with early-onset Parkinson's disease, as PINK1 contributes to mitochondrial quality control. Dysfunction in this pathway may lead to neuronal death, a hallmark of Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is involved in the ubiquitin-proteasome system and is part of a network that includes components of the autophagy pathway, such as BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1. Pathogenic variants in ATXN3, particularly those causing expansion of a CAG trinucleotide repeat, are associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder leads to progressive degeneration of the cerebellum and brainstem, resulting in ataxia, ocular motor abnormalities, and other neurological symptoms. The involvement of ATXN3 in autophagy suggests that impaired protein degradation may contribute to the disease pathology.\n\n\\boxed{Spinocerebellar ataxia type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of coordination, muscle stiffness, and other neurological symptoms. ATXN3 is part of a pathway involved in autophagy, which is crucial for cellular homeostasis. The network defined includes genes like BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1, all of which are critical components of the autophagy pathway. Dysfunctional ATXN3 may disrupt autophagy processes, contributing to the accumulation of misfolded proteins and cellular dysfunction, which are hallmarks of SCA3. \n\n\\boxed{Spinocerebellar ataxia type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is involved in the ubiquitin-proteasome system and autophagy, as indicated by its interaction with components of the autophagy pathway such as BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1. Mutations in ATXN3 are primarily associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado\u2013Joseph disease. This neurodegenerative disorder is characterized by progressive ataxia, dysarthria, and extrapyramidal signs. The expanded glutamine tract in ATXN3 leads to protein misfolding, aggregation, and loss of function, which disrupts autophagic processes, contributing to neuronal dysfunction and cell death. Thus, the ATXN3 allele contributes to the development of $\\boxed{\\text{Spinocerebellar Ataxia Type 3}}$."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele in this genomic pathway activates a signaling cascade starting with MET, leading through GRB2, SOS (SOS1/SOS2), and RAS (HRAS, KRAS, or NRAS) to RAF (BRAF, ARAF, or RAF1), MEK (MAP2K1 or MAP2K2), and ERK (MAPK1 or MAPK3), ultimately resulting in the activation of CCND1. This pathway is a key component of the MAPK/ERK signaling pathway, which promotes cell proliferation and survival. Mutations or aberrant activation of MET are associated with various cancers, particularly non-small cell lung cancer, gastric cancer, and some forms of glioblastoma. The dysregulation of this pathway contributes to uncontrolled cell growth and tumor development. \n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, through the pathway MET \u2192 GRB2 \u2192 SOS \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK \u2192 CCND1, activates a signaling cascade that promotes cell proliferation and survival. This aberrant activation can lead to uncontrolled cell growth, a hallmark of cancer. Specifically, mutations or overactivation of MET are strongly associated with various cancers, particularly those involving the RAS-RAF-MEK-ERK pathway. This pathway is a key driver in the development and progression of several malignancies, most notably non-small cell lung cancer (NSCLC), but also seen in gastrointestinal stromal tumors, renal cell carcinomas, and others. The activation of CCND1, a cyclin involved in the regulation of the cell cycle, further contributes to this neoplastic process.\n\n\\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, specifically the MET proto-oncogene, plays a key role in the activation of a signaling pathway that leads to cell proliferation and survival. When mutated or overactivated, MET can drive the phosphorylation of GRB2, leading to the activation of SOS, which in turn activates RAS. Activated RAS triggers a cascade through RAF, MEK, and ERK, ultimately resulting in the upregulation of CCND1, a protein involved in the regulation of the cell cycle. This pathway is commonly dysregulated in various cancers, particularly those involving the MET receptor tyrosine kinase. The overactivation of this signaling pathway is associated with tumor growth and progression. \n\n\\boxed{Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a protein that acts as a tumor suppressor by inhibiting the activity of cyclin-dependent kinases CDK4 and CDK6, thus preventing the phosphorylation of the RB1 protein. When CDKN2A is inactivated or mutated, the CDK4/6 complex can phosphorylate RB1, leading to the release and activation of E2F transcription factors, which promote cell cycle progression. This dysregulation can lead to uncontrolled cell proliferation and is a hallmark of cancer. Specifically, mutations in CDKN2A are strongly associated with melanoma and neurofibromatosis type 1. The pathway described illustrates how loss of CDKN2A function disrupts cell cycle control, thereby contributing to tumorigenesis. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a key tumor suppressor that inhibits the cyclin-dependent kinases CDK4 and CDK6, preventing the phosphorylation of RB1. When CDKN2A is mutated or inactivated, the cyclin D-CDK4/6 complex can phosphorylate RB1, releasing E2F transcription factors, which promote cell cycle progression. This loss of control over the G1/S transition in the cell cycle is a hallmark of uncontrolled cell proliferation. Mutations in CDKN2A are frequently observed in several cancers, including melanoma, neurofibromatosis type 1, and certain types of lymphomas and leukemias. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a tumor suppressor protein that inhibits the activity of cyclin D and cyclin-dependent kinases 4 and 6 (CDK4/6), thereby preventing the phosphorylation of the RB1 protein. When CDKN2A is dysfunctional or mutated, it leads to increased phosphorylation of RB1, which releases E2F transcription factors to promote cell cycle progression. This loss of control over the cell cycle can lead to uncontrolled cell proliferation, a hallmark of cancer. Mutations in CDKN2A are particularly associated with melanoma and certain neuroendocrine tumors.  \n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS-RAF-MEK-ERK signaling cascade, which is crucial for cell proliferation and survival. Activating mutations in NRAS (like NRAS*) can constitutively activate this pathway, leading to uncontrolled cell growth. This aberrant signaling is strongly associated with various cancers, particularly those involving hematologic malignancies and solid tumors. Specifically, NRAS mutations are frequently observed in melanoma, acute myeloid leukemia, and T-cell lymphomas. These mutations disrupt normal cell cycle regulation by upregulating CCND1, promoting cell cycle progression. \n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided genomic pathway outlines a key signaling cascade involving NRAS and KRAS, which activate RAF (including ARAF, BRAF, RAF1), leading to MEK (MAP2K1, MAP2K2) and subsequently ERK (MAPK1, MAPK3), which upregulates CCND1, a gene involved in cell cycle progression. Mutations in NRAS are known to cause constitutive activation of this pathway, promoting uncontrolled cell proliferation. This aberrant signaling is frequently observed in various cancers, particularly in melanoma, T-cell acute lymphoblastic leukemia, and others. The persistent activation of the RAS-RAF-MEK-ERK pathway due to NRAS mutations contributes to tumorigenesis by enhancing cell survival and proliferation.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS-RAF-MEK-ERK signaling cascade, which is a key driver of cell proliferation and survival. Mutations in NRAS, a GTPase, can lead to constitutive activation of this pathway, promoting uncontrolled cell growth. This aberrant activation is commonly found in various cancers, particularly in melanoma, leukemia, and certain solid tumors. The persistent activation of ERK and subsequent upregulation of CCND1, a cyclin involved in the G1/S phase transition of the cell cycle, contribute to oncogenesis. Therefore, the biological effect of a mutated NRAS allele is the promotion of tumorigenesis.\n\n\\boxed{Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that, when aberrantly activated (e.g., via the BCR-ABL fusion protein in chronic myeloid leukemia), leads to uncontrolled cell proliferation. The pathway described\u2014BCR-ABL \u2192 GRB2 \u2192 SOS \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK\u2014is a key signaling cascade involved in cell growth and survival. Activation of this pathway due to ABL1 dysregulation contributes to the development of hematologic malignancies, particularly chronic myeloid leukemia (CML). This disease is characterized by the presence of the Philadelphia chromosome, which results from a reciprocal translocation between chromosomes 9 and 22, leading to the formation of the BCR-ABL fusion gene. \n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when activated through the BCR-ABL fusion protein, initiates a signaling cascade through the GRB2-SOS-RAS-RAF-MEK-ERK pathway. This leads to uncontrolled cell proliferation and survival, contributing to the development of chronic myeloid leukemia (CML). The persistent activation of this pathway disrupts normal cell cycle regulation, resulting in the malignant transformation of hematopoietic cells.\n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele is a critical component of the BCR-ABL fusion protein, which is a hallmark of chronic myeloid leukemia (CML). This fusion protein results from a chromosomal translocation (t(9;22)), leading to the constitutive activation of the ABL tyrosine kinase, which drives uncontrolled cell proliferation. The activation of downstream signaling molecules such as GRB2, SOS, RAS, RAF, MEK, and ERK enhances the malignant transformation of hematopoietic cells. This aberrant signaling contributes to the development of CML and other myeloid malignancies.\n\n\\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system and mitochondrial quality control. Mutations in PRKN are a well-known cause of autosomal recessive juvenile Parkinson's disease (PD). Parkin functions in the PINK1-parkin pathway to mediate mitochondrial outer membrane depolarization and mitophagy, removing damaged mitochondria. Disruption of this pathway due to PRKN mutations leads to the accumulation of dysfunctional mitochondria, oxidative stress, and neuronal degeneration, particularly in dopaminergic neurons of the substantia nigra. This contributes to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin-protein ligase involved in mitochondrial quality control through mitophagy. Mutations in PRKN are a common cause of autosomal recessive juvenile parkinsonism, also known as Parkinson disease 5 (PARK5). The pathway involving PRKN and MFN1/2 is crucial for mitochondrial dynamics and function. Dysfunction in this pathway due to PRKN mutations leads to impaired mitophagy, mitochondrial dysfunction, and neuronal degeneration, primarily affecting dopaminergic neurons in the substantia nigra. This results in the clinical features of Parkinson's disease, including motor deficits and progressive neurodegeneration.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination of damaged mitochondrial proteins, facilitating their degradation. Mutations in PRKN are associated with autosomal recessive juvenile Parkinson's disease (also known as early-onset Parkinson disease). This pathway, involving PRKN and MFN1/2, is crucial for mitochondrial quality control through processes like mitophagy. Disruption of this pathway can lead to the accumulation of dysfunctional mitochondria, which is implicated in neurodegenerative diseases. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose mutant form is responsible for Huntington's disease. The provided pathway indicates that HTT interacts with CREB family members and TAF4, influencing the expression of PPARGC1A, a coactivator involved in mitochondrial biogenesis and energy metabolism. Mutations in HTT lead to the production of a toxic protein that causes progressive neurodegeneration. This pathway may reflect the molecular mechanisms underlying the disruption of cellular functions in Huntington's disease.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the molecular pathway described. This pathway involves CREB family members and TAF4, leading to the activation of PPARGC1A, a key coactivator involved in mitochondrial biogenesis and energy metabolism. Mutations in HTT, particularly the expansion of CAG trinucleotide repeats, lead to the production of a toxic huntingtin protein, which disrupts normal cellular functions, particularly in neurons. This disruption is the primary cause of Huntington's disease, an autosomal dominant neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms. The pathway described likely plays a role in the metabolic and transcriptional dysregulation observed in the disease.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose mutant forms are associated with Huntington's disease. In the given genomic pathway, HTT interacts with CREB family members and TAF4 to influence PPARGC1A, a coactivator involved in mitochondrial biogenesis and energy metabolism. Dysfunctional HTT can disrupt this regulatory network, leading to impaired mitochondrial function and energy metabolism, which are hallmarks of Huntington's disease. This pathway suggests that HTT's role in modulating CREB and TAF4 activity may contribute to the neurodegenerative processes seen in this disorder.\n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele is involved in a genomic pathway that includes PRKN, BAX, CYCS, APAF1, CASP9, and CASP3. This pathway is central to the mitochondrial apoptosis process. PINK1 and PRKN are known to be critical in maintaining mitochondrial function and integrity. Mutations in PINK1 are associated with autosomal recessive early-onset Parkinson's disease. These mutations may disrupt the normal function of the pathway, leading to impaired mitochondrial quality control and increased susceptibility to neuronal cell death, contributing to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele is involved in a genomic pathway that contributes to mitochondrial quality control and apoptosis. The pathway begins with PINK1, which activates PRKN (parkin), leading to the ubiquitination and degradation of damaged mitochondria. If this process is impaired, it can lead to the accumulation of defective mitochondria. In the event of mitochondrial damage, BAX is activated, leading to the release of CYCS, which then activates APAF1 and the caspase cascade (CASP9 -> CASP3), ultimately triggering apoptosis. Mutations in PINK1 are associated with autosomal recessive forms of Parkinson's disease, as they disrupt the normal mitochondrial function and stress response, leading to neurodegeneration. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 gene is involved in a mitochondrial pathway that contributes to apoptosis. When PINK1 is functional, it activates the PRKN (parkin) pathway, which is essential for mitophagy\u2014the selective degradation of damaged mitochondria. A dysfunctional PINK1 allele can lead to the accumulation of damaged mitochondria, which in turn can trigger the intrinsic apoptosis pathway through BAX, leading to the release of CYCS, activation of APAF1, and subsequent caspase activation (CASP9 and CASP3). This pathway is implicated in neurodegenerative disorders, particularly Parkinson's disease. Mutations in PINK1 are a known cause of early-onset Parkinson's disease, as they disrupt mitochondrial quality control and increase neuronal vulnerability. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN (nucleoredoxin) gene encodes a protein involved in cellular redox balance and signal transduction. In the given pathway, NXN interacts with DVL proteins (DVL1, DVL2, DVL3), which are key players in the Wnt/\u03b2-catenin signaling pathway. Disruption of this pathway has been implicated in various diseases, including cancer. Mutations or dysregulation of NXN might affect the proper functioning of DVL proteins, leading to aberrant Wnt signaling. This disruption can contribute to uncontrolled cell proliferation and tumor development. Specifically, alterations in the NXN gene have been associated with certain cancers, notably glioblastoma. \n\n\\boxed{Glioblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe gene *NXN* (nucleoredoxin) is involved in redox regulation and cellular signaling. In the given pathway, it interacts with DVL proteins (DVL1, DVL2, DVL3), which are key components of the Wnt/\u03b2-catenin signaling pathway. Disruption of this pathway can lead to various developmental and pathological conditions. Mutations in *NXN* may impair its regulatory role in this pathway, potentially leading to abnormal Wnt signaling. This can contribute to the development of certain cancers, including colorectal cancer, where dysregulated Wnt signaling is a common feature. Therefore, the biological effect of an *NXN* allele that disrupts its function may be linked to an increased risk of colorectal cancer.\n\n\\boxed{Colorectal cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN gene encodes nucleoredoxin, a protein involved in cellular redox regulation and antioxidant defense. In the given pathway, NXN interacts with DVL proteins (DVL1, DVL2, DVL3), which are key components of the Wnt signaling pathway. Disruption of this pathway can lead to various developmental and neoplastic disorders. Mutations in NXN have been associated with a rare autosomal recessive disorder known as **Hypomyelinating leukodystrophy 5 (HLD5)**, also referred to as **Hypomyelination and Spasticity with Lactic Acidosis (HSDLA)**. This condition is characterized by widespread hypomyelination, spasticity, and metabolic acidosis, often leading to severe neurological impairment and early mortality. The biological effect of the NXN allele in this context is primarily linked to this specific leukodystrophy.\n\n\\boxed{Hypomyelinating leukodystrophy 5}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the unfolded protein response (UPR) in the endoplasmic reticulum (ER), initiated by the accumulation of misfolded proteins. SOD1, a copper/zinc superoxide dismutase, is linked to the ER stress pathway through its interaction with BIP (GRP78), a chaperone that normally binds to ATF6. Under ER stress, BIP releases ATF6, allowing it to translocate to the Golgi and cleave to generate an active transcription factor that upregulates genes like DDIT3 (CHOP), promoting apoptosis. Mutations in SOD1 are associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. These mutations cause SOD1 to misfold, leading to ER stress, UPR activation, and ultimately, motor neuron death. Thus, the SOD1 allele contributes to the pathogenesis of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that plays a critical role in protecting cells from oxidative damage by catalyzing the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations can lead to the production of toxic SOD1 protein aggregates, which contribute to the progressive degeneration of motor neurons. The pathway described involves SOD1 interacting with the endoplasmic reticulum stress response, including BIP (an ER chaperone), ATF6 (a transcription factor), and DDIT3 (a gene induced by ER stress), highlighting the connection between oxidative stress and ER stress in the pathogenesis of neurodegenerative disease. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves SOD1, which is a copper-zinc superoxide dismutase that normally detoxifies superoxide radicals. In this network, SOD1 interacts with BIP (a chaperone protein) and ATF6, which is involved in the unfolded protein response (UPR), leading to the activation of DDIT3, a gene associated with stress responses. Mutations in SOD1 are strongly linked to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. These mutations can lead to protein misfolding and aggregation, disrupting mitochondrial function and triggering a toxic gain-of-function. The pathway described likely reflects the cellular stress response induced by mutant SOD1, contributing to the pathogenesis of ALS.\n\n\\boxed{Amyotrophic lateral sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of coordination, muscle rigidity, and other neurological symptoms. The pathway provided highlights the involvement of ATXN3 in calcium signaling, which is crucial for neuronal function. Mutations in ATXN3 lead to the production of an expanded polyglutamine tract, resulting in protein misfolding and aggregation, which disrupts cellular processes and contributes to neuronal death. This disruption in calcium homeostasis could exacerbate the neurodegenerative effects. \n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway describes a signaling cascade initiated by glutamate binding to GRM1, leading to calcium mobilization through IP3 and ITPR1, with ATXN3 implicated in this process. ATXN3 is a gene associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of motor control, coordination, and other neurological symptoms due to the toxic accumulation of ATXN3 protein with expanded polyglutamine repeats. \n\n\\boxed{Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in the ubiquitin-proteasome system. Mutations in ATXN3, particularly expansions of a polyglutamine tract, are associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of motor control, ophthalmoplegia, and other neurological symptoms. The pathway described involves glutamate signaling, calcium mobilization, and mitochondrial function\u2014processes that are often disrupted in neurodegenerative diseases. ATXN3\u2019s role in this pathway may contribute to the pathology of SCA3 by impairing calcium homeostasis and mitochondrial function, leading to neuronal dysfunction and cell death.\n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele is part of a pathway involving the VHL-E3 ubiquitin ligase complex, which targets the HIF (hypoxia-inducible factor) proteins for degradation under normoxic conditions. In the absence of functional VHL, HIF-\u03b1 subunits, such as EPAS1 (HIF-2\u03b1), are stabilized and dimerize with ARNT to activate transcription of downstream genes including VEGFA, CXCL8, SLC2A1 (GLUT1), and EPO. These genes are involved in angiogenesis, inflammation, and erythropoiesis. This pathway's dysregulation leads to excessive vascularization and cellular proliferation, which is a hallmark of von Hippel-Lindau (VHL) disease. VHL disease is an autosomal dominant disorder characterized by the development of benign and malignant tumors, most commonly hemangioblastomas in the central nervous system, retinal angiomas, and renal cell carcinomas.\n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor involved in the ubiquitin-proteasome system, regulating the stability of hypoxia-inducible factors (HIFs) like EPAS1. When VHL is dysfunctional, HIFs accumulate, leading to increased expression of genes such as VEGFA, CXCL8, and EPO, which promote angiogenesis and cell proliferation. This pathway is crucial in the development of clear cell renal cell carcinoma (ccRCC), a common type of kidney cancer. The VHL allele, when mutated, disrupts this regulatory mechanism, contributing to uncontrolled cell growth and tumor formation in the kidney.\n\n\\boxed{Clear cell renal cell carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor gene involved in the regulation of hypoxia-inducible factor (HIF) through the ubiquitination and degradation of HIF-1\u03b1. In this pathway, VHL, along with RBX1, ELOC, ELOB, and CUL2, forms an E3 ubiquitin ligase complex that targets EPAS1 (HIF-2\u03b1) for degradation. In the absence of functional VHL, EPAS1 stabilizes and dimerizes with ARNT, activating transcription of downstream genes such as VEGFA, CXCL8, SLC2A1 (GLUT1), and EPO. This leads to increased angiogenesis, cell proliferation, and survival, contributing to the development of clear cell renal cell carcinoma (ccRCC). Thus, mutations in the VHL gene are a key driver of this disease.\n\n\\boxed{Clear cell renal cell carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves NRAS and KRAS activating PI3K, leading to PIP3 production and subsequent activation of AKT, which phosphorylates BAD, promoting cell survival. NRAS is a proto-oncogene, and mutations in NRAS can lead to constitutive activation of this pathway, driving uncontrolled cell growth and proliferation. This contributes to the development of various cancers, including melanoma, leukemia, and certain solid tumors. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS (NRAS and KRAS) proteins activating PI3K, leading to PIP3 production, which in turn activates AKT. AKT phosphorylates and inactivates BAD, a pro-apoptotic protein, thereby promoting cell survival and proliferation. Mutations in NRAS, particularly in this pathway, can lead to constitutive activation of the PI3K/AKT signaling cascade, resulting in uncontrolled cell growth. This aberrant signaling is commonly observed in various cancers, especially melanoma, where NRAS mutations are well-documented. These mutations contribute to tumor initiation and progression by impairing normal cell cycle regulation and apoptosis. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway outlines a signaling cascade involving NRAS and KRAS, which both activate PI3K, leading to PIP3 production and subsequent activation of AKT. AKT then inhibits BAD, a pro-apoptotic protein, promoting cell survival. Mutations in NRAS, particularly in this pathway, can lead to constitutive activation of the PI3K/AKT axis, bypassing normal growth and survival control mechanisms. This aberrant signaling is commonly observed in various cancers, including melanoma, leukemia, and solid tumors. The persistent activation of this pathway contributes to uncontrolled cell proliferation and resistance to apoptosis, hallmarks of cancer. Therefore, NRAS mutations in this context are strongly associated with the development of cancer.\n\n\\boxed{Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene on chromosome 21 is central to the amyloid cascade hypothesis of Alzheimer's disease. The pathway begins with APP, which is cleaved to produce Abeta peptides. Accumulation of Abeta leads to the formation of amyloid plaques, a hallmark of Alzheimer's. This initiates a cascade involving PPID, MPTP, and CYCS, contributing to mitochondrial dysfunction and apoptosis. The involvement of VDACs and SLC25 family members suggests a role in mitochondrial membrane permeability and calcium regulation, which are critical in neuronal death. Thus, the APP allele contributes to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) allele is central to the amyloid pathway, where it is cleaved to produce Abeta peptides. Accumulation of these peptides leads to the formation of amyloid plaques, a hallmark of Alzheimer's disease. This pathway involves PPID, MPTP, and CYCS, indicating a mechanism that may trigger mitochondrial dysfunction and apoptosis. Genes such as VDAC1-3 and SLC25A4-6 are involved in mitochondrial function and calcium homeostasis, further linking this pathway to neurodegeneration. Collectively, these interactions contribute to neuronal damage and cognitive decline.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) allele is central to the amyloidogenic pathway, which generates the Abeta peptide. Accumulation of Abeta is a hallmark of Alzheimer's disease (AD). This pathway includes PPID, MPTP, and CYCS, which are involved in mitochondrial dysfunction and apoptosis. The involvement of VDACs and SLC25 family members suggests a role in mitochondrial membrane permeabilization and calcium homeostasis, both of which are disrupted in AD. Thus, the APP allele contributes to Alzheimer's disease through the generation of Abeta and downstream mitochondrial and apoptotic pathways.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nSOD1 (superoxide dismutase 1) is a key enzyme involved in the detoxification of reactive oxygen species. Mutations in the SOD1 gene are primarily associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations lead to the production of misfolded SOD1 proteins, which can accumulate and cause toxicity in motor neurons. The pathway provided involves SOD1 interacting with DERL1, which is involved in endoplasmic reticulum-associated degradation, and the ubiquitin-proteasome system, which is crucial for protein degradation. Dysfunctional SOD1 may impair this system, leading to protein aggregation and neuronal death. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that leads to the degeneration of motor neurons. The pathway described highlights the involvement of SOD1 in a network that includes proteasomal degradation, suggesting that impaired proteasome function may contribute to the toxic accumulation of misfolded or aggregated SOD1 proteins, which is a hallmark of ALS. Thus, the biological effect of certain SOD1 alleles, particularly those with pathogenic mutations, is the contribution to the development of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that neutralizes superoxide radicals. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig\u2019s disease. These mutations lead to misfolding and aggregation of the SOD1 protein, which can be targeted by the ubiquitin-proteasome system for degradation. The pathway described involves SOD1 interacting with DERL1 and the proteasome, highlighting the cellular machinery responsible for protein quality control. When this system is overwhelmed or dysfunctional, misfolded SOD1 accumulates, leading to motor neuron degeneration. \n\n\\boxed{Amyotrophic lateral sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is part of a pathway initiating with PSEN1 and PSEN2, which are associated with the production and processing of amyloid-beta peptides. This pathway leads to calcium dysregulation through RYR3, MCU, and other mitochondrial channels, potentially causing mitochondrial permeability transition (MPTP), release of cytochrome c (CYCS), and activation of the apoptotic cascade involving APAF1, CASP9, and downstream caspases such as CASP3 and CASP7. This dysfunction in calcium homeostasis and apoptosis is closely linked to neurodegenerative diseases, particularly Alzheimer's disease. PSEN1 mutations are strongly associated with early-onset familial Alzheimer\u2019s disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key component of the gamma-secretase complex, which is involved in the cleavage of amyloid precursor protein (APP) to produce amyloid-beta peptides. Accumulation of these peptides is a hallmark of Alzheimer's disease. The pathway described involves PSEN1 and PSEN2 in the activation of a cascade leading to mitochondrial calcium overload, permeability transition pore (MPTP) opening, and ultimately apoptosis via caspase activation. This apoptotic pathway is implicated in neurodegeneration. PSEN1 mutations are strongly associated with early-onset Alzheimer's disease, contributing to the accumulation of toxic amyloid-beta and the subsequent neuronal death observed in the condition.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 allele is involved in the amyloidogenic pathway, which leads to the production of amyloid-beta peptides. These peptides accumulate and form plaques in the brain, a hallmark of Alzheimer's disease. The pathway described connects PSEN1 and PSEN2 to the mitochondrial calcium handling and apoptosis processes, suggesting that dysfunction in these genes can lead to mitochondrial impairment and neuronal death, contributing to neurodegeneration. This genetic pathway is strongly associated with early-onset Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 gene encodes a receptor tyrosine kinase that plays a critical role in hematopoiesis. Mutations in FLT3, particularly internal tandem duplications (ITD) in the juxtamembrane domain or activating point mutations in the kinase domain, lead to constitutive activation of the FLT3 receptor. This persistent activation promotes uncontrolled cell proliferation and survival, contributing to the development of acute myeloid leukemia (AML). The pathway FLT3 \u2192 STAT5 \u2192 PIM1/2 is central to this process, as FLT3 phosphorylates and activates STAT5, which in turn upregulates PIM1 and PIM2, both of which are involved in promoting cell survival and proliferation. These effects are characteristic of leukemogenesis, particularly in AML. \n\n\\boxed{Acute Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 pathway, involving FLT3, STAT5, and PIM1/2, plays a key role in cellular signaling, particularly in the proliferation and survival of hematopoietic cells. Mutations in FLT3, especially internal tandem duplications (ITD) in its kinase domain, are commonly associated with acute myeloid leukemia (AML). These mutations lead to constitutive activation of FLT3, promoting uncontrolled cell growth and resistance to apoptosis. This aberrant signaling disrupts normal hematopoiesis and contributes to the malignant transformation of myeloid cells. \n\n\\boxed{Acute Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 gene encodes a receptor tyrosine kinase involved in signal transduction pathways critical for cell survival and proliferation. Mutations in FLT3, particularly internal tandem duplications (ITD) in the juxtamembrane domain, are commonly found in acute myeloid leukemia (AML). These mutations lead to constitutive activation of FLT3, promoting uncontrolled cell growth and resistance to apoptosis. The pathway FLT3 \u2192 STAT5 \u2192 PIM1/2 is central to this process, as it enhances survival and proliferation signals. This aberrant signaling contributes to leukemogenesis and is associated with poor prognosis in AML patients. \n\n\\boxed{Acute Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe LRRK2 gene is primarily associated with Parkinson's disease. This allele, through the defined pathway involving cytochrome c (CYCS), APAF1, and caspases (CASP9 and CASP3), appears to influence apoptotic signaling. Mutations in LRRK2 can lead to dysregulation of this pathway, contributing to neuronal apoptosis, a key feature in neurodegenerative disorders like Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nLRRK2 is a gene associated with Parkinson's disease (PD). The provided pathway involves a sequence of molecular events starting with LRRK2, which may lead to cytochrome c release and subsequent activation of the caspase cascade, culminating in apoptosis. This pathway is related to programmed cell death and mitochondrial dysfunction, which are implicated in neurodegenerative disorders such as Parkinson's disease. Mutations in the LRRK2 gene are among the most common genetic causes of familial Parkinson's disease. The biological effect of this LRRK2 allele likely involves the promotion of neuronal cell death through the intrinsic apoptotic pathway, thereby contributing to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway illustrates a sequence of events leading to apoptosis, starting with the LRRK2 allele, which activates cytochrome c release, leading to the activation of caspases through the intrinsic apoptotic pathway. Mutations in LRRK2 are strongly associated with Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. The LRRK2 protein is involved in multiple cellular processes, including protein phosphorylation, autophagy, and mitochondrial function. Dysfunctional LRRK2 may lead to impaired mitochondrial function and increased neuronal death, contributing to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes a subunit of the P/Q-type voltage-gated calcium channel, which is crucial for neurotransmitter release and neuronal function. Mutations in CACNA1A are associated with a range of neurological disorders, including episodic ataxia, hemiplegic migraine, and spinocerebellar ataxia type 6. These conditions are characterized by impaired motor coordination, recurrent episodes of ataxia, and, in some cases, seizures. The biological effect of the CACNA1A allele is therefore linked to these neurologic diseases due to dysfunctional calcium channel activity. \n\n\\boxed{Spinocerebellar Ataxia Type 6}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes a subunit of the P/Q-type voltage-gated calcium channel, which plays a critical role in neurotransmitter release and neuronal function. Mutations in CACNA1A have been implicated in several neurological disorders. Specifically, certain alleles of CACNA1A are associated with episodic ataxia, a condition characterized by recurrent episodes of uncoordinated muscle movement. Additionally, the CACNA1A gene is also linked to spinocerebellar ataxia type 6 (SCA6), an autosomal dominant neurodegenerative disorder that leads to progressive ataxia and cerebellar degeneration. The dysfunction of these calcium channels disrupts normal neuronal excitability and signaling, resulting in the clinical manifestations of these diseases.\n\n\\boxed{Spinocerebellar Ataxia Type 6}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha-1A subunit of the P/Q-type voltage-gated calcium channel, which is critical for neurotransmitter release and neuronal excitability. Mutations in CACNA1A have been implicated in several neurological disorders. Notably, it is a major cause of episodic ataxia type 2, a condition characterized by recurrent episodes of ataxia, nystagmus, and sometimes dysphonia. Additionally, CACNA1A mutations are associated with familial hemiplegic migraine, a rare subtype of migraine that can cause temporary paralysis on one side of the body. These mutations may also contribute to spinocerebellar ataxia type 6, an inherited neurodegenerative disorder. The biological effect of CACNA1A alleles is thus primarily linked to disorders of the central nervous system affecting movement and sensory processing.\n\n\\boxed{Episodic Ataxia Type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes synuclein alpha, which is involved in the unfolded protein response (UPR) pathway through interactions with BIP and ERN1, leading to activation of XBP1. Dysregulation of this pathway is associated with the accumulation of misfolded proteins in the endoplasmic reticulum, a hallmark of neurodegenerative diseases. Specifically, SNCA mutations or overexpression are strongly linked to Parkinson's disease, contributing to the formation of Lewy bodies and neuronal degeneration.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is implicated in the formation of Lewy bodies, a hallmark of Parkinson's disease. In the provided pathway, SNCA interacts with BIP (a chaperone protein) and ERN1 (which activates XBP1 in response to endoplasmic reticulum stress). This interaction suggests a role for SNCA in ER stress response pathways. Mutations or increased expression of SNCA are strongly associated with Parkinson's disease and other synucleinopathies. These diseases are characterized by the abnormal accumulation of alpha-synuclein in neurons, leading to neurodegeneration.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is implicated in the formation of Lewy bodies, a hallmark of Parkinson's disease. In the provided pathway, SNCA interacts with BIP (a chaperone protein) and ERN1 (an ER stress sensor), leading to the activation of XBP1, a transcription factor involved in the unfolded protein response. Dysregulation of this pathway may contribute to endoplasmic reticulum stress and neurodegeneration. The SNCA allele is associated with an increased risk of Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a common cause of early-onset autosomal recessive Parkinson's disease. The pathway defined includes ubiquitin-conjugating enzymes (UBCH7/8, UBE2L3, UBE2L6) and ubiquitin ligase PRKN, along with GPR37, suggesting a role in protein degradation and quality control. Dysfunction in this pathway likely leads to the accumulation of misfolded proteins, a hallmark of neurodegenerative diseases. Specifically, PRKN mutations impair mitochondrial function and increase susceptibility to dopaminergic neuron loss, which is central to Parkinson's disease pathology. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves PRKN (parkin), a gene encoding an E3 ubiquitin ligase essential for mitochondrial quality control through the process of mitophagy. Mutations in PRKN are a major cause of autosomal recessive juvenile Parkinson's disease (early-onset Parkinson disease). The pathway also includes ubiquitin-conjugating enzymes (UBCH7/8 and UBE2L3/UBE2L6) and GPR37, which may modulate parkin function or serve as substrates. Dysfunctional parkin activity disrupts the degradation of damaged mitochondria, leading to the accumulation of dysfunctional mitochondria and subsequent neuronal degeneration, particularly in dopaminergic neurons of the substantia nigra. This contributes to the motor and non-motor symptoms characteristic of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a major cause of early-onset autosomal recessive Parkinson's disease. The pathway defined includes components like UBCH7/8, PRKN, and PAELR, which are involved in ubiquitination and cellular stress responses. The presence of PRKN in this network underscores its role in the degradation of misfolded proteins and mitochondrial quality control. Dysfunction in this pathway due to a PRKN allele can lead to the accumulation of damaged proteins and impaired mitochondrial function, contributing to neurodegeneration. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is a key component in the pathogenesis of Parkinson's disease. Abnormal accumulation of alpha-synuclein leads to the formation of Lewy bodies, which are pathological hallmarks of Parkinson's disease. This allele's effect is primarily linked to the progressive degeneration of dopaminergic neurons in the substantia nigra, resulting in motor symptoms such as tremors, rigidity, and bradykinesia. Additionally, SNCA mutations have also been implicated in other neurodegenerative disorders, including dementia with Lewy bodies and multiple system atrophy.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is a component of Lewy bodies, abnormal protein aggregates found in the brains of patients with Parkinson's disease. Mutations or overexpression of SNCA are associated with the pathogenesis of Parkinson's disease and other synucleinopathies, such as dementia with Lewy bodies and multiple system atrophy. The pathway described involves the 26S proteasome, which is critical for protein degradation. Dysregulation of this proteasome system, possibly due to SNCA dysfunction, may contribute to the accumulation of misfolded proteins and subsequent neurodegeneration. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is a key component in the pathogenesis of Parkinson's disease. Abnormal accumulation of alpha-synuclein leads to the formation of Lewy bodies, a hallmark of Parkinson's disease and other synucleinopathies. The pathway described includes the proteasome, which is responsible for degrading misfolded or damaged proteins. Dysfunction in this proteasome system can impair the clearance of alpha-synuclein, contributing to its aggregation and subsequent neurodegeneration. Thus, the SNCA allele, particularly in the context of proteasome dysfunction, contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 allele is involved in a genomic pathway that initiates from PSEN1 and PSEN2, leading to calcium dysregulation through RYR3, MCU, and other mitochondrial calcium transporters. This pathway contributes to increased mitochondrial calcium levels, which can cause mitochondrial permeability transition pore (MPTP) opening. This event leads to the release of cytochrome c (CYCS), activation of APAF1, and downstream caspases (CASP9, CASP3, CASP7), ultimately resulting in apoptosis. PSEN2 mutations are strongly associated with early-onset Alzheimer's disease (AD). These mutations disrupt the normal processing of amyloid precursor protein, leading to accumulation of amyloid-beta plaques and neurodegeneration. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 allele is involved in a genomic pathway that contributes to Alzheimer's disease. This pathway begins with PSEN1 and PSEN2, which are presenilin proteins essential for the gamma-secretase complex. This complex cleaves amyloid precursor protein (APP) to generate beta-amyloid peptides, a hallmark of Alzheimer's disease. The pathway proceeds through RYR3, which releases calcium, leading to mitochondrial calcium uptake via MCU. Excessive calcium can trigger the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS), which activates APAF1 and caspases (CASP9, CASP3, CASP7), promoting apoptosis. Mutations in PSEN2 are linked to early-onset familial Alzheimer's disease, highlighting its role in neurodegeneration and pathogenesis.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves PSEN2, which is part of the gamma-secretase complex, leading to the processing of amyloid precursor protein (APP) and generating amyloid-beta (A\u03b2) peptides. Accumulation of A\u03b2 is a hallmark of Alzheimer's disease. The pathway connects PSEN2 to mitochondrial calcium dysregulation and apoptosis, implicating PSEN2 in neurodegenerative processes. Mutations in PSEN2 are associated with early-onset Alzheimer\u2019s disease. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is implicated in the network through its interaction with ITPR to regulate calcium signaling. Mutations in the HTT gene, particularly expansions of CAG trinucleotide repeats, lead to the production of a dysfunctional huntingtin protein. This malfunction disrupts calcium homeostasis, mitochondrial function, and ultimately induces apoptosis through the pathway described. These disruptions are central to the pathogenesis of Huntington\u2019s disease, a neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms. The involvement of this pathway highlights the role of calcium dysregulation in neuronal degeneration.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, specifically the mutant form of the huntingtin gene (HTT), leads to the production of a toxic huntingtin protein with abnormally long polyglutamine repeats. This causes a progressive neurodegenerative disorder known as Huntington's disease. The pathway described demonstrates how mutant HTT can disrupt calcium homeostasis and mitochondrial function, contributing to neuronal damage and apoptosis. The altered calcium signaling through IP3 receptors and the mitochondrial calcium uniporter (MCU) leads to increased mitochondrial permeability and release of cytochrome c, triggering caspase-dependent apoptosis. This aberrant pathway is central to the pathogenesis of the disease.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose mutation is associated with Huntington's disease. In the provided pathway, HTT interacts with ITPR to regulate Ca\u00b2\u207a release, which is crucial for mitochondrial function and apoptosis. A mutant HTT allele disrupts this regulation, leading to Ca\u00b2\u207a dysregulation, mitochondrial dysfunction, and ultimately neuronal cell death. These pathophysiological changes are hallmarks of Huntington's disease, a neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms.\n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is central to the pathogenesis of prion diseases. These are a group of fatal, transmissible, neurodegenerative disorders caused by the misfolding of the prion protein into a pathogenic form. The interaction with NOTCH1, a receptor involved in cell fate decisions and neural development, may influence the progression or cellular response in prion disease. The biological effect of the PRNP allele, particularly in the context of this pathway, contributes to conditions like Creutzfeldt-Jakob disease (CJD), a classic prion disease characterized by rapid cognitive decline and neurodegeneration.\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is central to prion diseases. When mutated, PRNP can produce misfolded prion proteins that lead to neurodegenerative disorders. These diseases include Creutzfeldt-Jakob disease (CJD), Gerstmann-Str\u00e4ussler-Scheinker syndrome, and fatal insomnia. The interaction with NOTCH1, a receptor involved in cell signaling, may influence the progression or pathology of these diseases. However, the primary pathological role is attributed to the PRNP allele itself.\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is central to the pathogenesis of prion diseases. These are a group of rare, progressive, and ultimately fatal neurodegenerative disorders. The PRNP allele, particularly when carrying certain mutations, can lead to the misfolding of the prion protein into a pathogenic form. This misfolded protein can cause aggregation and damage to neural tissue, resulting in the clinical features of prion disease. One well-known example is Creutzfeldt-Jakob disease (CJD), which can be sporadic, genetic, or acquired. Inherited forms of CJD are often linked to specific mutations in the PRNP gene.\n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, an enzyme involved in the ubiquitin-proteasome system, which regulates protein degradation. This system is crucial for maintaining cellular homeostasis by targeting misfolded or damaged proteins for degradation. Mutations in UCHL1 have been implicated in neurodegenerative diseases, particularly Parkinson's disease. These mutations may lead to the accumulation of misfolded proteins, contributing to neuronal dysfunction and death. The pathway described, involving ubiquitin and related proteins, highlights the role of UCHL1 in maintaining proper ubiquitin homeostasis. Dysregulation of this pathway due to a malfunctioning UCHL1 allele can disrupt normal cellular processes, especially in neurons, thereby contributing to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, an enzyme involved in the deubiquitination of proteins, playing a role in ubiquitin recycling and proteasome function. Given its involvement in the ubiquitin pathway, mutations in UCHL1 can disrupt this critical regulatory system. Studies have linked UCHL1 mutations to neurodegenerative conditions, particularly Parkinson's disease, and it is considered a susceptibility gene for this disorder. The enzyme's role in maintaining protein homeostasis suggests that impaired function could lead to the accumulation of misfolded proteins, a hallmark of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 (ubiquitin C-terminal hydrolase L1) gene is involved in the ubiquitin-proteasome system, which regulates protein degradation. In the given pathway, UCHL1 functions as a deubiquitinating enzyme, potentially reversing the ubiquitination of proteins such as UB(chain), UBA52, UBB, and UBC. Mutations in UCHL1 can impair its enzymatic activity, leading to the accumulation of ubiquitinated proteins. This dysfunction has been implicated in neurodegenerative disorders, particularly Parkinson's disease. UCHL1 is highly expressed in neurons, and its loss of function may contribute to the loss of dopaminergic neurons, a hallmark of Parkinson's disease. Thus, the UCHL1 allele in this context contributes to \\boxed{Parkinson's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that detoxifies reactive oxygen species. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The provided pathway includes components of the dynein-based transport system, which is crucial for intracellular trafficking. Dysfunctional SOD1 may contribute to oxidative stress and mitochondrial dysfunction, which can impair the transport and function of dynein-related proteins, exacerbating neuronal degeneration. Thus, this SOD1 allele contributes to \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 (superoxide dismutase 1) allele is associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. SOD1 is a copper-zinc superoxide dismutase that normally functions to neutralize superoxide radicals. Mutations in the SOD1 gene have been implicated in approximately 20% of familial ALS cases. These mutations can lead to the misfolding and aggregation of the SOD1 protein, which is toxic to motor neurons, ultimately resulting in their degeneration and the clinical manifestations of ALS. The pathway described, involving SOD1 and multiple dynein and dynactin subunits, may relate to the transport and function of SOD1 within the cell, further contributing to the disease pathology.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen, playing a critical role in protecting cells from oxidative damage. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. These mutations can lead to the misfolding and aggregation of the SOD1 protein, resulting in toxic gain-of-function effects that damage motor neurons. The network involving SOD1 and various dynein and dynactin subunits suggests a role in cytoskeletal transport and cellular maintenance, which may be impaired in ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway involves SOD1, which is associated with the unfolded protein response (UPR) in the endoplasmic reticulum (ER). SOD1 is known to interact with BIP (also known as GRP78), which is a key ER chaperone. ATF6, a transmembrane ER stress sensor, is activated when the ER is stressed, leading to the expression of DDIT3 (also known as CHOP), a transcription factor that promotes apoptosis. Mutations in SOD1 are strongly linked to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway described suggests that altered SOD1 function could contribute to ER stress and subsequent neuronal death, a hallmark of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves SOD1, which is known to be associated with amyotrophic lateral sclerosis (ALS). SOD1 is a copper-zinc superoxide dismutase that normally functions to detoxify reactive oxygen species. Mutations in the SOD1 gene lead to the production of toxic protein aggregates, which contribute to the degeneration of motor neurons. In the given pathway, SOD1 influences BIP (a chaperone protein), which in turn modulates ATF6, a transcription factor involved in the unfolded protein response. This response is crucial for maintaining endoplasmic reticulum (ER) homeostasis, and its dysregulation due to SOD1 dysfunction can lead to neuronal stress and death. This process is implicated in the pathogenesis of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway defined involves SOD1, which is linked to BIP, ATF6, and DDIT3, all of which are components of the unfolded protein response (UPR) in the endoplasmic reticulum (ER). Mutations in the SOD1 gene, which encodes copper\u2013zinc superoxide dismutase, are the most common cause of familial amyotrophic lateral sclerosis (ALS). These mutations lead to misfolding and aggregation of SOD1, triggering ER stress and activation of the UPR, which is reflected in this pathway. The involvement of ATF6 and DDIT3, as part of the UPR, supports the role of ER stress in the pathogenesis of ALS. Therefore, the SOD1 allele contributes to the development of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that is part of the BCR-ABL fusion gene, a hallmark of chronic myeloid leukemia (CML). This fusion gene results from a chromosomal translocation (t(9;22)), known as the Philadelphia chromosome, which leads to the constitutive activation of the ABL kinase. This uncontrolled kinase activity drives unregulated cell proliferation and survival, contributing to the development of CML. The pathway involving ABL1 includes downstream kinases such as GRB2, SOS, RAS, RAF, MEK, and ERK, which are part of the MAPK signaling cascade, crucial for cell growth and division. Dysregulation of this pathway by ABL1 is a key driver of the disease. \n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that plays a critical role in cellular signaling. When ABL1 is dysregulated, such as through chromosomal translocation to form the BCR-ABL fusion protein, it leads to constitutive activation of the tyrosine kinase signaling pathway. This uncontrolled activation drives unregulated cell proliferation and is a hallmark of chronic myeloid leukemia (CML). The BCR-ABL fusion protein initiates a signaling cascade through GRB2, SOS, RAS, RAF, MEK, and ERK, promoting malignant transformation. This specific pathway is a key driver of CML, and the disease is characterized by the presence of the Philadelphia chromosome.\n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that is central to the BCR-ABL fusion protein, a hallmark of chronic myeloid leukemia (CML). This fusion results from a chromosomal translocation, typically t(9;22), forming the Philadelphia chromosome. The BCR-ABL fusion protein is constitutively active, leading to uncontrolled cell proliferation and survival, which are key features of CML. The pathway activation involves GRB2, SOS, RAS, RAF, MEK, and ERK, promoting the MAPK/ERK signaling cascade, which drives cell growth and division. This aberrant signaling contributes to the malignant transformation of hematopoietic cells. \n\n\\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT pathway, involving KIT, GRB2, SOS, RAS, RAF, MEK, and ERK, is central to cellular growth, survival, and differentiation. Mutations in KIT, a receptor tyrosine kinase, can lead to constitutive activation of this signaling cascade, driving uncontrolled cell proliferation. Such mutations are commonly associated with gastrointestinal stromal tumors (GISTs), a type of cancer that originates in the digestive system. These tumors often depend on KIT signaling for growth and survival, making it a key therapeutic target.\n\n\\boxed{Gastrointestinal Stromal Tumor (GIST)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT allele, when mutated, can lead to constitutive activation of the KIT receptor tyrosine kinase, initiating a downstream signaling cascade through GRB2, SOS, RAS, RAF, MEK, and ERK. This uncontrolled signaling promotes cell proliferation and survival, contributing to the development of certain cancers. Specifically, mutations in KIT are frequently associated with gastrointestinal stromal tumors (GISTs), a type of soft tissue sarcoma. These mutations often occur in exon 11 of the KIT gene and are a common diagnostic and therapeutic target in GISTs.\n\n\\boxed{Gastrointestinal Stromal Tumor (GIST)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT pathway, as defined, involves a series of signal transduction events starting from the KIT receptor tyrosine kinase. This pathway plays a critical role in cell survival, proliferation, and differentiation. Mutations in KIT can lead to constitutive activation of the pathway, promoting uncontrolled cell growth, which is a hallmark of cancer. Specifically, activating mutations in KIT are commonly associated with gastrointestinal stromal tumors (GISTs), a type of cancer that originates in the gastrointestinal tract. These mutations often occur in the juxtamembrane domain of KIT, leading to its dimerization and autophosphorylation, thereby initiating downstream signaling through the RAS-RAF-MEK-ERK cascade. This aberrant signaling contributes to tumor initiation and progression.\n\n\\boxed{Gastrointestinal Stromal Tumor (GIST)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 gene is part of a critical signaling pathway involved in cell cycle regulation. In this pathway, CDK4 interacts with cyclins D (CCND1, CCND2, CCND3) to phosphorylate the RB1 protein, which releases E2F transcription factors to promote cell cycle progression. Dysregulation of this pathway, particularly through overactivation of CDK4, can lead to uncontrolled cell proliferation. Mutations or overexpression of CDK4 are commonly associated with various cancers, including melanoma, breast cancer, and glioblastoma. This pathway's aberrant activation contributes to tumor development by allowing cells to bypass normal growth controls.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 gene encodes cyclin-dependent kinase 4, which, when activated by cyclin D proteins (CCND1, CCND2, CCND3), phosphorylates the RB1 protein. This phosphorylation inactivates RB1, allowing E2F transcription factors to activate genes required for cell cycle progression. Dysregulation of this pathway, such as through overexpression of CDK4 or its cyclin D partners, can lead to uncontrolled cell proliferation. Such dysregulation is a hallmark of many cancers. Specifically, mutations or amplifications in CDK4 have been associated with melanoma and certain hematological malignancies. The aberrant activation of the E2F pathway due to hyperactive CDK4 contributes to tumorigenesis by promoting cell cycle progression and proliferation. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 gene is part of the G1/S phase transition regulatory pathway, where it interacts with cyclin D proteins (CCND1, CCND2, CCND3) to phosphorylate RB1, thereby releasing E2F transcription factors (E2F1, E2F2, E2F3) to activate genes required for DNA synthesis. Mutations or overexpression of CDK4 can lead to uncontrolled cell cycle progression, a hallmark of cancer. Specifically, germline mutations in CDK4 are associated with a rare hereditary cancer syndrome known as cyclin D1-CDK4-related neoplasia, which increases the risk of developing multiple tumors, particularly in the skin and soft tissues. This pathway alteration disrupts normal cell cycle control, contributing to tumorigenesis.\n\n\\boxed{Cyclin D1-CDK4-related neoplasia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 gene encodes sequestosome 1, a key player in autophagy, which is crucial for mitochondrial quality control. Mutations in SQSTM1 are associated with neurodegenerative disorders, particularly amyotrophic lateral sclerosis (ALS). These mutations can impair autophagy, leading to the accumulation of damaged mitochondria and protein aggregates, which contribute to neuronal dysfunction and death. Given its role in the PINK1-PRKN pathway, which is central to mitophagy, SQSTM1 dysfunction can significantly impact mitochondrial health and is implicated in the pathogenesis of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 gene encodes sequestosome 1, a protein involved in the ubiquitin-proteasome system and autophagy. In the given pathway, SQSTM1 is downstream of PINK1 and PRKN, which are central to mitophagy\u2014the process of removing damaged mitochondria. Mutations in SQSTM1 have been associated with neurodegenerative disorders, particularly amyotrophic lateral sclerosis (ALS). These mutations can disrupt the normal function of SQSTM1, impairing autophagy and leading to the accumulation of damaged mitochondria, which may contribute to neuronal dysfunction and death. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 gene encodes sequestosome 1, a protein involved in the ubiquitin-proteasome system and autophagy. It plays a critical role in the clearance of damaged mitochondria via mitophagy, a process regulated by the PINK1-PRKN pathway. Mutations in SQSTM1 can impair this pathway, leading to the accumulation of damaged mitochondria and the misfolding and aggregation of proteins. These effects are implicated in neurodegenerative diseases, particularly Parkinson's disease. Specifically, certain SQSTM1 alleles, such as those with missense mutations, have been associated with an increased risk of Parkinson's disease. Thus, the biological effect of the SQSTM1 allele is the disruption of mitochondrial quality control, contributing to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP gene encodes the amyloid beta precursor protein, which is central to the amyloid cascade hypothesis of Alzheimer's disease. The pathway described outlines a sequence of events starting with APP, leading through the production of Abeta, activation of the FAS death receptor, and subsequent caspase activation, culminating in apoptosis. This cascade is implicated in neuronal cell death, a hallmark of Alzheimer's disease. The accumulation of Abeta peptides, particularly Abeta42, is a key factor in plaque formation and neurodegeneration. Thus, abnormalities in the APP gene, including mutations or increased production of amyloid-beta, are strongly associated with the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (Amyloid Beta Precursor Protein) gene is central to the amyloid pathway, which is implicated in the development of Alzheimer's disease. The pathway described involves the production of Abeta peptides, which accumulate and form plaques in the brain, a hallmark of Alzheimer's disease. This cascade leads to mitochondrial dysfunction, activation of caspases, and ultimately, neuronal apoptosis. The involvement of FAS, FADD, and downstream caspases indicates a connection between the extrinsic and intrinsic apoptotic pathways, contributing to neurodegeneration. Therefore, the APP allele contributes to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described begins with the amyloid beta precursor protein (APP), which is cleaved to produce Abeta, a key component in the pathogenesis of Alzheimer's disease. The sequence of events outlines an apoptotic signaling cascade, starting with the activation of FAS and proceeding through caspases, which are central to programmed cell death. This pathway is implicated in neuronal loss, a hallmark of Alzheimer's disease. The accumulation of Abeta, as part of amyloid plaques, is a defining feature of the disease. Thus, the APP allele contributes to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT gene encodes a receptor tyrosine kinase that plays a critical role in signal transduction pathways involved in cell growth, survival, and differentiation. Mutations in KIT, particularly those that lead to constitutive activation, can result in uncontrolled cell proliferation. In the provided pathway, KIT activates PI3K, leading to the production of PIP3, which in turn activates AKT. AKT phosphorylates and inactivates BAD, a pro-apoptotic protein, thereby promoting cell survival. When KIT is mutated, it can continuously activate this pathway, contributing to the development of certain cancers. This pathway is commonly dysregulated in gastrointestinal stromal tumors (GISTs), where KIT mutations are frequently observed.\n\n\\boxed{Gastrointestinal Stromal Tumor (GIST)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT gene encodes a receptor tyrosine kinase that, when mutated, can lead to constitutive activation of the PI3K-AKT signaling pathway, which promotes cell survival and proliferation. In this pathway, KIT activates PI3K, which phosphorylates PIP3, leading to the activation of AKT. AKT then phosphorylates BAD, inhibiting its pro-apoptotic function. Mutations in KIT that result in continuous activation of this pathway are associated with various diseases, including certain types of leukemia and gastrointestinal stromal tumors (GISTs). Specifically, activating mutations in KIT are frequently observed in GISTs, a type of sarcoma. \n\n\\boxed{Gastrointestinal Stromal Tumor (GIST)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT pathway, involving KIT, PI3K, PIP3, AKT, and BAD, is crucial in cell survival, proliferation, and apoptosis regulation. Mutations in the KIT gene, particularly in the catalytic subunits of PI3K (e.g., PIK3CA, PIK3CB, PIK3CD) or in AKT (AKT1, AKT2, AKT3), can lead to constitutive activation of this pathway, promoting uncontrolled cell growth. This dysregulation is a hallmark of certain cancers, especially those involving mast cells or melanocytes. Mutations in KIT are commonly associated with gastrointestinal stromal tumors (GISTs), a type of sarcoma. Additionally, KIT mutations are found in some cases of acute myeloid leukemia (AML) and melanoma. These mutations often result in resistance to therapy and poor prognosis. \n\n\\boxed{Gastrointestinal Stromal Tumor}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway outlines a sequence of events in apoptosis, starting with the SOD1 gene, which is involved in mitochondrial function and oxidative stress. The pathway shows how SOD1 can influence BCL2, which in turn affects BAX and BAK1, leading to the release of cytochrome c (CYCS), activation of APAF1, and subsequent caspase activation (CASP9 and CASP3), all key steps in the intrinsic apoptotic pathway. Mutations in SOD1 are known to cause the neurodegenerative disease amyotrophic lateral sclerosis (ALS). These mutations can lead to the production of misfolded SOD1 protein, which is toxic to motor neurons and disrupts normal cellular processes, including apoptosis regulation. This contributes to the progressive degeneration observed in ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway illustrates a sequence of events in apoptosis, starting with the SOD1 gene, which is a key player in protecting cells from oxidative damage by catalyzing the dismutation of superoxide radicals. The pathway suggests that mutations or dysfunction in SOD1 could lead to an imbalance in the regulation of apoptosis, potentially resulting in neurodegenerative diseases. Specifically, mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disorder characterized by the loss of motor neurons. These mutations are thought to cause misfolding of the SOD1 protein, leading to its toxic gain of function, which triggers a cascade of events that promote neuronal death.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway represents a mitochondrial apoptosis cascade. SOD1 (super oxide dismutase 1) is an antioxidant enzyme that normally detoxifies reactive oxygen species. In the context of this pathway, a mutation in SOD1 could lead to increased oxidative stress, potentially causing damage to mitochondrial function. This may result in the destabilization of the mitochondrial membrane, leading to the release of cytochrome c (CYCS). This initiates the caspase cascade via APAF1 and CASP9, ultimately culminating in apoptosis. Mutations in the SOD1 gene are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The accumulation of misfolded SOD1 proteins can lead to toxic effects on motor neurons, contributing to the pathogenesis of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway defined by the network (MEN1*+KMT2A) // (CDKN1B,CDKN2C) involves genes related to tumor suppression and epigenetic regulation. MEN1 encodes menin 1, a protein involved in DNA repair and regulation of gene expression. Mutations in MEN1 are associated with loss of tumor suppression, leading to uncontrolled cell growth. This pathway is implicated in the development of neuroendocrine tumors. Specifically, germline mutations in the MEN1 gene are known to cause Multiple Endocrine Neoplasia type 1 (MEN1), a hereditary cancer syndrome characterized by tumors in the parathyroid, pituitary, and enteropancreatic endocrine tissues. \n\n\\boxed{Multiple Endocrine Neoplasia type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves the MEN1 gene, which encodes menin 1, and is associated with the Multiple Endocrine Neoplasia type 1 (MEN1) syndrome. This syndrome is an autosomal dominant disorder characterized by the development of tumors in multiple endocrine glands, such as the parathyroid, pituitary, and pancreas. The pathway also includes genes like KMT2A, CDKN1B, and CDKN2C, which are involved in chromatin remodeling and cell cycle regulation. Mutations in the MEN1 gene disrupt these regulatory processes, leading to uncontrolled cell growth and tumorigenesis. The effect of the MEN1 allele, when mutated, is the predisposition to multiple endocrine neoplasia type 1.\n\n\\boxed{Multiple Endocrine Neoplasia type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves the MEN1 gene, which encodes menin 1, and is linked to the (MEN1*+KMT2A) and (CDKN1B, CDKN2C) network. MEN1 is a tumor suppressor gene, and its inactivation is associated with Multiple Endocrine Neoplasia type 1 (MEN1), a hereditary disorder characterized by the development of tumors in multiple endocrine glands, including the parathyroid, pituitary, and pancreas. The interaction with KMT2A and cyclin-dependent kinase inhibitors suggests a regulatory role in cell cycle control and chromatin modification. Loss of function of MEN1 leads to uncontrolled cell proliferation and tumorigenesis. \n\n\\boxed{Multiple Endocrine Neoplasia type 1}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APC gene is a key tumor suppressor in the WNT signaling pathway. The provided network suggests that a dysfunctional APC allele leads to the stabilization and nuclear translocation of CTNNB1 (\u03b2-catenin), which then activates TCF/LEF transcription factors. This results in the upregulation of target genes such as BIRC5, MYC, and CCND1, which are involved in cell proliferation and survival. This aberrant activation of the WNT pathway is a hallmark of colorectal cancer. Therefore, mutations in APC are strongly associated with the development of colorectal cancer.\n\n\\boxed{Colorectal cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the Wnt/\u03b2-catenin signaling cascade, which is regulated by APC, a tumor suppressor gene. Mutations in APC, particularly those leading to loss of function, result in the stabilization and nuclear translocation of CTNNB1 (\u03b2-catenin), which then activates target genes such as TCF/LEF, leading to increased expression of BIRC5, MYC, and CCND1. These genes promote cell proliferation and are associated with tumorigenesis. Loss of APC function is a hallmark of colorectal cancer, specifically in the development of adenomatous polyps and their progression to malignancy. \n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway outlines the WNT/\u03b2-catenin signaling pathway, which is critical in cell proliferation and differentiation. The APC gene is a tumor suppressor involved in regulating \u03b2-catenin levels. A mutation or loss of function in APC leads to stabilization of \u03b2-catenin, allowing it to accumulate and translocate to the nucleus, where it activates transcription of downstream genes such as MYC, CCND1, and BIRC5. This aberrant activation promotes uncontrolled cell growth and is a hallmark of colorectal cancer. Thus, defects in the APC gene are strongly associated with the development of colorectal cancer.\n\n\\boxed{Colorectal Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen, thus playing a key role in protecting cells from oxidative damage. Mutations in the SOD1 gene are primarily associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations lead to the production of a toxic, misfolded SOD1 protein that accumulates in motor neurons, causing their degeneration and ultimately leading to the symptoms of ALS. The pathway described involves SOD1 and the proteasome system, highlighting the potential role of protein degradation in the disease mechanism. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the SOD1 allele, as indicated by its involvement in a pathway that includes DERL1 and the proteasome, relates to protein degradation and quality control. SOD1 (superoxide dismutase 1) is primarily known for its role in mitochondrial function and antioxidant activity. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. This pathway suggests that SOD1 may be involved in proteasomal degradation processes, which are critical in clearing misfolded or damaged proteins. Dysregulation in these processes could contribute to ALS pathogenesis. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that plays a critical role in the detoxification of reactive oxygen species. Mutations in the SOD1 gene have been linked to amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations can lead to the production of a misfolded SOD1 protein, which may accumulate and cause toxicity to motor neurons. The pathway described involves the ubiquitin-proteasome system, which is responsible for degrading misfolded or damaged proteins. Components like DERL1, ubiquitin genes, and 26S proteasome subunits are involved in this process, highlighting the role of protein degradation in the disease mechanism. The biological effect of a dysfunctional SOD1 allele, therefore, is the contribution to the development of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that neutralizes superoxide radicals, which are harmful reactive oxygen species. Mutations in the SOD1 gene are strongly associated with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that leads to the degeneration of motor neurons. The provided pathway involves components of the dynein complex, which is critical for intracellular transport. Dysfunctional SOD1 can lead to the accumulation of toxic protein aggregates, mitochondrial dysfunction, and ultimately neuronal death. These effects are particularly detrimental in motor neurons, contributing to the hallmark symptoms of ALS such as muscle weakness and atrophy. The interaction between SOD1 and the dynein pathway may exacerbate the disease process by impairing axonal transport and cellular maintenance in neurons.  \n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the dismutation of superoxide radicals into oxygen and hydrogen peroxide. Mutations in the SOD1 gene are a common cause of the most common form of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations lead to the production of a misfolded SOD1 protein, which is toxic to motor neurons, resulting in their progressive degeneration. The pathway described includes several genes involved in intracellular transport and ciliary function, which may be affected by the misfolded SOD1 protein, exacerbating the disease process. \n\n\\boxed{Amyotrophic lateral sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that neutralizes superoxide radicals. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that leads to the degeneration of motor neurons. The pathway described involves several dynein and dynactin subunits, which are essential for intracellular transport and ciliary function. Dysfunctional SOD1 can lead to protein misfolding, aggregation, and mitochondrial dysfunction, contributing to neuronal death. This pathway\u2019s components, including DCTN and DNAH/DNAI/DNAL genes, are crucial for axonal transport, and their disruption may exacerbate the neurodegenerative process in ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein involved in synaptic function. The pathway described involves SNCA interacting with VMAT2 (SLC18A2), a vesicular monoamine transporter. Dysregulation of this interaction is implicated in the accumulation of alpha-synuclein, which is a hallmark of Parkinson's disease. Mutations or increased expression of SNCA can lead to abnormal protein aggregation, contributing to neuronal degeneration. This genetic pathway is closely associated with the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein involved in synaptic function. The pathway defined includes SNCA and VMAT2 (gene SLC18A2), which is responsible for vesicular monoamine transport. Abnormal accumulation of alpha-synuclein is a hallmark of Parkinson's disease, leading to degeneration of dopaminergic neurons. This pathway may be disrupted in Parkinson's disease, contributing to its pathogenesis.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein involved in synaptic function and regulation of neurotransmitter release. The pathway defined (SNCA -| VMAT2) suggests a regulatory interaction between SNCA and VMAT2 (encoded by SLC18A2), which is crucial for dopamine packaging in synaptic vesicles. Abnormal SNCA function or overexpression is implicated in the pathological accumulation of alpha-synuclein, forming Lewy bodies, which are a hallmark of Parkinson\u2019s disease. Mutations or duplications in SNCA are associated with autosomal dominant Parkinson\u2019s disease. This allele's biological effect, therefore, is primarily linked to the development of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an essential enzyme in the urea cycle. The pathway involves the production of N-acetylglutamate, a required activator for carbamoyl-phosphate synthase 1 (CPS1), which catalyzes the first committed step of the urea cycle. A deficiency or malfunction of NAGS leads to a block in the urea cycle, causing the accumulation of ammonia. This results in hyperammonemia, a life-threatening condition. The disease associated with NAGS deficiency is **N-acetylglutamate synthase deficiency**, also known as **CPS1 deficiency** when the defect is in CPS1. However, in the context of NAGS, the disease specifically is \\boxed{N-acetylglutamate synthase deficiency}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, which is essential for the synthesis of N-acetylglutamate, a required activator of carbamoyl-phosphate synthase 1 (CPS1) in the urea cycle. A deficiency in NAGS leads to a lack of N-acetylglutamate, which in turn inhibits CPS1 activity, resulting in the accumulation of ammonia. This condition is known as N-acetylglutamate synthase deficiency, a rare autosomal recessive disorder that contributes to hyperammonemia and can lead to severe neurological damage if untreated. \n\n\\boxed{N-Acetylglutamate Synthase Deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an essential enzyme in the urea cycle. This enzyme provides the activator molecule N-acetylglutamate for carbamoyl-phosphate synthase 1 (CPS1), which is also part of the urea cycle. A deficiency in NAGS leads to impaired urea cycle function, resulting in the accumulation of ammonia in the blood (hyperammonemia). This condition is associated with a rare autosomal recessive disorder known as NAGS deficiency, which is a type of congenital hyperammonemia. The disease is characterized by severe neurological symptoms, including seizures, coma, and developmental delays if left untreated. Early diagnosis and management, such as dietary restrictions and ammonia scavengers, are critical for mitigating the severity of the condition.\n\n\\boxed{NAGS Deficiency}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that detoxifies reactive oxygen species. Mutations in SOD1 have been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. This pathway involves the endoplasmic reticulum stress response, with SOD1 interacting with BIP (HSPA5), which is involved in protein folding and the unfolded protein response. ERN1 activates XBP1, a transcription factor that helps the cell adapt to ER stress. Dysfunctional SOD1 may lead to ER stress and subsequent neurodegeneration, contributing to the development of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that detoxifies superoxide radicals. Mutations in SOD1 are associated with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that leads to the death of motor neurons. The provided pathway involves SOD1, which may influence ER stress response through interactions with BIP and ERN1, ultimately affecting XBP1. This pathway may reflect the cellular stress response mechanisms that are dysregulated in ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nSOD1 (superoxide dismutase 1) is a key enzyme that catalyzes the dismutation of superoxide radicals into hydrogen peroxide and molecular oxygen, playing a critical role in protecting cells from oxidative damage. Mutations in the SOD1 gene are associated with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that leads to loss of motor neurons. The SOD1 allele in this genomic pathway is linked to the endoplasmic reticulum (ER) stress response via the unfolded protein response (UPR) pathway, involving BIP, ERN1, and XBP1. This pathway is activated in response to ER stress and can contribute to neuronal dysfunction and death. Therefore, the SOD1 allele contributes to the pathogenesis of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the RAS (NRAS and KRAS) proteins activating PI3K, leading to PIP3 production, which in turn activates AKT. AKT then negatively regulates BAD, a pro-apoptotic protein, promoting cell survival. Mutations in NRAS, especially in the context of this pathway, can lead to constitutive activation of the PI3K/AKT signaling cascade, promoting uncontrolled cell proliferation and inhibiting apoptosis. This aberrant signaling is commonly associated with certain cancers, particularly melanoma, where NRAS mutations are frequently observed. These mutations contribute to tumor growth and progression by disrupting normal cellular regulation.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway describes a signaling cascade starting with NRAS and KRAS, which activate PI3K, leading to PIP3 production and subsequent activation of AKT. AKT then phosphorylates BAD, inhibiting apoptosis. Mutations in NRAS, particularly in this context, can result in constitutive activation of the PI3K/AKT pathway, promoting cell survival and proliferation. This dysregulation is commonly observed in various cancers. Specifically, mutations in NRAS are frequently associated with melanoma, a type of skin cancer. These mutations can drive tumor growth by enhancing cellular growth and survival signals.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe network defined involves the RAS/MAPK and PI3K/AKT pathways, both of which are critical for cell growth, survival, and proliferation. NRAS is a GTPase that, when mutated, can become constitutively activated, leading to continuous signaling through these pathways. This uncontrolled signaling contributes to unregulated cell growth and is frequently observed in certain cancers. Specifically, NRAS mutations are commonly associated with melanoma, a type of skin cancer. These mutations can drive tumor initiation and progression by promoting cell survival and proliferation. Therefore, the biological effect of an NRAS allele with a mutation in this context is oncogenic transformation, contributing to the development of melanoma.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene, located on chromosome 17, encodes the p53 protein, a critical tumor suppressor that regulates cell cycle arrest, DNA repair, and apoptosis. Mutations in TP53 can lead to loss of function, disrupting these protective mechanisms and promoting uncontrolled cell growth. The pathway includes genes involved in DNA damage response and apoptosis such as CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, indicating its role in DNA repair and stress response. Loss of functional TP53 is strongly associated with a variety of cancers, most notably Li-Fraumeni syndrome, a hereditary disorder characterized by a high risk of developing multiple types of cancers, including sarcomas, breast cancer, and brain tumors. \n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene, located on chromosome 17, encodes the tumor protein p53, which is a critical regulator of the DNA damage response, apoptosis, and cell cycle control. The provided pathway includes downstream targets such as CDKN1A, GADD45A/B/G, BAX, BAK1, DDB2, and POLK, all of which are involved in DNA repair, cell cycle arrest, and apoptosis. Mutations in TP53 that disrupt its function can lead to loss of these protective mechanisms, increasing the risk of uncontrolled cell proliferation and tumorigenesis. This gene is commonly mutated in a wide range of cancers due to its central role in maintaining genomic integrity. Therefore, the biological effect of a defective TP53 allele is the promotion of cancer development.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene encodes the p53 protein, a critical tumor suppressor involved in regulating the cell cycle, DNA repair, and apoptosis. The listed pathway includes target genes such as CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, which are all involved in DNA damage response, apoptosis, and cell cycle control. Mutations in TP53 are known to disrupt these processes, leading to uncontrolled cell growth and genomic instability. This dysfunction is a hallmark of various cancers, most notably Li-Fraumeni syndrome, which is characterized by a high risk of developing multiple types of tumors at a young age. \n\n\\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway defined by DJ1 (PARK7) and TP53 leading to DUSP1 suggests a regulatory mechanism involving oxidative stress response and apoptosis. PARK7, also known as DJ1, is crucial in protecting neurons from oxidative damage. Mutations in PARK7 are associated with early-onset Parkinson's disease, contributing to mitochondrial dysfunction and increased susceptibility to oxidative damage. This leads to progressive degeneration of dopaminergic neurons, a hallmark of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene encodes the DJ1 protein, which is involved in protecting cells from oxidative stress and maintaining mitochondrial function. The pathway described includes TP53, a tumor suppressor, and DUSP1, a phosphatase that modulates MAP kinase signaling. In this context, the DJ1* allele may contribute to impaired cellular responses to stress, leading to neurodegeneration. Mutations in PARK7 have been associated with early-onset Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves the gene PARK7 (also known as DJ1), which is associated with the neurodegenerative disorder Parkinson's disease. The network suggests that PARK7 may interact with TP53, a tumor suppressor gene, leading to the activation of DUSP1, a dual specificity phosphatase. This interaction may influence cellular responses to stress and possibly contribute to neuronal degeneration. Mutations or dysfunction in PARK7 have been linked to early-onset Parkinson's disease, indicating its role in maintaining neuronal health.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 gene encodes a receptor tyrosine kinase involved in cellular proliferation and differentiation. In the provided pathway, FGFR3 activates a signaling cascade through GRB2, SOS, RAS, RAF, MEK, ERK, MSK1, and ultimately MYC, which is a key transcription factor regulating cell growth and division. Mutations in FGFR3 that lead to constitutive activation of this pathway can result in uncontrolled cell proliferation and are strongly associated with the development of certain cancers. Specifically, activating mutations in FGFR3 are commonly found in\u8180\u80f1\u764c (bladder cancer), where they contribute to tumor growth and progression.\n\n\\boxed{Bladder Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is involved in cellular proliferation and differentiation. Activating mutations in FGFR3 can lead to constitutive signaling, promoting uncontrolled cell growth. This aberrant signaling is associated with several diseases, including achondroplasia, a common form of dwarfism, and certain cancers such as bladder cancer and multiple myeloma. The pathway's downstream effects, including activation of RAS, RAF, MEK, ERK, and MYC, are typically involved in oncogenic transformation and tumor progression.\n\n\\boxed{Bladder Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway, as defined, involves a series of intracellular signaling components that transmit external signals to regulate cellular functions such as proliferation, differentiation, and survival. Mutations in FGFR3, particularly in the kinase domain, can lead to constitutive activation of the pathway, even in the absence of its ligand. This uncontrolled activation promotes abnormal cell growth and division. Such alterations are commonly observed in various cancers, particularly bladder cancer, where FGFR3 mutations are frequent and contribute to tumor development and progression. The downstream effectors of this pathway, like RAS, RAF, MEK, ERK, and MYC, are well-known oncogenic drivers in multiple malignancies. Therefore, the biological effect of this FGFR3 allele is the promotion of tumorigenesis.\n\n\\boxed{Bladder Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET proto-oncogene is a receptor tyrosine kinase involved in the RET/PI3K/AKT/MTOR signaling pathway. Mutations in RET, particularly in the tyrosine kinase domain, lead to constitutive activation of this pathway, promoting uncontrolled cell proliferation and survival. This aberrant signaling is implicated in the development of multiple endocrine neoplasia type 2 (MEN2), including medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia. RET mutations are also associated with congenital hypothyroidism and other neurocristopathies. The continuous activation of PI3K, AKT, and MTOR downstream of RET contributes to tumorigenesis by enhancing cell growth, resistance to apoptosis, and metabolic reprogramming.\n\n\\boxed{Multiple Endocrine Neoplasia Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, specifically in the context of the PI3K-AKT-MTOR pathway, contributes to the development of medullary thyroid carcinoma (MTC). RET is a receptor tyrosine kinase, and activating mutations in RET lead to constitutive activation of downstream signaling pathways, including PI3K/AKT/MTOR. This unregulated signaling promotes cell survival, proliferation, and resistance to apoptosis, all of which are hallmarks of cancer. The activation of this pathway is a key driver in the oncogenic process of MTC, a neuroendocrine tumor of the thyroid. \n\n\\boxed{Medullary Thyroid Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET proto-oncogene is a receptor tyrosine kinase involved in the RET/PI3K/AKT/mTOR signaling pathway. Germline or somatic mutations in RET can lead to constitutive activation of this pathway, promoting uncontrolled cell growth and proliferation. This aberrant signaling is implicated in several diseases, most notably multiple endocrine neoplasia type 2 (MEN2), which includes medullary thyroid carcinoma (MTC), pheochromocytoma, and parathyroid hyperplasia. RET mutations are also associated with other conditions such as congenital hypothyroidism and familial medullary thyroid carcinoma. Additionally, RET alterations have been identified in some cases of non-MEN2-related thyroid cancer and other malignancies.  \n\\boxed{Multiple Endocrine Neoplasia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 (profilin 1) plays a critical role in actin dynamics by binding to monomeric actin and regulating its polymerization into filamentous actin. Mutations in PFN1 have been linked to a rare neurodegenerative disorder known as **proline-rich transmembrane protein 2 (PRRT2)-associated neurological disorders**, although more specifically, mutations in PFN1 itself are associated with a condition called **dystonia 11**. This disease is characterized by involuntary muscle contractions, typically beginning in childhood, and may be accompanied by other neurological symptoms such as seizures or autonomic dysfunction. The disruption of PFN1 function likely impairs normal actin regulation, leading to abnormalities in neuronal structure and function.\n\n\\boxed{Dystonia 11}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 (profilin 1) is a key regulator of actin dynamics, playing a critical role in the nucleation and elongation of actin filaments. Mutations in PFN1 have been associated with a neurodegenerative disorder known as Amyotrophic Lateral Sclerosis (ALS), also referred to as Lou Gehrig's disease. These mutations can lead to the gain of toxic function, promoting the aggregation ofPFN1 and subsequent disruption of normal actin polymerization processes, which is essential for neuronal function and survival. This disruption may contribute to the progressive degeneration of motor neurons observed in ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PFN1 gene encodes profilin 1, a protein involved in actin dynamics and RNA binding. Mutations in PFN1 have been linked to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. These mutations can disrupt the normal function of profilin 1, leading to impaired actin filament assembly and RNA processing, contributing to neuronal dysfunction and degeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway begins with PSEN1 and PSEN2, which are involved in the gamma-secretase complex, critical for processing amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). The pathway progresses through calcium release and mitochondrial dysfunction, culminating in apoptosis. This sequence aligns with the pathophysiology of AD, where impaired calcium homeostasis and mitochondrial dysfunction contribute to neuronal death. Thus, the PSEN1 allele contributes to the development of \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key component of the gamma-secretase complex, which processes amyloid precursor protein (APP) into amyloid-beta (A\u03b2) peptides. Abnormal processing of A\u03b2 leads to the accumulation of A\u03b2 plaques, a hallmark of Alzheimer's disease. The provided pathway shows that PSEN1 and PSEN2 are upstream regulators of a calcium signaling cascade that influences mitochondrial permeability transition pore (MPTP) opening, leading to the release of cytochrome c (CYCS) and subsequent activation of the apoptotic cascade involving APAF1, CASP9, CASP3, and CASP7. This pathway connects PSEN1 to both neurodegeneration and apoptosis, which are central to Alzheimer's disease pathogenesis. Therefore, mutations in PSEN1 contribute to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a component of the \u03b3-secretase complex involved in amyloid precursor protein (APP) cleavage. In the provided pathway, PSEN1 and PSEN2 are upstream of RYR3, which is part of a cascade leading to calcium release, mitochondrial dysfunction, and ultimately apoptosis via the intrinsic pathway. Pathogenic variants in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). These variants disrupt normal APP processing, increasing production of amyloid-\u03b2 (A\u03b2) peptides, which accumulate as plaques in the brain, a hallmark of AD. This contributes to neurodegeneration and cognitive decline. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive juvenile parkinsonism, also known as Parkinson disease 5 (PARK5). This pathway, starting with PRKN and involving PLCG1, IP3, and ITPR, suggests a role in calcium signaling. Calcium dysregulation is implicated in neurodegenerative diseases, including Parkinson's. Thus, dysfunction of the PRKN allele likely contributes to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are strongly associated with early-onset Parkinson's disease (PD), specifically a form known as autosomal recessive juvenile parkinsonism (ARJP). Parkin is critical for mitochondrial quality control and may also play a role in autophagy. Disruption of PRKN function leads to impaired clearance of damaged mitochondria, accumulation of oxidative stress, and neuronal degeneration, particularly in dopaminergic neurons of the substantia nigra, which is a hallmark of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination and degradation of proteins. Mutations in PRKN are associated with early-onset Parkinson's disease (PD), specifically the recessive form known as Parkinson disease 6 (PARK6). The pathway described suggests a role for PRKN in calcium signaling through its interaction with PLCG1 and ITPR, which are involved in intracellular calcium release. Disruption of this pathway could lead to neuronal dysfunction and degeneration, contributing to the pathogenesis of Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the pathogenesis of Huntington's disease. This neurodegenerative disorder is caused by a CAG trinucleotide repeat expansion in the HTT gene, leading to the production of a mutant huntingtin protein. This mutant protein aggregates in neurons, particularly in the striatum and cortex, causing progressive neuronal dysfunction and death. The network involving HTT and components of the ubiquinol-cytochrome c reductase complex (Complex III) may reflect mitochondrial dysfunction, which is implicated in the disease's progression. The interaction of HTT with the cytochrome c (CytC) pathway may also suggest a role in apoptosis. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is associated with Huntington's disease. This neurodegenerative disorder is caused by a mutation in the HTT gene, specifically an expanded CAG trinucleotide repeat. The mutant huntingtin protein leads to neuronal dysfunction and death, primarily affecting the brain's basal ganglia and cerebral cortex. The provided pathway involves the electron transport chain, particularly complex III, which is crucial for mitochondrial function. Disruption of this pathway may contribute to the mitochondrial dysfunction observed in Huntington's disease, exacerbating the neurodegenerative process. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the molecular pathway involving mitochondrial complex III (CxIII) and cytochrome c (CytC). Mutations in HTT, specifically CAG trinucleotide repeat expansions, lead to the production of an aberrant huntingtin protein. This mutant protein disrupts mitochondrial function, particularly affecting the electron transport chain, leading to oxidative stress, mitochondrial dysfunction, and neuronal damage. These effects are particularly pronounced in neurons, leading to progressive degeneration. The disease associated with this HTT allele is Huntington's disease, an autosomal dominant neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms.\n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET gene is a proto-oncogene that encodes a receptor tyrosine kinase involved in the RET/PTP signaling pathway. Mutations in RET can lead to constitutive activation of the pathway, promoting uncontrolled cell proliferation and survival. In the given pathway, RET activates RAS (HRAS, KRAS, or NRAS), which in turn activates RAF (ARAF, BRAF, or RAF1), followed by MEK (MAP2K1 or MAP2K2) and finally ERK (MAPK1 or MAPK3). This is a key component of the MAPK/ERK signaling cascade, which regulates cell growth and differentiation. Gain-of-function mutations in RET are implicated in several diseases, most notably multiple endocrine neoplasia type 2 (MEN2), which includes medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia. Therefore, the biological effect of a RET allele with activating mutations is the promotion of tumorigenesis, particularly in the context of MEN2.  \n\\boxed{Multiple Endocrine Neoplasia Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, when mutated, can activate the RET proto-oncogene, leading to constitutive signaling through the RAS-RAF-MEK-ERK pathway. This uncontrolled signaling promotes cell proliferation and survival. Inherited RET mutations are strongly associated with Multiple Endocrine Neoplasia type 2 (MEN2), which includes medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia. RET mutations are also implicated in some cases of papillary thyroid cancer. \n\n\\boxed{Multiple Endocrine Neoplasia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET proto-oncogene is a receptor tyrosine kinase involved in the RET/RAS/RAF/MEK/ERK signaling pathway. Mutations in RET can lead to constitutive activation of this pathway, promoting uncontrolled cell growth and proliferation. This aberrant signaling is implicated in the development of multiple endocrine neoplasia type 2 (MEN2), including medullary thyroid carcinoma and pheochromocytoma. Additionally, RET mutations have been associated with other tumorigenic processes in various cancers.  \n\\boxed{Multiple Endocrine Neoplasia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PIK3CA gene encodes the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), which is a key component of the PI3K/AKT/mTOR signaling pathway. Mutations in PIK3CA can lead to constitutive activation of this pathway, promoting cell growth, proliferation, and survival. This aberrant activation is implicated in various cancers, including breast, colon, and endometrial cancers. The given pathway\u2014PI3K* -> PIP3 -> AKT -> MTOR -> S6K\u2014illustrates the downstream signaling cascade that contributes to tumor progression. PIK3CA mutations are frequently observed in human cancers and are associated with resistance to targeted therapies. Thus, the biological effect of this PIK3CA allele is the promotion of tumorigenesis.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PIK3CA gene encodes the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), which is a key activator in the PI3K/AKT/mTOR signaling pathway. Mutations in PIK3CA, such as the E545K or H1047R alleles, lead to constitutive activation of this pathway, promoting cell proliferation, survival, and metabolism. This dysregulation is implicated in various cancers by enhancing tumor growth and resistance to apoptosis. Specifically, PIK3CA mutations are frequently observed in breast, colon, and endometrial cancers. These mutations contribute to oncogenesis by driving uncontrolled cell growth through persistent signaling via AKT and mTOR, which in turn activates downstream effectors like S6K involved in protein synthesis. \n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PIK3CA gene encodes the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), which is the initial enzyme in the described pathway. Mutations in PIK3CA can lead to constitutive activation of the PI3K/AKT/mTOR signaling pathway, promoting cell survival, proliferation, and growth. This aberrant activation is commonly observed in various cancers, including breast, colon, and endometrial cancers. The pathway's downstream effectors, such as AKT and mTOR, are central to oncogenic processes. PIK3CA mutations are frequently associated with tumorigenesis and cancer progression.\n\n\\boxed{Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are strongly associated with early-onset Parkinson's disease (PD). Specifically, PRKN is a major susceptibility gene for autosomal recessive juvenile parkinsonism (ARJP), a form of Parkinson's disease. The pathway involving PRKN, UBCH7/8, and alpha-synuclein (SNCA) is crucial for the degradation of misfolded proteins and the maintenance of neuronal health. Dysfunction in this pathway can lead to the accumulation of alpha-synuclein, a hallmark of Parkinson's disease, and impaired proteostasis, contributing to the degeneration of dopaminergic neurons in the substantia nigra. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a major cause of early-onset autosomal recessive Parkinson's disease. The pathway includes ubiquitin conjugating enzymes (UBCH7/8, UBE2L3, UBE2L6) and alpha-synuclein (SNCA), which are involved in protein degradation and neuronal health. Dysfunctional parkin leads to impaired ubiquitination, accumulation of misfolded proteins, and subsequent neuronal degeneration. This contributes to the loss of dopaminergic neurons in the substantia nigra, a hallmark of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a common cause of early-onset autosomal recessive Parkinson's disease. This pathway, involving PRKN and related ubiquitin conjugating enzymes, is critical for mitochondrial quality control through mitophagy. Dysfunctional parkin impairs this process, leading to the accumulation of damaged mitochondria and subsequent neuronal degeneration in the substantia nigra, characteristic of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 gene is a key component of the mitochondrial quality control pathway, working in conjunction with PRKN (parkin) and MFN1/2 (mitofusins) to maintain mitochondrial health. Mutations in PINK1 are associated with early-onset Parkinson's disease. This pathway is involved in mitophagy, the selective degradation of damaged mitochondria. When PINK1 is functional, it phosphorylates ubiquitin and other substrates, tagging damaged mitochondria for removal by the proteasome. Loss-of-function mutations in PINK1 disrupt this process, leading to the accumulation of dysfunctional mitochondria, oxidative stress, and neurodegeneration, particularly in dopaminergic neurons. These defects are implicated in the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 gene is part of a pathway involving PRKN (parkin) and MFN1/2 (mitofusins), which are crucial for mitochondrial quality control through a process called mitophagy. Mutations in PINK1 lead to dysfunctional mitochondrial dynamics and impaired clearance of damaged mitochondria. This pathway is central to the pathogenesis of Parkinson's disease. PINK1 is an essential kinase that phosphorylates ubiquitin and promotes the recruitment of parkin to damaged mitochondria, initiating their degradation. Loss of PINK1 function disrupts this process, leading to the accumulation of defective mitochondria, neuronal stress, and eventually neurodegeneration, particularly in dopaminergic neurons of the substantia nigra. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 gene is a key component of the mitochondrial quality control pathway, working with PRKN (parkin) and MFN1/2 (mitofusins) to maintain mitochondrial integrity. Mutations in PINK1 lead to impaired mitochondrial function, increased oxidative stress, and neuronal degeneration. This pathway is critical in the clearance of damaged mitochondria through mitophagy. Dysfunction in this process is strongly associated with Parkinson's disease. PINK1 mutations are a known cause of early-onset, autosomal recessive Parkinson's disease. The PINK1 allele is therefore implicated in the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a crucial component of the gamma-secretase complex involved in the processing of amyloid precursor protein (APP). Mutation in PSEN1 leads to abnormal cleavage of APP, resulting in the accumulation of beta-amyloid peptides, which are a hallmark of Alzheimer's disease. The pathway described involves PSEN1 activating GSK3B, which in turn regulates the activity of kinesin motor proteins (KIF5) and their light chain subunits (KLC), likely influencing intracellular transport and signaling. This disruption may exacerbate the pathophysiology of Alzheimer's disease. Therefore, mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPSEN1 (presenilin 1) is a key component of the gamma-secretase complex, which is involved in the proteolytic cleavage of the amyloid precursor protein (APP). This process generates amyloid-beta peptides, which accumulate in the brain and are a hallmark of Alzheimer's disease. The pathway defined includes PSEN1 activating GSK3B, which in turn modulates the kinesin motor complex (KIF5 + KLC). These proteins are involved in intracellular transport, and their dysregulation may contribute to neuronal dysfunction. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease, leading to the accumulation of amyloid-beta plaques and neurofibrillary tangles. The biological effect of this PSEN1 allele, therefore, is a significant contribution to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in amyloid-beta peptide processing. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease. The provided pathway indicates that PSEN1 influences GSK3B, which in turn regulates the phosphorylation status of tau protein, and modulates the activity of KIF5 and KLC proteins, which are essential for microtubule-based transport. Dysregulation of this pathway may lead to altered tau phosphorylation and disruption of intracellular transport, both of which are implicated in neurodegenerative processes. These molecular changes are linked to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a core component of the gamma-secretase complex involved in the proteolytic processing of the amyloid precursor protein (APP). This processing generates amyloid-beta peptides, which are central to the pathogenesis of Alzheimer's disease. The pathway described involves PSEN1 influencing GSK3B, a kinase implicated in tau hyperphosphorylation, a hallmark of Alzheimer's pathology. GSK3B also modulates the activity of KIF5 and KLC proteins, which are involved in intracellular transport. Dysregulation of these processes may contribute to neuronal dysfunction and degeneration. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the proteolytic processing of amyloid precursor protein (APP). This processing generates amyloid-beta peptides, which accumulate in Alzheimer's disease (AD). Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease. The provided pathway highlights the interaction of PSEN1 with GSK3B and the kinesin light chain (KLC) subunits of the kinesin-5 family, which are involved in intracellular transport. These interactions may modulate the trafficking and processing of APP, thereby influencing amyloid-beta production. Thus, the PSEN1 allele contributes to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a protein involved in the gamma-secretase complex, which processes amyloid precursor protein (APP) into amyloid-beta peptides. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease. The network definition provided indicates a pathway involving PSEN1, GSK3B, and the KIF5+KLC complexes, which are involved in intracellular transport and signaling. The biological effect of PSEN1 mutations in this context is the disruption of amyloid processing and accumulation, leading to neurodegeneration and the clinical manifestation of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a common cause of early-onset autosomal recessive Parkinson's disease. The pathway includes components involved in ubiquitination, such as UBCH7/8 (ubiquitin conjugating enzymes), PRKN (the E3 ligase), and PAELR (a ubiquitin-like modifier). The presence of PRKN in this network underscores its role in protein degradation and mitochondrial quality control. Malfunction of parkin leads to accumulation of damaged proteins and impaired mitochondrial function, which are key features in Parkinson's disease. Thus, this PRKN allele contributes to $\\boxed{Parkinson's disease}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with early-onset Parkinson's disease, particularly the recessive form known as PARK2. This allele contributes to the pathogenesis of Parkinson's disease by impairing mitochondrial function and leading to the accumulation of defective proteins, which results in neuronal degeneration, primarily in dopaminergic neurons of the substantia nigra. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a common cause of autosomal recessive early-onset Parkinson's disease. The pathway described involves ubiquitin conjugating enzymes (UBCH7/8 and UBE2L3/UBE2L6), PRKN, and GPR37, all of which are implicated in protein degradation and cellular stress responses. Dysfunction of parkin leads to impaired mitochondrial function and accumulation of damaged proteins, contributing to neurodegeneration. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene is central to a pathway involving Abeta, NMDAR, Ca2+ signaling, mitochondrial calcium uptake, and the release of cytochrome c, which are all key elements in the pathogenesis of Alzheimer's disease. This pathway is implicated in neurodegeneration, synaptic dysfunction, and neuronal apoptosis, all characteristic of Alzheimer's. The accumulation of Abeta peptides, derived from APP, leads to plaque formation, while overactivation of NMDARs and subsequent Ca2+ overload contributes to mitochondrial dysfunction and cell death. Therefore, this APP allele contributes to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene is involved in the production of amyloid-beta peptides, which accumulate in the brain and form plaques. These plaques are a hallmark of Alzheimer's disease. The described pathway illustrates how APP contributes to a cascade leading to neuronal dysfunction and cell death, involving Abeta, NMDAR activation, Ca2+ overload, mitochondrial dysfunction, and ultimately the release of cytochrome c. This sequence of events is closely associated with the pathogenesis of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the amyloid precursor protein (APP) and its downstream effects, including the production of amyloid beta (Abeta), activation of NMDA receptors, and subsequent mitochondrial calcium overload leading to the release of cytochrome c. This cascade is closely associated with neurodegeneration. The APP gene is a key player in Alzheimer's disease, as mutations in APP can lead to increased production of harmful Abeta peptides, which accumulate as plaques in the brain. These plaques are a hallmark of Alzheimer's disease and are linked to neuronal dysfunction and death.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the thyroid hormone synthesis process, where TPO (thyroid peroxidase) catalyzes the iodination of tyrosine residues on thyroglobulin (TG), leading to the formation of monoiodotyrosine (MIT), diiodotyrosine (DIT), and ultimately T3 and T4. A malfunctioning TPO allele would impair this critical enzymatic activity, disrupting the production of thyroid hormones. This would result in hypothyroidism, a condition characterized by insufficient thyroid hormone levels, which can lead to developmental and metabolic issues. The disease specifically associated with TPO dysfunction is congenital hypothyroidism. \n\n\\boxed{Congenital Hypothyroidism}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TPO gene encodes thyroid peroxidase, a critical enzyme in thyroid hormone synthesis. The pathway described involves TPO-mediated iodination of tyrosine residues on thyroglobulin (TG) to form monoiodotyrosine (MIT) and diiodotyrosine (DIT), which are then coupled to form triiodothyronine (T3) and thyroxine (T4). Mutations in TPO can impair this process, leading to congenital hypothyroidism. This condition results from inadequate production of thyroid hormones, which are essential for normal growth and development. If left untreated, it can cause intellectual disabilities and growth retardation. Therefore, the biological effect of a dysfunctional TPO allele is the development of congenital hypothyroidism.\n\n\\boxed{Congenital Hypothyroidism}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TPO (thyroid peroxidase) enzyme is critical in the synthesis of thyroid hormones by catalyzing the oxidation of iodide and its incorporation into tyrosine residues of thyroglobulin (TG), forming monoiodotyrosine (MIT) and diiodotyrosine (DIT), which further combine to form T3 and T4. Mutations in the TPO gene can impair this process, leading to a deficiency in thyroid hormone production. This results in congenital hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormones, often from birth. If untreated, it can cause growth and developmental issues, including intellectual disability. \n\n\\boxed{Congenital Hypothyroidism}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, which is critical for the synthesis of N-acetylglutamate, an essential activator of carbamoyl-phosphate synthetase 1 (CPS1) in the urea cycle. A defective NAGS allele leads to a loss of function in this enzyme, resulting in impaired urea cycle function. This disrupts the body's ability to detoxify ammonia, leading to the accumulation of ammonia in the blood (hyperammonemia). The resulting condition is a rare inherited metabolic disorder known as N-acetylglutamate synthase deficiency, which is a cause of neonatal-onset hyperammonemia and is part of the urea cycle disorders.\n\n\\boxed{N-Acetylglutamate Synthase Deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an essential enzyme in the urea cycle. The pathway shown includes NAGS, NAG (N-acetylglutamate), and CPS1 (carbamoyl-phosphate synthase 1), which are all critical for the synthesis of N-acetylglutamate, a required activator of CPS1. Mutations in the NAGS gene lead to a deficiency in N-acetylglutamate synthase, resulting in a lack of N-acetylglutamate and subsequently impairing CPS1 activity. This disruption impairs the urea cycle, leading to the accumulation of ammonia in the blood (hyperammonemia), which is toxic to the nervous system. This condition is known as NAGS deficiency, a rare autosomal recessive metabolic disorder. \n\n\\boxed{NAGS Deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS (N-acetylglutamate synthase) gene is critical in the urea cycle, as it produces N-acetylglutamate, an essential activator of CPS1 (carbamoyl-phosphate synthase 1), which is the first enzyme in the urea cycle. A deficiency in NAGS leads to an inability to activate CPS1, resulting in impaired ammonia detoxification. This deficiency causes elevated ammonia levels in the blood (hyperammonemia), which can lead to severe neurological damage. The condition is known as NAGS deficiency, a rare autosomal recessive disorder. Symptoms include metabolic crises, vomiting, lethargy, and in severe cases, coma or death if untreated. The disease is part of the broader group of urea cycle disorders.\n\n\\boxed{NAGS Deficiency}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive ataxia, dystonia, and other neurological symptoms. ATXN3 is part of a protein interaction network that includes components of the autophagy pathway, such as BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1. These proteins are involved in autophagy, a cellular process that degrades and recycles damaged components. Dysfunctions in this pathway may contribute to the accumulation of toxic proteins and cellular stress, leading to neuronal degeneration. Therefore, mutations in ATXN3 disrupt this critical pathway, ultimately contributing to the pathogenesis of SCA3.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the ATXN3 allele in this genomic pathway is associated with the progression of spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. ATXN3 is a key component of the autophagy pathway, and its dysfunction may impair the clearance of misfolded proteins, leading to the accumulation of toxic proteins in neurons. This pathway, which includes BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1, plays a critical role in autophagosome formation and cellular homeostasis. Mutations or dysregulation of ATXN3 may disrupt autophagy, contributing to neuronal degeneration observed in SCA3.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is primarily associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is caused by the expansion of a CAG trinucleotide repeat in the ATXN3 gene, leading to the production of an abnormally long ataxin-3 protein. The expanded protein accumulates in neuronal cells, causing toxicity and progressive degeneration of the cerebellum and brainstem. The provided pathway indicates interactions with autophagy-related genes (BECN1, PIK3C3, ATG14, PIK3R4, AMBRA1), suggesting that ATXN3 may influence autophagy processes. Impairment in autophagy could exacerbate the accumulation of misfolded proteins, contributing to neuronal dysfunction and disease progression.\n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene encodes a serine/threonine kinase involved in the MAPK/ERK signaling pathway, which is critical for cell growth and differentiation. Mutations in BRAF, such as the V600E substitution, lead to constitutive activation of the kinase, causing continuous signaling through MEK and ERK. This aberrant signaling promotes uncontrolled cell proliferation and can lead to tumor formation. Specifically, BRAF mutations are frequently observed in melanoma, a type of skin cancer. These mutations are implicated in the pathogenesis of about 50% of melanomas and are also found in other cancers, including thyroid, colorectal, and ovarian cancers. Targeted therapies have been developed to inhibit BRAF-mutant tumors, such as vemurafenib and dabrafenib. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene is part of the MAP kinase signaling pathway, which is critical for cell proliferation and survival. The network defined by BRAF \u2192 MEK \u2192 ERK is a core component of the RAS-RAF-MEK-ERK signaling cascade. Mutations in BRAF, particularly the V600E mutation, lead to constitutive activation of this pathway, resulting in uncontrolled cell growth. This aberrant signaling is frequently observed in various cancers, most notably in melanoma. The presence of this BRAF allele contributes to the development of melanoma by promoting tumorigenesis and tumor progression. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene encodes a serine/threonine kinase that plays a critical role in the MAPK/ERK signaling pathway, which is essential for cell proliferation and survival. Mutations in BRAF, particularly the V600E mutation, lead to constitutive activation of the BRAF kinase, resulting in continuous signaling through MEK and ERK. This uncontrolled activation promotes unregulated cell growth and division, contributing to the development of various cancers. The pathway involves BRAF \u2192 MEK (MAP2K1 or MAP2K2) \u2192 ERK (MAPK1 or MAPK3). This aberrant signaling is frequently observed in melanoma, thyroid cancer, and certain leukemias. The persistent activation of the ERK pathway is a hallmark of these malignancies. \n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO allele is a key component of the Hedgehog (Hh) signaling pathway, which is critical for embryonic development and tissue homeostasis. In its active form, SMO promotes the activation of GLI transcription factors, leading to the expression of downstream target genes such as GLI1, PTCH, HHIP, and others. Mutations in SMO that enhance its activity can result in aberrant activation of the Hh pathway, contributing to uncontrolled cell proliferation and tumorigenesis. This dysregulation is implicated in various cancers, particularly medulloblastoma, a type of brain tumor that frequently arises in children. The pathway's involvement in developmental processes also links SMO mutations to congenital disorders, such as nevoid basal cell carcinoma syndrome (Gorlin syndrome), which is associated with mutations in PTCH but can also be influenced by SMO pathway dysregulation.\n\n\\boxed{Medulloblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO allele is part of the Hedgehog (Hh) signaling pathway, which plays a critical role in embryonic development and tissue homeostasis. Mutations in SMO can lead to constitutive activation of the Hh pathway, disrupting normal developmental processes. This aberrant signaling is implicated in the development of certain cancers, particularly basal cell carcinoma (BCC), a common form of skin cancer. Additionally, SMO mutations have been associated with other malignancies such as medulloblastoma and some types of leukemia. The dysregulation of SMO contributes to uncontrolled cell proliferation and tumor growth by altering the downstream effects of the Hh pathway. \n\n\\boxed{Basal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO allele is a key component of the Hedgehog signaling pathway, which is essential for embryonic development and tissue maintenance. Mutations in SMO can lead to aberrant activation of this pathway, contributing to the development of various cancers, including basal cell carcinoma, medulloblastoma, and other malignancies. Specifically, gain-of-function mutations in SMO can result in constitutive activation of GLI transcription factors, promoting uncontrolled cell proliferation. This pathway dysregulation is also associated with conditions such as Gorlin syndrome (nevoid basal cell carcinoma syndrome), which is characterized by multiple basal cell carcinomas and other developmental abnormalities.\n\n\\boxed{Basal Cell Carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene is located on chromosome 21 and is central to the amyloidogenic pathway. The pathway described involves the production of Abeta (amyloid beta), which is a key component in the formation of amyloid plaques. These plaques are a hallmark of Alzheimer's disease. The network implies that Abeta interacts with components of the cytochrome c oxidase complex (CxIV), which is part of the electron transport chain in mitochondria, potentially affecting mitochondrial function. This interaction may lead to oxidative stress and neuronal dysfunction. The accumulation of Abeta and subsequent mitochondrial impairment is strongly associated with the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene is located on chromosome 21 and is central to the amyloidogenic pathway, where it is cleaved to produce amyloid-beta (A\u03b2) peptides. The network described includes the production of A\u03b2, which can accumulate and form plaques, a hallmark of Alzheimer's disease. The pathway also involves cytochrome c oxidase (COX) subunits, which are critical components of the mitochondrial respiratory chain. Disruption of this pathway may impair mitochondrial function and contribute to neurodegeneration. APP mutations, especially those leading to increased A\u03b2 production, are strongly associated with early-onset Alzheimer's disease. Therefore, the biological effect of this APP allele is the contribution to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene is associated with Alzheimer's disease. The pathway described involves the production of Abeta, a protein fragment that accumulates in the brain and is a hallmark of Alzheimer's. The involvement of cytochrome c oxidase (COX) subunits suggests that mitochondrial dysfunction may also play a role in the disease process. The biological effect of the APP allele, particularly in the context of this pathway, contributes to the development of Alzheimer's disease through the accumulation of Abeta and associated mitochondrial impairment.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele is involved in the NRG (neuregulin) signaling pathway, which plays a critical role in neural development, myelination, and synaptic plasticity. Mutations in the ERBB4 gene have been implicated in several neuropsychiatric and neurodevelopmental disorders. Specifically, alterations in ERBB4 function are associated with schizophrenia, a complex mental disorder characterized by disturbances in thought, perception, and behavior. This pathway is essential for proper neuronal function and communication, and disruptions in ERBB4 signaling can lead to impaired neural connectivity and function, contributing to the pathogenesis of schizophrenia.\n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase involved in cell signaling, and it interacts with various neuregulins (NRG1-4). Mutations or dysregulation in ERBB4 have been implicated in several neurological and psychiatric disorders. Specifically, variants in ERBB4 have been associated with schizophrenia, contributing to altered neural development and synaptic function. This pathway is critical in neurodevelopment and may influence brain connectivity, which is disrupted in schizophrenia. \n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele, specifically within the NRG // ERBB4* pathway, is involved in signaling processes that influence neural development and function. Mutations or dysregulation in ERBB4 have been implicated in psychiatric disorders, particularly schizophrenia. This contribution is supported by evidence showing that ERBB4 is a susceptibility gene for schizophrenia, and its interaction with neuregulin (NRG) genes further modulates this risk. These genes are critical in synaptogenesis and neuronal migration. Disruption of their function may lead to altered brain development and connectivity, which are hallmarks of schizophrenia.\n\n\\boxed{Schizophrenia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves ATXN1, which is a known causative gene for Spinocerebellar Ataxia Type 1 (SCA1), a neurodegenerative disorder characterized by progressive loss of coordination and motor control. ATXN1 interacts with RORA and KAT5, which may modulate its function or stability. These interactions could influence downstream targets like ITPR1, SLC1A6, and GRM1, involved in calcium signaling, neurotransmitter transport, and glutamate signaling, respectively. Dysregulation of these processes may contribute to neuronal dysfunction and death, hallmark features of SCA1. Therefore, the biological effect of this ATXN1 allele is likely to contribute to the development of $\\boxed{Spinocerebellar Ataxia Type 1}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway involves the gene ATXN1, which is known to be associated with spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disorder. ATXN1 is a transcriptional repressor that, when mutated, leads to the expansion of a CAG trinucleotide repeat. This expansion causes the production of a toxic, polyglutamine-expanded ATXN1 protein, which disrupts normal cellular functions and leads to the progressive loss of Purkinje neurons in the cerebellum. This pathway also includes RORA and KAT5, which are involved in transcriptional regulation and chromatin remodeling. The downstream genes, such as ITPR1, SLC1A6, and GRM1, are involved in calcium signaling and glutamatergic neurotransmission, processes that are affected in SCA1. Thus, the biological effect of this ATXN1 allele contributes to $\\boxed{\\text{Spinocerebellar Ataxia Type 1 (SCA1)}}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN1 gene is associated with spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. This allele contributes to the disease by causing abnormal expansion of a CAG trinucleotide repeat within the gene, leading to the production of a toxic, expanded ATXN1 protein. This mutant protein disrupts normal cellular functions, particularly in neurons of the cerebellum and brainstem, leading to neuronal degeneration. The pathway involves interactions with RORA and KAT5, which may modulate ATXN1 function or stability, impacting downstream effectors such as ITPR1, SLC1A6, and GRM1, potentially influencing calcium signaling, glutamate receptor activity, and other processes vital for neuronal health. \n\n\\boxed{Spinocerebellar Ataxia Type 1}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a cyclin-dependent kinase inhibitor that plays a crucial role in cell cycle regulation and tumor suppression. Mutations in CDKN2A are associated with the inactivation of the p16INK4a protein, which normally inhibits CDK4/6 activity, preventing the phosphorylation of RB1. Loss of this inhibition leads to the activation of E2F transcription factors, promoting cell cycle progression and proliferation. This disruption in the G1/S checkpoint is a hallmark of various cancers. Specifically, germline mutations in CDKN2A are strongly linked to melanoma, as well as some cases of pancreatic neuroendocrine tumors and other neoplasms. The pathway described highlights how loss of CDKN2A function can lead to uncontrolled cell growth.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a cyclin-dependent kinase inhibitor that regulates the cell cycle by inhibiting CDK4/6, thereby preventing the phosphorylation of RB1. In the provided pathway, CDKN2A is positioned upstream of MDM2 and TP53, suggesting its involvement in the p53 pathway, which is crucial for DNA repair and apoptosis. Mutations or inactivation of CDKN2A can lead to uncontrolled cell proliferation due to loss of its tumor-suppressive function. This contributes to the development of various cancers, particularly melanoma and neurofibromatosis type 1. The gene's role in cell cycle regulation and its association with tumor suppressor pathways indicate that alterations in CDKN2A are strongly linked to oncogenesis.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a cyclin-dependent kinase inhibitor that plays a crucial role in regulating the cell cycle and acting as a tumor suppressor. Its function is to inhibit CDK4/6, thereby preventing the phosphorylation of RB1, which is necessary for cell cycle progression. The provided network indicates that mutations or loss of CDKN2A function could lead to uncontrolled cell proliferation due to the activation of the E2F pathway, which promotes cell cycle progression. This disruption contributes to the development of melanoma and other cancers, as the loss of CDKN2A leads to unchecked cell growth and division. \n\n\\boxed{Melanoma}"]]